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ABSTRACT 
Hepatitis C virus (HCV) induces one of the most prevalent, potentially fatal 
chronic viral infections worldwide. This virus symptomatically infects 
approximately 170 million people (2 .5% of the global population) . Although HCV 
is primarily a hepatotropic virus, accumulated experimental and clinical evidence 
indicates that HCV can also replicate in cells of the immune system. The ability 
of HCV to infect human cells is currently interpreted in the context of the 
interactions identified between the Japanese fulminant hepatilis -1 (JFH-1) strain 
of HCV or HCV pseudoparticles and human hepatoma cell lines, particularly 
Huh7.5 clone. The factors determining HCV tympholropism remained unknown. 
Based on previous observations demonstrating that wild-type HCV can 
infect and replicate in human T lymphocytes both in vivo and in vitro , we 
hypotheSized that HCV utilizes certain T cell-specific molecules to enter these 
cells and, therefore, that HCV uses (at least in part) different strategy to infect 
immune cells than Huh7 cells or primary hepatocytes. 
This thesis is comprised of three related studies In the first study, we 
established an in vitro infection system applying readily available human T cell 
lines, such as Molt4 and Jurkat T cells, and naturally occurring wild -type HCV 
obtained from patients with chronic hepatitis C. Employing this system, we 
confirmed that HCV infects primary T lymphocytes as well as the mentioned T 
cell lines, as evident by detection of HCV RNA negative (replicative) strand and 
virus non-structural (NS5A) and structural (core) proteins. However, some T cell 
lines were not susceptible to HCV infection. We found that cells prone to HCV 
infection are endowed with CDS, a scavenger receptor that belongs to the 
cysteine-rich superfamily. We documented that this molecule serves as HCV T 
cell receptor by multiple supplementing each other approaches 
In the subsequent study, we evaluated whether other molecules proposed 
to serve as HCV receptors based on the JFH-1-Huh7 cell studies may contribute 
to establishment of HCV infection in T lymphocytes. For this purpose, the mRNA 
and protein expression of the different HCV cand idate receptors , such as C081 
(mRNA only), scavenger receptor class B type1 (SR-B1), occludin (OCLN) , 
claudin-1 (CLoN-1), claudin-4 (CLoN-4) and claudin-6 (CLoN-6) , in addition to 
COS molecule identified in the first study, were investigated. We examined T cell 
lines, peripheral blood mononuclear cells (PBMC) and affinity-purified primary 
human T cells and their C04+ and CD8+ subsets, and compared to hepatoma 
Huh7.S and HepG2 cell lines and primary human hepatocytes (PHH). We found 
that while CDS, C081 , and OCLN are likely involved in mediating T cell 
susceptibility to HCV infection, SR-B1 and CloN-1 are not. This validated the 
concept that HCV uses different receptors to infect various cell types naturally 
targeted by this virus. In general, this study narrowed the range of factors utilized 
by HCV infecting T lymphocytes amongst those identified using HCV 
preparations and Huh7.5 cells . 
In the third study, we tested the ability of the recombinant HCV JFH1 T 
virus , a culture-adapted JFH-1 strain demonstrating significantly higher infectivity 
towards Huh7.5 cells than the classical JFH-1 strain, to infect T cell lines, human 
PBMC and primary T cells , in comparison to the plasma-derived wild-type HCV. 
We also examined the susceptibility of Huh7.S cells to the plasma-derived wild-
type HCV. The resul ts revealed that T cell lines, PBMC and primary human T 
cells were susceptible to the patient-derived wild-type HCV but not to JFHh 
clone, while Huh7.S cells were only prone to JFHh but not to wild-type virus. This 
study demonstrated contrasting differences between wild -type HCV and JFH 
clones in terms of cell tropism and suggested that HCV -T cell infection system 
can be more representative of the actual (wild-type) virus behaviour than 
genetically modified and Huh7.S cell culture-adapted viruses. 
Overall, our findings have provided conclusive evidence that wild-type 
HCV can infect and replicate not only in primary human T lymphocytes but also in 
some readily available human T cell lines . We identified CDS, a glycoprotein 
belonging to the scavenger receptor cysteine-rich superfamily, as a T cell-specific 
molecule mediating the cell susceptibility to HCV infection. In addition, CD81 
was found to act as a co-receptor, while OClN is likely involved in infection of the 
virus-prone T cell lines but unlikely primary T cells. 
In general , our research provided the first insight into the molecular 
mechanism determining HCV ability to infect cells of the immune system. 
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CHAPTER ONE: 
INTRODUCTION: 
1.1 VIRAL HEPATITIS 
Hepatitis viruses comprise a group of diverse pathogens thai primarily 
infect the liver and belong to different virus families with very different replication 
strategies. They are infecting hundreds of millions people. causing either acute or 
chronic infections. Some of these vifuses cause diseases progressing to liver 
cirrhosis and hepatocellular carcinoma (Hee), which are the lead ing causes of 
death worldwide. Among these viruses, hepatitis A virus (HAV), hepatitis E virus 
(HEV) and hepatitis G virus (HGV) are transmitted via the oral-fecal route, 
whereas hepatitis B virus (HBV) , hepatitis C virus (HCV) and hepatitis 0 virus 
(HDV) parenteraly 
1.1. 1. Hepatitis A virus 
HAV belongs to the genus hepatovirus within the Picomaviridae family. It 
is a nonenveloped agent with an icosahedral capsid of -30-nm in diameter 
containing a positive single-stranded (ss) RNA genome of 7.5 kilobase (kb) (112, 
11 4). The genome open reading frame (ORF) encoding a polyprotein of 2225 
amino acids (aa) is preceded by a s'-untranslated region (s'-UTR) and followed 
by a much shorter 3'-UTR The translated polyprotein is cleaved into 11 proteins 
through a cascade of proteolytic events mediated mainly by the viral 3C protease 
(365). HAV infection has an acute course and does not progress to chronic 
hepatitis (265) . Vaccines against HAV provide lifelong protection from infection 
(410). HAV is primarily transmitted by the fecal-oral route (288) via contaminated 
water and food , and fomites act as vehicles of transmission (4) . Virus occurs in 
the feces of infected patients at very high concentration (up to 10 11 genome 
copies/g) for 2 weeks after the onset of symptoms and lasts at lower levels for at 
least 4 more weeks (78) . 
1.1.2. Hepatitis B virus 
HBV is an enveloped DNA virus and is the smallest mammalian DNA virus 
known (diameter of 42 nm). It has an icosahedral nucleocapsid of approximately 
30nm in diameter that encloses the viral partially double-stranded DNA genome 
and viral DNA polymerase. The complete genome encodes viral proteins through 
four highly overlapping (67%) ORFs called S, C, P, and X. HBV belongs to genus 
hepadnavirus within the family Hepadnaviridae. HBV infects as a symptomatic, 
serologically detectable infection more than 370 million people, while more than 2 
billion people worldwide show serological and/or molecular evidence of exposure 
to this virus . Virus may cause acute and chronic liver disease, as well as 
asymptomatic occult long-term infection (291 ). Acute HBV infection is self-limited 
in 95% of infected adults and in 10 - 70% in children and young adults . However, 
virus clearance may fail especially in newborns of HBV-infected mothers (288, 
399) . Up to 30% of patients with chronic hepatitis B progress to liver cirrhosis 
(LC) and HCC (WHO, 2000a) . Lifelong persistent occult infection appears to be a 
common consequence of resolution of acute hepatitis B (276, 341 , 272, 275, 
341) . In this regard , investigations in the woodchuck model of hepatitis B were 
essential in recognition of this pathogenically and epidemiologically important 
form of hepadnaviral infections (272). Currently, vaccines that confer lasting 
immunity against HBV are widely available . However, new infections in vaccine 
non.protected individuals and in children born to HBV-infected mothers are still a 
great global health problem (175). 
1.1.3. Hepatitis D virus 
HOV is a negative sense, single-stranded, closed circular RNA virus of the 
genus deltavirus. HOV is a satellite virus for HBV in that it requires coinfection 
with HBV to infect, assemble and release virions (107). There are eight 
genotypes of HOV. The infection of HOV can occur simultaneously with HBV or 
as superinfection of a chronic HBV carrier. The former pattern can be associated 
with "eradication" of both agents, whereas superinfection mostly evolves to HDV 
chronicity. HDV can enhance progression of chronic hepatitis to cirrhosis (305). 
1.1.4. Hepatitis E virus 
HEV is a small non-enveloped single-stranded positive-sense RNA virus. 
It is the sale member of the genus herpevirus and is mainly transmitted by the 
fecal-oral route (293) . HEV has four genotypes but only one serotype 
Genotypes 1 and 2 exclusively infect humans, whereas genotypes 3 and 4 infect 
pigs and several other mammalian species. The disease usually affects young 
adults , and is particularly severe among pregnant women and persons with pre-
existing liver cirrhosis (g) 
1.1.5. Hepatitis G virus 
HGV was isolated from the plasma of a HCV-infected patient. It is a single 
stranded, positive-sense RNA virus belonging to the Flaviviridae family. HGV has 
a close sequence homology and genomic organization to HCV (38). However, 
unlike HCV, HGV is neither hepatotropic nor causes acute or chronic hepatitis 
(2 17). The virus replicates in the lymphatic system, including the spleen, bone 
marrow (38) and peripheral blood mononuclear cells (PBMC), including CD4+ T 
cells (418) . No disease has been associated with HGV infection, but co-infection 
of individuals infected with human immunodeficiency virus (HIV) decreases 
morbidity and mortality and slows progression to acquired immunodeficiency 
syndrome (38) 
1.2 HEPATITIS C VIRUS 
HCV is the subject of this dissertation and will be described in detail in this 
and following sections. 
1.2.1. Epidemiology 
HCV infection is a worldwide endemic disease and is characterized by a 
high degree of geographical variation in its distribution. It is estimated that 123-
170 million people are infected with HCV (14,368,407) . However, this number is 
likely under-estimated considering the sensitivity of the current clinical assays 
available for detection of HCV RNA and anti-HCV antibodies. In the United 
Stales, HCV infection is currently the most common chronic blood-borne infection 
with an estimated 3.2 million individuals chronically infected (19). Due to lack of 
vaccine or effective treatment and post-exposure prophylaxis, prevention and 
control of hepatitis C is the main point of focus for health authorities in many 
countries. The prevalence of HCV in industrialized countries is relatively low 
(0.01-0.5%) and is mainly attributed to injection drug users (254, 368) . In 
Canada, approximately 300,000 individuals are chronically infected with HCV 
(Fischer et al., 2006) . In Northern Africa and Asia , higher prevalence of HCV 
infection has been reported (39 , 368). In developing nations. such as Egypt. 
Hubei, Mongolia and Pakistan high prevalence of HCV infection (17-26%) has 
been reported (106, 132, 407). HCV infections in these countries are largely 
attributed to unsafe medical procedures and blood transfusions (331, 368) and to 
incomplete or lack of screening of donated blood (331). Although transmission of 
HCV via sexua l, occupational (e.g., in health care personnel) and perinatal 
exposures can occur, this mode of virus spread is not well documented 
compared to percutaneous exposure (1, 331, 368) . It is estimated that 75-85% of 
individuals infected with HCV develop asymptomatic chronic hepatitiS C (CHC) 
depending on virus genotype (1, 39) . Between 5 and 25% of patients with CHC 
develop LC (258), and approximately 5% of cirrhotic patients wi ll eventually 
progress to HCC (233) 
Initially, 11 genotypes were described (55, 379), which were later 
reclassified into 6 major genotypes due to the similarity in nucleotide sequences 
(368, 381). These different genotypes have variable geographical distribution 
(264 , 407), where genotypes 1 through 3 occur worldwide and genotype 1b is the 
most common stra in overall (380) . Genotype 1a is the main virus type prevailing 
in Europe and North America, whereas 1b is predominant in Japan (160, 381) . 
Genotype 2 occurs frequentry in the Mediterranean region , Western Africa, and 
the Far East (264, 380) . Genotype 3 is common in Southeast Asia. India and 
Australia , and genotype 4 is the predominant strain in Egypt, Northern Africa and 
the Middle East (343). In South Africa , genotype 5 is the most prevalent, while 
type 6 occurs in Southeast Asia and Australia (283, 380, 381). 
1.2.2. Transmission Routes and Infection Risk Factors 
HeV is a highly infectious blood-borne virus (75). The major risk factor 
associated with HeV transmission is intravenous drug use (IOU) (15). It is 
estimated that as much as 80% of new HeV infections are due to IOU (218) and 
the prevalence of HCV can be as high as 95% in active IOU (121) . The risk of 
HeV transmission by sexual contact is less than 3% among individuals with 
single partners, however, the risk is higher in homosexuals and among those with 
multiple partners (389). Other more common risk factors include: intranasal 
cocaine use. haemodialysis, tattooing, piercing and needle stick injuries (75, 104, 
120,132,198,298, 393). Approximately six out of every 100 infants born to HCV-
infected mothers become symptomatically infected, which occurs predominantly 
during or near delivery. However. in the case of maternal HeV viremia at delivery 
or HIV-HCV coinfection , the risk of transmission is 2- 3 times greater. HCV 
transmission through breast milk has not been reported ; however, HeV-positive 
mothers should consider abstaining from breastfeeding if their nipples are 
cracked or bleeding (415). 
1.3 FLAVIVIRIDAE FAMILY 
Flaviviridae family includes three genera: the flaviviruses (from the latin 
flavus , yellow), the pesliviruses (from the Latin pestis, plague) , and the 
hepaciviruses (from the Greek hepalos, liver) . The flavivirus genus includes 
dengue virus , West Nile virus, tick-borne encephalitis virus, Murray Valley 
encephalitis virus, St. Louis encephalitis virus, Japanese encephalitis virus, and 
yellow fever virus (228). The Pestivirus genus includes viruses such as bovine 
viral diarrhea virus (8VDV) and border disease virus , and classical swine fever 
(hog cholera) virus (74) . The hepacivirus genus includes only HeV (228) 
The Fla viviridae family members share a number of common structural 
and virological characteristics. Thus, all possess envelopes constituted by a lipid 
bilayer that surrounds the nucleocapsid, which is composed of multiple copies of 
a small basic protein called core , and contains the RNA genome. The genome is 
positive-strand RNA, rang ing in size from 9.6 to 12.3 x103 nucleotides (nt) , with a 
singular ORF encoding a 3000-aa or longer polyprotein (228) . The structural 
proteins of the virus are encoded by the N-terminal part of the ORF, whereas the 
remaining portion of the ORF codes for the nonstructural proteins (NS) (Figure 
1.1). Sequence motif-conserved RNA protease-helicase and RNA-dependant 
RNA polymerase (RdRp) are found at sim ilar locations in the polyproteins of all 
f1aviruses (277). In addition, Flaviviridae share similar polyprotein hydropathic 
profiles, with flaviviruses and hepaciviruses being closer to each other than 10 
pesliviruses (68). The ORF is flanked by 5'- and 3'-UTR of 95--555 and 114-624-
nt in length, respectively (Figure 1.1) (395). Viruses of Flaviviridae bind to one or 
more cellular receptors organized as a receptor complex and appear to trigger 
receptor-mediated endocytosis. Fusion of the virion envelope with cellular 
membranes delivers the nucleocapsid to the cytoplasm. After decapsidation, 
translation of the viral genome occurs in the cytoplasm, leading to the production 
of a precursor polyprotein , which is then cleaved by both cellular and viral 
proteases into structural and NS proteins. Replication of the viral genome is 
carried out by the viral replication complex which is associated with cellular 
membranes. Viral replication occurs in the cytoplasm via the synthesis of full -
length negative-strand RNA intermediates. Assembly of virions occurs in 
cytoplasmic vesicles by budding through intracellular membranes. Then, mature 
virions are released into the extracellular milieu by exocytosis . Despite the above 
mentioned similarities with the members of Flaviviridae genera, HCV does exhibit 
a number of differences (see also Sections 1.2.1 and 1.2.2) Flaviviruses 
translation is cap-dependent, i.e ., mediated by a type I cap structure located in 
the 5'-UTR (48). In contrast , the HCV 5'-UTR is not capped and, like that of 
pestiviruses and HGV virus, folds into a complex secondary RNA structure . This 
structure is forming , together with a portion of the core-Coding domain, an internal 
ribosome entry site (IRES) that mediates direct binding of ribosomal subunits and 
cellular factors, and subsequent genome translation . The 3'-UTR of Flaviviridae 
viruses is highly structured, while that of HCV is relatively short, less structured, 
and contains a polyuridyl tracl thai varies in length. Unlike HCV, which has a 
narrow host specificity and tissue tropism and is transmitted exclusively through 
direct contact with human body fluids, flaviviruses are mainly transmitted by 
arthropods, such as mosquitoes or ticks, and can infect a broad range of 
vertebrate animals, with humans being a dead-end host. Further, pestiviruses 
cannot infect humans and no known insect vector transmitting these viruses has 
been identified. In contrast to HCV. infections caused by flaviviruses are acute 
and self-limited in vertebrates. Furthermore, HCV induces immune responses 
that frequently fail to prevent infection and do not confer protection against 
reinfection with other virus strains . On the opposite, strong humoral and cellular 
immune responses are induced by infections with flaviviruses and pestiviruses 
that lead to self-recovery (108) 
1.4 HEPATITIS C VIRUS GENOME AND PROTEINS 
1.4.1. Genome Organization 
HCV possesses a 9.6-Kb RNA genome which is flanked by highly 
structured 5'- and 3'-UTRs. 
1.4.1.1 ORF 
The HCV ORF contains 9024 to 9111 nt depending on the virus genotype. 
The ORF encodes 11 proteins , including 3 structural proteins , 6 NS proteins and 
the frame shift "F" protein (see Section 1 A.2) . in addition to p7 protein which 
function has not yet been clearly defined (see Section 1 A .3). 

Figure 1.1. Schematic representation of the HCV genome and encoded viral 
proteins. The boxed area corresponds to the single open reading frame of the 
HCV genome, The slem-Ioop structures represent the 5' and 3' UTR regions, 
including the IRES and 3'X regions, C-E1 , E1 -E2, E2- p7 and p7-NS2 junctions 
are cleaved by a cellu lar signal peptidase{s) to yield structural proteins. Interferon 
{IFN)-sensitivity-determining region (ISDR), has been linked to the response to 
IFN-a therapy in some strains of HCV. ARFP/F, alternative reading-frame 
protein/frameshift protein; LDLR, low-density lipoprotein receptor; RdRp, RNA-
dependent RNA polymerase. Image from reference (385) 
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1.4.1.2 S'·UTR 
The HCV 5'-UTR contains 341 nt located upstream of the ORF translation 
initiation codon. It is the most conserved region of the HCV genome and displays 
nt sequence identity of - 60% with HGV and approximately 50% with pestiviruses 
(68, 165). The 5'-UTR contains four highly structured domains, numbered I to IV, 
containing numerous stem-loops and a pseudoknot (50 , 406) . Domains II , III and 
IV, together with the first 12 to 30-nt of the core coding region, constitute the 
IRES (173). The HCV IRES has the capacity to form a stable pre-initiation 
complex by directly binding the 40S ribosomal subunit without the need of 
canonical translation initiation factors, an event that likely constitutes the first step 
of HCV polyprotein translation. Tissue compartmentalization of HCV with different 
IRES sequences was reported in several studies (215, 223, 294, 371) . Among 
others, infection of lymphoid cell lines with HCV genotype 1a H77 strain led to the 
selection of a quasispecies with nucleotide substitutions within the 5'-UTR (223, 
243). Furthermore, different translation efficiencies of HCV quasispecies variants 
isolated from different cell types in the same patient were observed, suggesting 
cell type-specific IRES interactions with cellular factors may also modulate 
polyprotein translation (127, 213, 223) 
1.4.1.3 3'·UTR 
The 3'-UTR is approximately 225-nt long and contains three regions 
These regions , from the 5'- to 3'-end, consist of a variable region of 
approximately 30-40 nt, a long poly(U)-poly(U/UC) Iract, and a highly conserved 
3'-lerminal stretch of 98 nt (3'X region) that includes three stem-loop structures 
12 
SL 1, SL2 and SL3 (202, 386, 387). The 3'-UTR interacts with the NSS8 RdRp 
and with two of the four stable stem-loop structures located at the 3'-end of the 
NSS8-coding sequence (66, 133, 182, 220, 421) . The 3'-X region and the S2-nt 
fragment upstream of the poly(UlC) tract were found to be essential for RNA 
replication , whereas the remaining sequence of the 3'-UTR appears to enhance 
viral replication (133, 182, 421,422) . 
1.4.2. Polyprotein Translation and Processing 
As with other plus-strand RNA viruses, HCV replication starts with 
synthesis of a complementary negative strand RNA using the genome as a 
template. Then, positive-strand RNA is produced from a negative-strand RNA 
template, catalyzed by the NSS8 RdRp. The positive-strand RNA progeny is 
transcribed at a level 5- to 10-fold greater than that of negative-strand RNA. HCV 
genome is translated through a S'-cap independent pathway, utilizing the IRES 
within the S'-UTR. This IRES binds the 40S ribosomal subunits directly, 
bypassing the need for pre-initiation factors, and inducing an mRNA-bound 
conformation in the 40S subunit (383). The IRES-40S complex then recruits 
eukaryotic initiation factor (elF) 3 and joins the ternary complex of Met-tRNA-
eIF2-GTP to fonn a non-canonical 48S intermediates. Association with 60S 
ribosomal subunit allows transition to the translationally active 80S complex that 
initiates viral protein synthesis (114, 185, 31 1). The generated polyprotein is then 
targeted to the endoplasmic reticulum (ER) where it is co- and post-translationally 
cleaved by host and viral proteases into 10 viral proteins (Figure 1.1). The amino-
terminal one-third of the polyprotein encodes three HCV structural proteins: core 
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(C) protein, and the glycoprotein envelops E1 and E2. The p7 protein , a small 
integral membrane protein , seems to function as an ion channel (162). The rest 
of the genome encodes the NS proteins NS2, NS3, NS4A. NS4B, NS5A and 
NS5B, which control the intracellular processes of the virus life cycle . The 
structural proteins mature by signal peptidases. HCV also encodes a small 
protein , called F (frame shift) or ARFP (alternative reading frame protein) , that 
can be produced by ribosomal frame shifting into an alternative reading frame 
within the core gene (47 , 229). 
1.4.3. Functions of Viral Proteins 
HCV EI and E2 proteins are transmembrane glycoproteins that constitute 
the virus envelope and are required for viral entry into cells. E2 has been found to 
bind many putative HCV receptors (see Section 1.5). Highly heterogeneous 
hypervariable regions (HVR) have been identified in the aa sequence of the E2 
envelope glycoprotein. HVR1 is constituted by the first 27 aa of the E2 
ectodomain. The variability of the HVR1 reg ion seems to be driven by selection of 
immune-escape variants and is responsible for significant inter- and intra-
individual variation of the infecting virus, which may represent an important 
pathogenic mechanism leading to immune escape and persistent infection (91 , 
408). 
Another short membrane peptide produced by cleavage of the polyprotein 
by host signal pep\idases that appears to have ion channel features is the p7 
protein (J09). This protein is essential for HCV infectivity of chimpanzees (356) , 
as well as for assembly and release of infectious virions (384) . Recent data 
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suggest that p7 could be a viroporin (239) . Additionally, mutations in the coding 
region of p7 led to inhibition of HCV replication and release from Huh-7 cells 
(384). 
The NS proteins are proteolytically processed by the NS2-3 and NS3-4 
viral proteases. NS2 is a membrane spanning protein (359) . It has been shown 
that adaptive mutations in the NS2 alone can lead to enhanced production of 
HCV (352). The NS3-4A serine protease cleaves all downstream sites at NS3/4A, 
NS4N4B, NS4B/5A and NS5N5B (228). NS4A is a small protein (54-aa) that 
anchors NS3 to cellular membranes through an N-terminal hydrophobic peptide 
(414) . NS4B, an integral membrane protein , associates with the ER membranes 
and induces the formation of the membranous web necessary for HCV replication 
(310). Replication enhancing mutations have been identified in NS4B in the JFH-
1-based cell culture system which will be described in Section 1.10.5.3 (321) . The 
NS5A protein is a membrane-associated phosphorylated multidomain protein that 
has been found to playa role in HCV replication (228) . In the JFH-1 Huh-7 
infection system, adaptive mutations in NS5A confer more robust HCV replication 
(91) . Several cellular proteins are capable of interacting with NS5A. In addition , 
NS5A has been shown to contain an interferon sensitivity determining region 
(ISOR) found al aa position 237-276. Mutations in this region can result in higher 
interferon sensitivity and lower HCV RNA loads in hepatoma cell lines in vitro 
treated with alpha interferon (IFN) (136). To date, several small molecule 
compounds targeting the HCV NS proteins, including protease, polymerase and 
NS5A, have been developed and are at various stages of clinical development 
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(18 , 141). The NS5B protein is a RdRp, the enzyme which drives HCV 
replication. NS58 is post-translationally inserted into the ER membrane, an 
association that has been found to be required for RdRp activity. Inhibitors of 
the HCV NS5A protein and NS5B polymerase are potentially active across 
different HCV genotypes and have shown promising antiviral efficacy in early 
clinical studies (325, 326), which will be discussed in details in Section 1.10.1.5 
1.5 HCV LlFECYCLE 
1.5.1 Virus Attachment 
HCV entry and infection of target cells appears to be a highly orchestrated 
multistep process that is mediated by interaction of several viral and cellular 
factors. These molecules seem to function by initially concentrating the virus on 
the surface of the target cells to enable virions to come in contact with other 
receptors and co-receptors that further facilitate virus cell entry. Most of the HCV 
candidate receptors were identified mainly by using in vitro systems such as, 
virus-like particles produced by expression of structural HCV proteins in insect or 
mammalian cells, liposomes contain ing HCV E1 -E2 proteins, HCV pseudotype 
particles (HCVpp) as well as the JFH-1 -Huh7 system that will be described in 
details in Section 1.10.1.5 
1.5.2. Postulated HCV Recep tors 
Several cell surface molecules have been proposed to mediate HCV cell 
binding and internalization 
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1.5.2.1 DC-SIGN and L-SIGN 
The dendritic cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN or CD209) and the liver/lymph node-specific intercellular 
adhesion molecule-3 (ICAM-3)-grabbing integrin (l -SIGN or CD209l) are C-type 
lectins that have been proposed as capture receptors for HCV. DC-SIGN is 
expressed by dendritic cells while. l-SIGN is expressed by sinusoidal endothelial 
cells in the liver and lymph nodes (144, 236, 327) . However, these lectins are not 
expressed on hepatocytes ; therefore, they are not considered HCV receptors for 
hepatocytes but rather may contribute to HCV capture and persistence in the liver 
or eventually other organs (204). The capture of HCVpp by both DC-SIGN and l -
SIGN is believed to be mediated via binding to HCV E2 protein (238) . However, 
neither l -S IGN nor DC-SIGN can be used for HCV entry of hepatocytes (235) . 
1.5.3.1 LDL Recep tor 
HCV particles in the blood were found to be associated with lipoproteins 
that faci litate uptake of lipoprotein-associated HCV into hepatocytes by low-
density lipoprotein receptor (lDl-R) (56). The l Dl-R is an endocytic receptor 
that transports lipoproteins . mainly the cholesterol-rich lDls, into cells through 
receptor-mediated endocytosis (70) . Upregulation of lDl receptors on the 
surface of Daudi cell lines, a B lymphoblastic cell line, upregulated the expression 
of HCV RNA positive strands in these cells (10) . Also , free l Dl was able to block 
HCV attachment to human fibroblasts (282) . In addition, binding of infectious 
HCV particles recovered from plasma correlated with the density of l Dl 
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receptors at the surface of Molt4 cells and fibroblasts, and binding was inhibited 
by LDL but not by soluble CD81 (417). 
1.5.4.1 ASGP Receptor 
The asialoglycoprotein receptor (ASGP-R) has been postutated to mediate 
binding and intemalization of structural HCV core, E1 , E2 and p7 proteins 
expressed in a baculovirus system. Transfection of 3T3-L 1 mouse fibroblast cell 
line with the human hepatic ASGP-R major and minor subunits (H1 and H2) 
allowed binding and entry of these proteins in vitro (362). However, contribution 
of this receptor to HCV entry to hepatocytes remains hypothetical 
1.5.5. 1 GAGs and HSPGs 
Glycosaminoglycans (GAGs) are ubiquitously expressed by mammalian 
cells. They have been found to be involved in the binding of serum-derived HCV 
to Vero cells (147). E2, in particutar its HVR-1, has been shown to bind heparan 
sulfate proteoglycans (HSPGs) with a stronger affinity than other envelope 
glycoproteins, other viruses, such as human herpes virus or dengue virus. 
However, it is conceivable that HSPG may serve as the initial docking site for 
HCV attachment and the virus is subsequently transferred to another high -affinity 
receptor (or receptor complex) triggering the entry of HCV (25). 
1.5.6.1 CD81 
Human CD81 is a 25-kDa molecule belonging to the tetraspanin 
superfamily. CD81 is the most extensively studied HCV receptor (322) . It is 
expressed at the surface of numerous cell types and, therefore , cannot alone 
determine hepatotropic or Iymphotropic nature of HCV. It has four hydrophobic 
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transmembrane regions (TM1 to TM4) and two extracellular loops, the small 
extracellular loop (SEL) and the large extracellular loop (LEL) of 28-aa and 80-aa, 
respectively. The intracellular and transmembrane domains of CD8 1 are highly 
conserved among different species . In contrast, the lEl sequence is variable, 
except between humans and chimpanzees. the only two species naturally 
permissive to HCV infection (248, 404) . The CD81 lEl has been shown to 
mediate binding of HCV through its envelope glycoprotein E2 (322) (123). The E2 
epitopes involved in C081 binding remain controversial. Early studies suggested 
the involvement of aa 480-493 and 544-55 1 in the truncated soluble form of E2 
(123), whereas a more recent study pointed to a role for two other domains, 
including aa 613-618 and a second domain spanning the two HVRs (aa 384-410 
and 476-480) (348) . Several studies showed that C081 is necessary but not 
sufficient to initiate HCV infection and that factors other than CD81 are required . 
It is possible that the CD81 molecule could act as a post-attachment entry co-
receptor and that other cellular factors may act together with C081 to mediate 
HCV cell binding and entry (77) 
1.5.7.1 SR-B1 
The scavenger receptor B type 1 (SR-B1) is a 509-aa glycoprotein with a 
large extracellular loop anchored to the plasma membrane at both N- and C-
termini by means of transmembrane domains with short cytoplasmic extensions 
(206). SR-B1 has been proposed as another candidate receptor for HCV (363). It 
is expressed at high levels in hepatoCyies and steroidogenic cells (21, 206) . SR-
61 was found to bind high density lipoproteins (HOl) which are internalized 
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through nonclathrin-dependent endocytosis. This process mediates cholesterol 
uptake and recycling of HOL apoprolein (377). HCV genotypes 1a and 1b 
recombinant E2 envelope glycoproteins were shown to bind HepG2 cells (a 
human hepatoma cell line that does not express C081) by interacting with an 82-
kDa glycosylated SR-B1 molecule (363) . Binding of HCV E2 to SR-B1 appeared 
to be species specific, as transfection of rodent cells with human or tupaia SR-B1 
(88% aa identity with human SR-B1) resulted in E2 binding, whereas neither 
mouse SR-B1 (80% aa identity) nor the closely related human scavenger 
receptor CD36 (60% aa identity) bound E2. The SR-B1 lEl appeared to be 
responsible for HCV binding to E2-HVR1 that was recently suggested to be 
facilitated by serum HDLs (28, 363, 402) . However, the fact that antibodies 
directed against SR-B1 resulted only in a partial blockade of the binding suggests 
that SR-B1 is not the only cell surface molecule involved in HCV binding to 
hepatocytes (24). In add ition, SR-B1 is expressed by many cell types implying an 
indirect role in HCV hepatotropism. 
1.5.8.1 Claudin-1 
Claudin-1 (ClDN-1) belongs 10 a family of highly conserved 
transmembrane proteins involved in the formation of tight junctions (T J) (286). 
Claud ins consist of short cytoplasmic amino and carboxy-termini, four membrane 
spanning domains, and a large (EL 1) and a small (EL2) extracellular loop. They 
are expressed in most tissues, including the liver, and they interact with each 
other to form intercellular T J strands (155) . In add ition, most claudins carry a 
protein-protein recognition module (POl)-binding motif at their C-terminus 
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through which they directly interact with the TJ -associated zonula occludens (lO) 
proteins -1, -2 , and -3 (183). Blocking this interaction results in the formation of 
aberrant T J strands along the lateral cell membrane (259), suggesting that the 
interaction with lO-1 protein and/or additional factors is essential for the correct 
incorporation of claudins into T J structure. Furthermore, it has been shown that 
claudins are crucial for the barrier function of TJ , as mutations in CloN-16 and 
CloN-4 (paraceUin-1) impairs the paracellular permeability to calcium, and 
magnesium and sodium, respectiYely (177, 382). Accordingly. CloN-1 knockout 
mice die from dehydration within one day of birth due to defects in their epidermal 
barrier function (137) 
Although , C081 and SR-81 appear to be required for HCV entry, they do 
not confer susceptibility of HCV to non-hepatic celis (27, 428) , suggesting that 
additional factor(s) are required to establish productive HCV infection. The study 
by Evans and colleagues (2007) demonstrated that non -permissive human 
embryonic kidney 293 cells (HEK-293T cells) that express CoB1 and SR-BI. but 
not CloN-1, become susceptible to HCVcc (cell culture produced JFH-1 
particles) infection after ectopic expression of this claudin (102). This suggested 
that CloN-1 is an essential HCV entry receptor, at least for hepatoma-derived 
Huh7 and related cell lines. In addition , it was proposed that virus receptor 
interactions prior to Cl oN-1 engagement might trigger conformational changes in 
the T J protein that allow HCV binding, similar to HIV. wh ich interacts first with 
C04 before binding to the CCR5 receptor (416). 
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1.5.9.1 Cfaudin-6 and -9 
CLDN-6 and CLDN-9. which are expressed in the liver and PBMC. were 
proposed as add itional co-receptors for HCV (429) as HEK-293T cells expressing 
CLDN-6 or CLDN-9. but not other claudins. become HCVpp permissive 
Interestingly, however, not every CDB1+/SR-B1+ non-permissive human cell 
lines become susceptible to HCV infection, even when ectopically expressing 
CLON-1 (102. 323). This suggests that productive viral infection requires at least 
one or more human-specific viral entry factors 
1.5.10.1 Occludin 
Occludin (OCLN) is another T J protein that was proposed recently to be 
essential for HCV entry (323). The expression of OCLN allows nonpermissive 
murine and human cell lines to become susceptible to infection with HCVpp, 
whereas silencing of OCLN in permissive cells impaired HCV entry (323) . On the 
other hand. a study by Hikosaka et al. (2011) found , contrary to the previous 
study. that expression of human COB1 . CLDN-1 . SR-B1. and OCLN receptors in 
mouse hepatocytes did not confer susceptibility to HCV infection (172) 
1.5.2. Entry and Uncoating 
Following viral attachment. the HCV nucleocapsid is released in the 
cytoplasm as a result of a fusion process between viral envelope and cellular 
membranes. Specialized viral proteins mediate fusion of HCV with the plasma 
membrane and viral entry into endosomes. This process is guided by vira l 
glycoproteins and is pH-dependant (10) . In general, there are two classes of 
fusion proteins (I and II) (224) and only class II fusion proteins enhance the 
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process of receptor-mediated endocytosis (228). Studies have shown that HCV 
envelope glycoproteins belong to class II fusion proteins (419) and they do not 
require cellular protease cleavage during their journey through the secretory 
pathway (303) . In addition, E2 was shown to share structural homology with class 
II fusion proteins. The existence of a fusion peptide has been suggested in the 
ectodomain of E1 of HCVenvelope (122, 350, 224, 419) . 
1.5.3. Replication Strategy 
Several research groups have demonstrated that HCV replication is 
mediated through a replication complex (RC). which has been shown to mediate 
replication of plus-stranded RNA viruses , such as polio virus (40), mouse 
hepatitis virus (157), and f1aviviruses (409) . RC is comprised of viral proteins, 
replicating RNA and altered cellular membranes. The existence of an HCV RC 
has been clearly shown in cell culture models of HCV (156). Studies employing 
the replicon system have demonstrated that in HCV-transfected Huh? celis, ali of 
the HCV NS proteins , as well as HCV RNA plus -strand, coexist in the context of 
membranous web (156). 
1.5.4. Assembly and Release 
Studies on HCV assembly and release were limited until the 
discovery of the JFH-1 strain of HCV capable of producing infectious viral 
particles in cell culture. HCV core protein has been shown to self-assemble in 
yeast in the absence of viral RNA generating virus-like particles with an average 
diameter of 35 nm (6, 7). Replication of HCV occurs at specialized sites on the 
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ER membrane termed, the membranous web (92, 95) . Initiation of virion 
assembly appears to require the release of HCV genomes from such sites to 
allow contact with core protein , which forms the virion capsid. HCV core protein is 
located on the cytosolic side of the ER membrane where assembly is believed to 
start in the cytosol before further maturation. The release is in itiated by transfer of 
nascent particles across the ER membrane to access the cell secretory 
pathways. Thus, assembly of infectious HCV particles has two interconnected 
phases: (1) an in itiation phase, which takes place at the cytosolic side of the ER 
membrane and (2) maturation and release phases taking place at the luminal 
side of the ER membrane. Overall, particle formation might be initiated by the 
interaction of HCV genomic RNA with core protein which can bind positive-strand 
RNA through stem-loop domains I and III and nt 23-41 (375, 388) . In the 
presence of nucleic acid , HCV core proteins can efficiently self-assemble to yield 
nucleocapsid-like particles with a spherical morphology and a diameter of 60-nm 
(208). Therefore, it is believed that core-RNA interaction plays a role in the switch 
from replication to packaging. Moreover, 45 to 60-nm virus-like particles were 
produced in HeLa and HepG2 cells Iransfected with a full-length of HCV RNA 
These particles were found to be synthesized and assembled in the cytoplasm 
and budded into the ER cisternae to form coated particles (84, 279). Although 
much has been known about the HCV assembly and release, the mechanisms 
underlying exportation of mature virions in the pericellular space have yet to be 
understood. 
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1.5.5. Virion Ultrastructure and Biophysical Properties 
Recent studies have shown that both host and viral factors can affect the 
buoyant density profile of HeV particles . Host lipoprotein, immunoglobulins and 
HeV immune complexes, as well as the stage of infection are examples of these 
factors (171, 334). Electron microscopy studies revealed that HeV virions are 
spherical, -40- to -75-nm in diameter, pleomorphic particles. In addition, 
previous ultrastructural studies, using patient-derived plasma, reported particles 
with heterogeneous diameters ranging from 35 to 100-nm (189, 225, 246, 400). 
In Huh7.5 cells infected with JFH-l , two major HeV particles of -60 and - 45 nm 
in diameter were identified. The 60-nm particles are characterized by a 
membrane bilayer (an envelope) and higher infectivity. Other studies have found 
that enveloped HeV virions display heterogeneous buoyant densities ranging 
from 1.04 to 1.11 g/mL in a sucrose density gradient and between 1.18 and 1.25 
g/mL in a cesium chloride gradient (145. 171 , 190). In contrast, the 45-nm 
particles lacking a membrane bilayer display a higher buoyant density and a 
lower infectivity (145). Similarly, studies have shown that the HeV nucleocapsid 
ranges in size from 25 to 50 nm with a density of 1.24 g/mL in a sucrose gradient 
and 1.33 g/mL in cesium chloride (190, 246, 400). In general, low density 
particles have been shown to be associated with lipoproteins, and found to be 
more infectious than high density particles associated with immunoglobulins 
(171). Importantly , the ratio between infectious and non-infectious HeV particles 
in vivo has been shown to range from 1: 1 00 to 1: 1 000 (53) . 
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1.6 HCV MUTANTS AND QUASISPECIES: 
HCV is genetically diversified and exists in the host as a population of 
closely related variants that evolve in large part as a result of selective pressures 
exerted by host immune responses (252). This may have important implications 
in diagnosis, pathogenesis, treatment, and vaccine development (54). HCV 
replicates at very high levels with production of virions estimated at up to 1012 
copies/day (252) . This high rate of replication, combined with lack of an error 
correction mechanism and ongoing but variable immune selection , results in 
development of both synonymous and nonsynonymous mutations. In addition , 
immune selection puts pressure on key antigen-recognition sites and drives the 
emergence of a closely related virus family that can be identified the serum of 
infected patients . The dynamics and diversity of HCV viral population have 
predicted critical insights of HCV short-term outcomes including early 
spontaneous viral clearance (110), IFN-associated viral clearance , and HCV 
emergence following liver transplantation (336) 
1.7 HCV TISSUE TROPISM 
1.7.1 HCV Hepatotropism 
Hepatocytes are considered the primary site of HCV infection HCV 
hepatotropism has been explained by the higher expression of certain receptors, 
such as CD81, SR-B1 , CLDN-1 and OCLN , as summarized in Section 1.5.2. 
However, most of these proposed HCV receptors were shown to be expressed 
by other HCV-nonsusceptible tissues or cells, which make it difficult to explain 
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how they mediate highly cell-restricted tropism of this virus. Furthermore, 
expression of all proposed HCV receptors in murine cells did not confer 
susceptibility to HCV infection (172) 
1.7.2 HeV Lymphotropism 
Much evidence accumulated in the recent years indicate that HCV can 
also invade and replicate in immune cells at levels, in some situations, 
comparable to that of primary human hepatocytes (PH H). In fact, HCV RNA 
negative-strand has been detected by reverse transcription (RT)-PCR in PBMC 
of infected individuals (44 , 222, 374). Data also indicate that in the absence of 
detectable HCV RNA in the serum, virus can be detected in the PBMC and their 
subsets , such as CD4+ and CD8+ T cells , B cells and monocytes (85, 314, 315, 
319) . Further, ex vivo stimulation of PBMC with mitogens significantly augments 
HCV replication leading to detection of virus genomes in apparently HCV non-
reactive cells (314, 315). On the other hand, de novo infection of T cells with 
plasma-derived HCV was associated with release of infectious HCV particles to 
the culture superanatant (243) . HCV genome sequences detected in lymphoid 
cells have been found to be distinct from the virus in circulation (3 12. 315. 339, 
371) supporting the existence of extrahepatic replication in immune cells. Shimizo 
and colleagues (1997) found that one out of thirteen patient-derived HCV inocula 
tested was able to induce infection persisting in human lymphocyte cell lines 
(371). In certain cases, HCV sequence polymorphisms within the IRES of 5'-UTR 
were identified which may promote HCV replication in immune cells but not in 
nonhaematopoetic cells (127, 212, 212). Analysis of HCV compartmentalization 
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in patients with CHC revealed the presence of replicating virus in T and B 
lymphocytes, as well as in monocytes (93, 314, 158, 315, 317, 319, 373, 437) 
Furthermore, it was uncovered that HCV not only replicates in lymphoid cells in 
patients with CHC but is also in individuals with apparent complete therapy-
induced or spontaneous resolution of hepatitis C (315, 318, 339). In terms of the 
HCV RNA loads in intact lymphoid cells, it has been shown that between 100 and 
1000 vge/107 cells can be detected in approximately 30% of patients with OCI 
who have apparently resolved hepatitis , while up to 104 vge/1 07 cells in patients 
with CHC were identified (314). Further, comparable levels of HCV RNA were 
found in immune cells in -10% of patients with OCI (318). In regard to potential 
clinical consequences of HCV Iymphotropism, replication of HCV in the immune 
cells may facilitate reinfection of liver grafts post-transplantation (304) and 
predispose to the development of Iymphoproliferative disorders (42). Overall, 
evidence of active propagation of HCV has been uncovered in the main immune 
cell subtypes independent of whether infection is symptomatic or clinically silent, 
as well as in in vitro infection experiments with wild-type virus. However, factors 
mediating susceptibility of immune cells to HCV are yet to be identified. Due to 
the low virus load per cell and the high cell turnover per day, investigations on 
HCV Iymphotropism remain challenging and require sensitive detection 
techniques and meticulous approaches 
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1.8 NATURAL HISTORY OF HCV INFECTION 
1.8.1 Acute Hepatitis C 
The majority (60-70%) of infected individuals with acute HeV infection 
(AH) asymptomatic. However, some may present with non-specific 
symptoms, such as jaundice, fatigue and flu-like symptoms (1 , 335). The 
detection of HeV in the serum or liver is the first diagnostic marker of acute HeV 
infection and can be identified within one to 8 weeks after exposure to virus. Up 
to 50% of patients with AH show spontaneous resolution (271). Patients who 
contracted HeV infection at young age tend more likely to spontaneously clear 
symptoms than those who become infected at an older age (369). The HeV RNA 
load in patients during AH range from 104 to 107 genome copies or vge/mL (16 , 
152), with subsequent liver cells injury leading to high levels of serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) (392). Studies 
have shown that the frequency of spontaneous , apparent complete clearance of 
viremia in patients with asymptomatic acute infection, is lower than that in those 
with symptomatic infection (358) . 
1.8.2 Spontaneous Resolution of Hepatitis C 
15~50% of cases with AH can spontaneously resolve hepatitis (271). On 
the other hand, only 6% of the children have spontaneous resolution of AH (184). 
Spontaneous recovery was found to be associated with a strong and vigorous 
immune response, includ ing HCV~specific CD4. and CD8. T cell reactivity against 
multiple viral epitopes (358 , 390) In addition , patients infected with genotype 3 
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have a greater frequency of resolution of hepatitis C than those with genotype 1 
(22 1). Variation in genes involved in the immune response has already been 
linked to outcome of AH (391) . However, most variability in spontaneous HCV 
clearance remains unexplained. 
1.8.3 Chronic Hepatitis 
CHC is defined as HCV RNA persistence in plasma for 6 months or longer 
post-exposure. Up to 85% of HCV-infected patients, depending on HCV 
genotypes, fail to clear the virus and develop chronic infection with persistent 
viremia (392). The majority of patients with CHC are asymptomatic and 20% may 
experience nonspecific symptoms, such as fatigue, nausea and anorexia (174) 
Persistent normal liver enzymes is common in patients with CHC with high anti-
HCV antibodies . Evidence of CHC is usually shown by necroinflammation on 
histological examination of liver biopsy. 10-15% of CHC patients will develop liver 
cirrhosis in 20-30 years (1 4 , 392) 
1.8.4 Factors Affecting Progression of Liver Disease 
Several factors may affect liver disease progression in CHC and 
development of cirrhosis, which appear to be both host and virus related . Many 
independent host factors have been associated with a faster rate of progression 
of liver damage, among those are : (1) male sex (pOSSibly due to a protective 
effect of estrogen in females) (87) ; (2) alcohol consumption (>50 g/day) (364), 
and (3) age of acquisition of infection (ages >40 at time of infection show more 
severe disease). The median time from the acquisition of HCV infection to 
cirrhosis is estimated to be 30 years . However, men infected after the age of 40 
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years have been seen to progress to cirrhosis with a median of only 13 years, 
while women who did not consume alcohol progress to cirrhosis in a median of 
42 years (329), Furthermore, other factors, such as duration of infection, 
immunosuppressive therapy and low CD4+ T cell count due to infection with HIV, 
HBV infection or schistosomiasis coinfection, non-alcoholic steatohepatitis , and 
non-responsiveness to antiviral therapy can also progress faster to CHC (392), 
Iron overload in the liver and mutations of the hemochromatosis gene have also 
been suggested to accelerate progression to cirrhosis (99). In addition to the host 
factors mentioned before, virus-related factors, such as action of HCV proteins, 
can affect the degree of liver disease and fibrosis progression. For example, HCV 
core protein has been shown to induce oxidative stress, alter mitochondrial 
function and increase the production of reactive oxygen species , which in turn 
promote apoptosis (300). Expression of activated caspases , which are mediators 
of apoptosis, in sera of patients with CHC, was found to be associated with a 
higher degree of fibrosis (22) . Coinfection with HIV has been shown to augment 
progression to fibrosis in patients with CHC and is accompanied by higher serum 
levels of HCV RNA (33). On the other hand, certain antiviral therapies, such as 
protease inhibitors appear to be associated with lower rate of cirrhosis when 
given to patients coinfected with HIV or HCV (34, 329). So far, to accurately 
predict the rate of progression of CHC to fibrosis for individual patients based on 
known virus and host factors is still not possible . The course of CHC in children 
seems to be milder with a slower rate of progression to fibrosis (49). Therefore , 
most children are diagnosed incidentally and rarely have symptoms. The 
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explanation for a milder course of infection and slower progression to fibrosis 
could be attributed to possible immune tolerance of HCV at birth or early in life 
(1 42) 
1.8.5 Occult HCV Pers is tence 
The application of highly sensitive nucleic acid amplification assays based 
on RT-PCR/nucieic acid hybridization (NAH), capable of detecting below 10 
vge/mL or 2.5 IU/mL allowed for the detection of very low levels of HCV RNA 
positive strand in individuals who have resolved AH spontaneously or CHC due 
to antiviral therapy with IFN-a and ribavirin (RBV) (315). Detection of HCV RNA 
positive strands in the serum, and both positive and negative HCV RNA strands 
in PBMC and/or liver of individuals who have been found to be repeatedly HCV 
RNA non-reactive by standard clinical laboratory tests and displayed repeatedly 
normal serum ALT levels is defined as occult infection (OCI) (273, 314, 315, 
339). Persistence of HCV replication for years after apparent spontaneous or 
therapeutically-induced resolution of hepatitis C is now well documented (242, 
312, 315) . In addition , as indicated before (Section 1.7.2) HCV replication has 
been detected in different immune cell subsets, including T cells, B cells and 
monocytes (314). HCV RNA positive and negative strands have also been 
detected in liver biopsy samples taken from patients who had apparently cleared 
the virus for up to 8 years after achieving sustained virological response (SVR) 
(312, 339) . Due to inadequate follow-up periods , it is not known whether or not 
occult HCV infection persists for the entire life, like other persistent viral 
infections, such as HBV (276) , Epstein-Barr virus (EBV) , herpes simplex virus 
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(HSV) and cytomegalovirus (CMV) (20) . In a recent study, examining 276 
individuals with normal liver enzyme levels , and negative anti-HCV antibody and 
plasma HCV RNA, 3.3% of them were found to carry HCV RNA in intact (mitogen 
unstimulated) PBMC (85) , supporting the notion that sampling of multiple 
compartments is necessary when testing for OCI. Furthermore, detection of HCV-
specific T cell immune responses in the absence of clinical markers of viremia 
appears to reflect persistence of HCV in this form of HCV infection (337). In 
addition to OCI progressing after resolution of AH or CHC, a low level HCV 
replication was detected in patients with ongoing mild liver pathology evidenced 
by persistently elevated liver enzymes. Thus, HCV RNA was detected in 57 of 
100 patients who had no detectable virus by standard clinical assays (62, 63) . 
Those patients were more likely to have liver fibrosis and mild liver inflammation 
(63) 
Studies in this laboratory indicate that sensitivity of the assays used for 
detection of HCV RNA positive strands should be .:=. 10 vge/mL and testing should 
include samples obtained from all 3 compartments of virus occurrence, i.e., 
plasma, PBMC and liver, and preferably serial samples (273). Potential 
consequences of OCI are related to the risk of virus transmission by infected 
blood or organs donated by silently infected individuals (315) . The presence of 
residual virus with ability to replicate may also lead to HCV reactivation after 
apparent successful antiviral treatment. Recurrence of HCV infection after SVR 
has been reported to be as high as 20% (86). The study of 97 subjects who 
achieved SVR, which were followed by HCV RNA testing every 6 months over a 
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7-year period , revealed that 11 .3% of these patients developed viral recurrence 
(71). Recipients of liver, kidney (266) or bone marrow transplants (426) 
experienced HCV recurrence after being negative for HCV RNA by clinical 
laboratory assays, suggests that immunosuppressive therapy may contribute to 
reactivation of HCV infection (219) . 
1.9 EXTRAHEPATIC MANIFESTATIONS OF HCV INFECTION 
HCV may trigger a wide spectrum of alterations in the host's immune 
system, possibly due to variable combinations of infectious, environmental and 
genetic factors . Extrahepatic manifestations (EHM) of HCV infection can involve 
the skin , eyes, joints , kidneys and the immune and nervous systems. Some of 
these conditions , such as cryoglobulinemia type 2 are more common and well-
documented, while others are infrequent or their association with HCV infection 
has not yet been fully proven. Several studies have found that between 70-74% 
of patients with CHC experience EHM (58) . In some cases , EHM could be the 
only presenting sign of HCV infection. EHM associated with HCV infection has 
been classified into four groups A-D which were defined according to the 
accumulated evidence of pathogenic associations between HCV and EHM. Thus , 
group A is defined as having the strongest evidence of association and includes 
mixed cryoglobulinemia type 2 and type 3 (Me) and 8-cell non-Hodgkin's 
lymphoma (NHL) , while group 0 includes only anecdotal observation (432). The 
infected extrahepatic tissues might act as reservoirs of HCV and playa role in 
both HCV persistence and reactivation of infection (138, 312) 
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1.9.1 Mixed Cryoglobulinemia 
In 1990, Pascual and his colleagues were the first to describe an 
association between HCV and EHM. reporting two patients with MC (306). MC is 
the most commonly studied syndrome associated with HCV Infection (12 , 278. 
278, 278. 297). It is a benign B-cell proliferation that. in some cases, can switch 
to a frank lymphoma with different grades of malignancy (297) . It was classified 
according to the immunoglobulin clonality into 3 types. HCV infection is strong ly 
associated with MC type II and III (1 1), In some studies. up to 80% of patients 
with type II MC were found to be infected with HCV (11). The prevalence of MC 
increases with the CHC duration and only a small fraction of those patients with 
CHC who developed MC (less than 15%) have symptoms (138) . Expansion of 
CD5+, CD81+ B cells in the liver of HCV-infected patients was observed. wh ich is 
thought to be related to B cell proliferation and IgM production due to direct 
interaction between CD81 and HCV E2 glycoproteins (81. 113). Peripheral 
neuropathy is the most common complication of MC (117, 435) and renal 
involvement is one of the worst prognostic indices in the natural history of MC 
(119, 434). Several studies have shown an epidemiological association between 
MC and liver steatosis and severe liver damage (196, 240, 353) , Current data 
suggest that antiviral therapy should be considered as the first choice treatment 
in MC and that combined peg lFN-a and RBV therapy is the most effective one 
(435). Recently, the introduction of Rituximab, a chimeric monoclona l anti-CD20 
antibody, has been proven to be useful in improving most clinical manifestations 
and B-celilymphoproliferation in the majority of MC patients (357) . 
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1.9.2 B Cell Non-Hodgkin 's Lymphoma 
MC and the subsequent appearance of NHl represent two different clinical 
steps of the same disease process. B-cell NHl is defined as an uncontrolled 
proliferation of B lymphocytes associated with a high incidence of circulating 
monoclona l B cells (251 , 263). HeV RNA in circulating lymphoid cells has been 
found in the majority of HCV patients with NHl (11 5, 378) . However, a direct 
pathogenic role of HCV in NHl , if any, is not delineated 
1.9.3 Other Extrahepatic Disorders and Syndromes 
Porphyria cutanea tarda and oral lichen planus are among EHM of HeV 
infection (79) However, these cutaneous disorders are only triggered by 
HCV infection in genetically predisposed individuals (435) . Neurologic 
disorders, as well as nephropathies, have been associated with HCV infection in 
the absence of Me (11 , 186, 226, 307). As well. HCV-related chronic 
polyarthritis can be observed in patients with CHC, both with and without Me 
(119). Intermittent oligoarthritis, generally not erosive and involving the big and 
middle articulations , was frequently observed in CHC (119). A SjOgren-like 
syndrome is also frequently observed in HeV-positive patients , mainly in the 
context of Me (164, 267) . A high prevalence of diabetes mellitus type 
2 associated with high insulin-resistance, as a part of a complex virus-induced 
dysmetabolic syndrome, including hepatic steatosis, were observed in patients 
with chronic HCV infection (17 , 201). In addition , an association between aortic 
atherosclerosis and HeV infection has also been suggested (45, 181). The 
association between HCV infection and hypertrophic cardiomyopathy and dilated 
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cardiomyopathy has also been postulated. Additional potential associations 
include thyroiditis, erectile dysfunction (116) and psychopathological disorders 
(96,128, 434) . 
1.9.4 Immune Cell Abnormalities Coinciding with HCV Infection 
1.9.4.1 T Lymphocyte Dysfunctions 
Dysfunction of the virus-specific T cells is a common feature in persistent 
vira l infections, including infection with HCV. Resolution of hepatitis C requires a 
robust CD4+ and CD8+ T cell responses directed against mu ltiple epitopes of 
HCV. It was observed that C08+ T cells from patients with CHC overexpress 
various inhibitory receptors, such as programmed cell death 1 (PO-1) (90). The 
role of other inhibitory receptors , such as cytotoxic T lymphocyte-associated 
antigen-4 (CTLA-4) and T cell immunoglobulin and mucin domain-containing 
molecule 3 (Tim-3), have also been demonstrated in T-cell dysfunctions occurring 
in the course of CHC (90, 344. 345). In addition, deficient IFN-gamma (IFN-y) 
and IL-2 production by T cells (367) and their impa ired proliferation in response to 
stimulation with HCV antigens have been identified (153). On the other hand, 
exposure of T cells to HCV in vitro resulted in impaired IFN-y signalling. and 
suppress ion of STAT-1 and T bet mRNA levels after stimulation with IFN-y 
compared to un infected T cells (203). The higher expression of inhibitory 
receptors on HCV-specific T cells may account for the functional deterioration of 
T cells resulting in the inh ibition of T cell proli feration and cytokine production 
(43). It has been demonstrated that PD-l expression on total T cells and C08+ T 
cells in the peripheral blood and in the livers of patients with CHC is significantly 
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higher than that in those who spontaneously resolve HCV (153) . Furthermore, 
blocking the PD-I/PD ligand (PDL-1) interaction with antibodies to PD-L 1 and/or 
PD-L2 led to recovery of proliferation , IFN-y secretion and IL-2 production in 
previously dysfunctional , HCV-specific CTLs (153, 295) . In addition , TIM-3 
interaction with its ligand galectin-9 has been implicated as another possible 
mechanism of T cell exhaustion in CHC. Thus, binding of TIM-3 to galectin-9 
results in negative regulation of T-helper type 1 (TH1 ) responses and the 
induction of peripheral tolerance (354, 431). TIM-3 expression has been shown to 
be upregulated on CD4. and CD8. T cells in CHC patients (153). In addition, the 
greatest proportion of PD-lfTlM-3-dual expressing T cells was found in the liver of 
CHC patients and blocking of TIM-3 and TIM-3 ligand interaction rescued 
proliferation of T cells and IFN-y production (153). As indicated before (Section 
1.7.2), HCV active replication , although at low levels , was found in both CD4+ 
and CD8+ T cells in CHC and persistent OCI. However, a potential direct effect of 
HCV infection of the phenotype and function of the effector cells remains 
unrecognized 
1.9.4.2 B Cell Dysfunction 
In patients with CHC, B cells exhibit a nonspecific polyclonal activation 
with higher levels of the early activation marker, CD69, the costimulatory 
molecule, CD86, and the CCR5 chemokine receptor, CD195, when compared 
with B cells from healthy donors in response to stimulation with 
phytohaemagglutinin (PHA) (197, 338) . Moreover, the B-Iymphocyte stimulator 
(BL YS) , known as tumour necrosis factor and Apo-l -related leucocyte-expressed 
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ligand-1 (TALL-1), was found to be up-regulated on the surface of B cells from 
HCV patients in response to PHA or HCV core antigen stimulation (105) . This up-
regulation of TALL-1 was associated with vigorous memory B-cell responses to 
viral antigenic stimulation. Additionally, suppressor of cytokine signall ing -1 
(SOCS-1), a negative feedback immunomodulator was inhibited in B cells from 
HCV-infected patients when compared to healthy ind ividuals (284) 
1.9.4.3 HCV-Re/ated Dysfunctions of NK Cells 
NK cells are a key player in early immune response against pathogens 
and in the activation and maintenance of adaptive immune responses , with the 
abi lity to rapidly produce large amounts of cytokines, as well as. cellular 
cytotoxicity. NK cells promote the differentiation of adaptive T cells and their 
proliferation (438). Similarly, NK cells play an important role in the defence 
against viral infection (41) and surveillance of tumour micro environment (424). 
Morishima et al (2006) reported a decrease in the frequency of NK cells in both 
blood and livers of HCV-infected patients with liver cirrhosis (285). However, 
Corado et al. reported that while there were no differences in the frequency of 
CD3- CD56+ cells , persons with chronic HCV infection had a 4-fold lower level of 
spontaneous cytotoxicity than normal healthy individuals (76) . In vitro , ligation of 
CD81 by HCV E2 protein has been shown to directly block NK cell function, as 
evidenced by inhibited IFN-y and TNF-a production, as well as diminished 
cytotoxic granule release and decreased CD25 expression by NK cells (80 , 401). 
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1.9.4.4 Monocytes Dysfunctions 
HCV core protein interferes with toll like receptor (TLR2)-mediated 
monocyte activation and induces tumour necrosis factor-alpha (TNF-a) and Il-10 
cytokines that lead to apoptosis of plasmacytoid DC and inhibition of IFN-a 
production (88). In addition , studies of patients with apparent spontaneous 
resolution of HCV infection identified low Il-10 and TNF-a production by 
monocytes in response to stimulation with HCV core protein (253) 
1.10 HeV EXPERIMENTAL SYSTEM 
1.10.1 Animal Models 
The chimpanzee is the only reliable animal model for HCV (109). The lack 
of robust small animal models naturally susceptible to HCV infection has impaired 
the ability to study almost all aspects of HCV pathogenicity and HCV responses 
to preventive and therapeutic strategies. Recently, several small animal models 
for HCV infection have been evaluated, including the albumin (Alb)-urokinase 
plasminogen activator (uPA)-severe combined immunodeficiency disorder (SCID) 
mouse (199, 200) ; HCV trimera mouse (98, 139): the Tupaia belangeri ; 
NOD/SCID mouse model , and transgenic mice expressing HCV proteins (244, 
256. 397) 
1.10.1.1 The Chimpanzee ModeJ 
The chimpanzee has been known to be susceptible to HCV (or the non-A, 
non-B hepatitis agent) and has long been used as a sole animal model for HCV 
infection (46) . However, due to ethical reasons and vast costs , the use of this 
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animal for HCV research is strictly limited. Chimpanzees have been used to 
investigate hepatitis C immunopathogenesis, natural history and potential 
antiviral preventive and therapeutic strategies, including: (1) the role of HCV-
specific CD4+ and CD8+ T cell responses in viral clearance (159, 376); (2) the 
infectivity of lymphocyte-derived virus (372): (3) the efficacy of vaccination and 
anti-HCV antibodies (100, 333, 349), and (4) anti-HCV efficacy of selected 
antivirals. It has been demonstrated that chimpanzees can produce HCV virions 
at high levels, between 105 to 107 vge/mL (53). Immunization of chimpanzees 
with virus-like particles induced an HCV-specific CD4+ or CD8+ T cells , 
suppressing the development of high viral loads in chimpanzees rechallenged 
with HCV (97). Chimpanzees inoculated with recombinant adenovirus vector 
encoding HCV NS proteins also induced HCV-specific immune T-cell response 
that subsequently inhibited the replication of HCV genotype 1a rechallenged 
chimpanzees (126). The development of CHC in chimpanzees ranges between 
39% to 60% depending on study (29, 5, 126, 247), while in humans it is 
estimated to range between 45% and 85% depending on virus genotype (174). In 
addition, hepatitis is significantly milder in chimpanzees and liver fibrosis and 
cirrhosis have never been observed, while the development of HCC has only 
been reported in one animal (289). Studies using IFN-a, with or without R8V, as 
well as adenovirus-based gene therapy to upregulate expression of IFN-a in the 
liver, fai led to decrease HCV load despite the fact that high levels of IFN-a were 
found to be circulating in the treated animals (210) . On the other hand, silencing 
of miroRNA-122 in chronically infected chimpanzees lead to long lasting 
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suppression of HCV virem ia with no evidence of viral resistance or side effects 
(2 11 ) 
1.10.1.2 The Tupaia Model 
The tree shrew or tupaia (Tupaia be/angen) is a small. squirrel-like 
mammalian that is related to primates (60). In a study by Tong et al. 2011, it was 
demonstrated that tupaia C081. SR-81. CLON-1. and OCLN can mediate entry of 
HCVpp and HCVcc. with the latter resulting in the full cycle of virus replication 
and appearance of infectious progeny virus. The tupaia and human OCLN aa 
sequences shared 88% homology (397). The key functional region interacting 
with HCV during virus entry was found to be located in the human OCLN large 
extracellular loop (EL2) (323). Tupa ia and human OCLN EL2 are 91% 
homologous. with 4 of 45 residues in this region being different. Mouse and 
human OCLN EL2 are 86% homologous, with six residues being different (397). 
1.10.1.3 Mouse Models 
1.10.1.3.1 The AlbluFA-SCID Mouse Model 
The Alb/uPA SCID-beige mouse containing a human-mouse chimeric liver 
(200, 268) is currenlly the most reliable small animal model capable of supporting 
HCV infection. In this model, among others, the genetic basis of the host 
response to HCV infection and gene expression profi les from HCV-infected mice 
and those from HCV-infected patients were investigated (244. 405). The results 
demonstrated that host factors, such as the initial interferon response, the 
differences in the level of activation of interferon stimulatory genes (ISGs) and the 
duration of infection influence the host response to HCV infection They also 
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showed that HCV mediates changes in the host gene expression, including 
genes regulating lipid metabolism (405) . However, the model has a number of 
limitations, among which is the lack of pathogenic antiviral immune responses. In 
addition, mice infection with HCV are only induced by higher doses of HCV, i.e ., 
greater than or equal to 105 copies per mouse (268). Consequently, infection with 
lower doses of HCV, characterizing aCI, cannot be investigated. FinaUy, this 
animal model is labour intensive and requires high quality PHH, which are hardly 
available even from specialized liver transplantation centers . 
1.10.1.3.2 The Trimera Mouse Model 
The HCV-trimera mouse model was developed by using lethally 
irradiated mice reconstituted with bone marrow ceUs from SCID mouse, in which 
human liver fragments infected ex vivo with HCV had been grafted. HCV viremia 
determined by detection of HCV RNA positive strand, peaked 18 days after 
transplantation of a liver fragment with 85% infection rate . Viral replication in liver 
grafts was evidenced by identification of HCV RNA negative (replicative) strand 
(179) . The trimera mouse model has been employed to test the efficacy of 
neutralizing antibodies in inhibiting HCV infection in human liver grafts (98 , 139) 
and evolution of antiviral agents (179) 
1.10.1.3.3 The Nod/SefD Mouse Model 
An alternative to the trimera model, are non-obese diabetic (NOD)/SCID 
engrafted with human liver tissue. Although very good engraftment 
(approximately 90%) was observed in these mice, inoculation of these animals 
with either HCV-posilive human serum or culture media containing an infectious 
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HCVcc resulted in HCV very low titres being at the limit of detection by the PCR-
based assay. HCV RNA sequences were detected in the engrafted liver tissue by 
in situ PCR. Overall, there is no robust animal model to study HCV replication or 
to be appl ied for evaluation of anti-HCV therapies (245) 
1.10.1.3.4 Transgenic Mice 
A number of transgenic mouse models have been developed to examine 
the potential pathogenic effects of the HCV core protein and/or the envelope 
glycoproteins on hepatocytes either alone (195, 249) or in combination with each 
other (257,308). Thus , the model was mainly used to investigate the role of HCV 
proteins in the immunopathogenesis of liver injury, the modulation of apoptotic 
cell death, the development of HCC and the induction of steatosis . However. 
conflicting results have been reported and no conclusive evidence regarding a 
contribution of HCV structural proteins into the pathogenicity of liver injury was 
demonstrated (26) 
All aforementioned models that were described depend on detection and 
quantification of HCV RNA by RT -peR. The main advantage of these models is 
that HCV infection and replication occurs in human hepatocytes and represent a 
potentially less expensive in vivo model for studying HCV relative to the 
chimpanzee. Compared to the tissue culture replicon systems, adaptive 
mutations in the HCV genome do not seem to be required for replication in the 
xenograft models. However, due to the technical difficulty in creating and 
maintaining the mice. the limited availability of human hepatocytes, variable 
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human cell engraftment and inconsistent viral titters, none of these models has 
yet to gain widespread popu larity (26). 
1.10.2 Cell Culture Models 
1.10.2.1 HCV Pseudoparticles 
HCVpp were designed to study the early stages of viral life cycle. HCVpp 
are produced by transfecting two or three vectors in the HEK-293 cells. First 
vector encodes retroviral Gag and Pol proteins, which are responsible for particle 
budd ing at the plasma membrane and RNA encapsidation. Second vector 
encodes a reporter protein (Luciferase) or green fluorescent protein (GFP). Third 
vector encodes HCV glycoproteins E1 and E2. which were found to mediate 
tropism and fusion of HCVpp with target cell membrane. HEK-293 cells secreted 
HCVpp at an average of 105 particles/ml , which can be used to infect hepatoma-
derived Huh7 cells. The infectivity can be evaluated by quantification of amount 
of luciferase or GFP expressed in HCVpp-positive Huh7 cells. These virus like 
particles can be neutralized with monoclonal antibody (mAb) against HCV 
glycoprotein E1 or E2 and sera from HCV-infected patient carrying anti-HCV and 
they offer a tool to identify inhibitors which block HCV entry (59. 178). In addition, 
HCVpp have been employed to investigate putative HCV co-receptors , such as 
lDl-R (28), CD81 (77) , SR-B1 (402), CLDN-1 (102) and OCLN (323), as well as, 
a tool to indentify factors which may enhance HCV infectivity of target cells, such 
as apolipoprotein CI (270) 
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1.10.2.2 HCV Rep/icon Systems 
The replicon system, which was based on the transfection of selected viral 
RNA clones that replicates autonomously in the target cells , was first described in 
1999 (234). The replicon system has evolved to an efficient system allowing for 
forward and reverse genetic screens. The replicon has also served as a valuable 
tool for screening small antiviral molecules. The system has been established for 
several viruses, including HeV, bovine diarrhoea virus , Lassa virus , and Sindbis 
virus (30 , 13S, 166). The majority of HeV replicon research has been conducted 
on adapted subclones of human hepatoma-derived cell line, Huh7. Although this 
line has been incredibly useful in characterizing the different aspects of HeV 
biology, the cells are clearly different from the authentic PHH. In general , the 
Hev replicon systems have enriched our understanding of the HeV life cycle and 
allowed recognition of roles of individual HeV viral proteins in this cycle, as well 
as provided a tool for development of antiviral therapies potentially targeting HeV 
(209) . 
1.10.2.3 HCVcc System 
JFH-1 , a genotype 2a strain of HeV, was isolated from a 32 year old 
Japanese male with fulminant hepatitis. It replicates only efficiently in the human 
hepatoma Huh7 cells (230, 403, 430). Using Huh7 cells as host, JFH-l clone is 
able to support virus assembly and secretion of infectious particles into the 
culture supernatant, enabling the study of the full HeV life cycle , which is 
considered a major improvement of this system in comparison to the HeV 
repl icon system. However, Huh-7.S cells are deficient in relinoic acid inducible 
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gene I (RIG-I) and TLR3. They are also characterized by abnormal proliferation, 
deregulated gene expression, dysfunctional milochondria, and aberrant signalling 
and endocytosis pathways. These fealures are likely responsible for Ihe cells 
high susceptibility to JFH- l HCV (52, 188, 207). The JFH-l particles, assembled 
in Huh7 cells, display biophysical properties compatible wilh complele HCV 
virions of 50-65-nm in diameler and a buoyant densily of 1.01101 .17 g/mL with 
the peak of infectivity corresponding to a buoyant density between 1.09-1.11 
g/mL (230, 403, 430) . 
In regards to attempts to infect PHH with JFH-l, Ploss et a/. (2010) was 
able to express JFH-1 virus in microscale PHH using micropatterened cocultures 
(MPCCS), which sustained very low levels of viral presence for several weeks , as 
has been shown by employing a highly sensitive fluorescence- and 
luminescence-based reporter systems. However, neither HCV RNA positive and 
negative strands, nor HCV proteins were detectable by RT-PCR and Western 
blotting or immunofluoresence, respectively (324). On the other hand, JFH-1 
particles do not seem to infect or replicate in lymphoid cells , but may support 
HCV JFH-1 translation and polyprotein processing (292). Although this strain 
replicates efficiently and produces infectious virus in Huh7 cell cultures, its 
replication capacity and pathogenicity in vivo, when injected into HCV-naive 
chimpanzees, were very low, as indicated by the luciferase activity measured in 
subgenomic replicons generated from JFH-l strains isolated from infected 
chimpanzees (355). In addition , low-level of viremia without evidence of hepatitis, 
and no seroconversion were detected in chimpanzees (193). Isolates other than 
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HCV JFH-1 genotypes that efficiently replicate in cell culture have not yet been 
identified. However, infectious strains of full -length JFH-1 have been developed 
that are intergenotypic and intragenotypic chimeras of JFH-1 nonstructural 
proteins with structural proteins from other 2a strains and other HCV genotypes, 
including 1a, 1b and 3a (320). These HCV chimeras replicate at different 
efficiencies in Huh-7 cells and some require adaptive mutations for infectivity 
(423). In conclusion, high replication efficiency of JFH-1 strain in hepatoma Huh7 
cells created opportunities for investigation of whole HCV life cycle. However, the 
system has a number of important limitations wh ich may not properly reflect wild-
type HCV replication in naturally occurring cell targets and need to be verified in 
future studies. 
1.10.2.4 In Vitro Infection of Primary Hepatocytes 
In vitro infection of PHH with serum-derived HCV or HCVcc derived from 
JFH-1 has been attempted (111). Nonetheless, establishing and maintaining 
cultures of PHH that sustain HCVcc replication has proven difficult (111) . PHH 
appear to support HCV replication at very low levels which has been confirmed 
by detection of HCV RNA negative (replicative) strand (61, 131 , 280, 281. 403) 
The rate of JFH-1/HCVcc replication in PHH appeared to be one order of 
magnitude greater than that observed after infection of the cells with serum-
derived wild-type HCV, whereas it has one order of magnitude smaller than that 
observed for Huh7.5 cells (281) . Anti-CD81 and soluble CD81 (sCD81) are both 
capable of inhibiting HCVcc infection of PHH. In contrast, serum-derived HCV 
infection of PHH could not be inhibited by sCD81, although the virus remained 
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sensitive to the neutralizing effects of anti-CDS1 antibodies (37 , 124, 425). In 
addition , exogenous HDL promotes HCVcc and HCVpp infection or interaction 
with PHH via binding to SR-B1{27, S9 , 270, 402, 425), but has a minimal or no 
effect{s) on serum-derived HCV infection of PHH (2S0) . The aforementioned 
observations suggest that wild-type HCV may significantly differ from HCVcc of 
JFH-1 (111) 
1-11 THERAPY OF HCV INFECTION 
1.11.1 Standard of care and Treatment Strategies 
No vaccine against HCV is currenlly available and prophylaxis with 
immune globulin is not effective in preventing HCV infection after exposure. 
(415). In regard to treatment of CHC. it has early been established that IFN-a 
could be employed (176). Different IFN-a preparations with or without RBV are 
now used as the standard of care for patients with CHC (250, 261, 330) 
Standard regimen includes subcutaneously administered pegylated IFN-a 2a 
(1S0 ~glweek) or pegylated IFN-a 2b (1.5 ~gfkg/week) together with oral RBV at 
doses of 0.8 to 1.2 g/day , depending on body weight (168, 169) for 48 weeks in 
infections with genotype 1 and 4, and 24 weeks for other genotypes (101) . The 
current treatment efficacy is approximately 80% in patients infected with 
genotypes 2 and 3, and approximately 45% in patients with HCV genotype 1 
infection (168, 250). The strongest predictors of SVR are: (1) the recently 
identified genetic polymorph isms located in chromosome 19. close to the region 
coding for Il28B (or IFN-A3) (146) ; (2) the HCV genotype, and (3) the stage of 
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fibrosis. Other predictors of response to IFN/RBV therapy include: baseline HCV 
RNA levels , the dose and duration of IFN therapy, body mass index. age, insulin 
resistance, gender, and the characteristics of liver disease (including levels of 
AL T, AST and GGT) and/or co-infection with another hepatotropic virus or with 
HIV (101 , 250) . Currently, patients infected with HCV genotype 1 who fai led to 
diminish HCV viral load to an undetectable serum level after therapy wi th 
pegylated IFN/RBV can be re-treated with direct acting antivirals (e.g. HCV 
protease inhibitors) in combination with pegylated IFN/RBV, as will be detailed 
later. The first generation protease inhibitors , such as telaprevir (TLPV) and 
boceprevir (BOC) are not recommended for treatment of CHC caused by 
genotypes other than genotype 1 (101 ). Therefore, identification of the HCV 
genotype prior to initiation of therapy is a key element in determining the course 
of antiviral treatment . Measurement of the rapid virological response (RVR), 
undetectable serum HCV RNA, by standard clinical assay , at week 4, and the 
early virological response (EVR) , a 2-109 10 viral reduction at week 12, allow for 
early prediction of antiviral treatment efficacy and decisions of whether to stop or 
continue the treatment (427). Data have shown that the course of IFN/RBV 
therapy for patients who achieve an RVR can be shortened to between 12 and 16 
weeks for genotypes 2 and 3 and to 24 weeks for genotype 1, respectively (167) 
Patient infected with HCV genotypes 1, 4, 5 or 6 who did not experience 2 log or 
more drop in the viral load by 12 weeks of therapy has a 0-3% chance of 
achieving SVR after 48 weeks of treatment. However, patients who respond 
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poorly to IFNfRBV therapy in the first 4 weeks of administration, a prolonged, 72-
week course of treatment has been shown to increase SVR rates (167) 
1.11.2 Recent and Future Therapies 
A large number of direct-acting antivira l drugs against HCV are at different 
stages of precl inical and clinical development (370) . The aim of the new 
therapeutic strategies is to increase the efficacy, decrease the duration of 
treatment, improve tolerability and patient adherence, and facilitate easier 
administration. The European Medicines Agency (EMA) and Food and Drug 
Administration (FDA) approval have recently been reported for two NS3f4 
protease inhibitors, TLPV and BOC, in combination with pegylated IFNfRBV in 
both na"lve and non-responder patients infected with HCV genotype 1 (3 , 148) 
Limited phase 2 testing has shown that TLPV also has activity against HCV 
genotype 2 infection, but not against genotype 3 (129, 130), while BOC has 
activity against genotype 2 and 3 (148) . However. currently , neither drug should 
be used to treat patients with genotype 2 or 3 HCV infections When either drug 
is administered as monotherapy, without IFNfRBV, resistant variants are selected 
leading to treatment fa ilure (129) . Because protease inhibitors have been 
developed using HCV genotype 1-based enzymatic assays, they have not been 
optimized against other genotypes. In a study done on intergenotype chimeras of 
JFH-1 clone, broader efficacy range of TLPV between genotypes was shown with 
genotypes 1 and 2 being most susceptible, and genotypes 4 and 5 most resistant 
(180). Other OM drugs are at earlier stages of clinical development, including 
additional protease inhibitors, nucleosidefnucleotide analogues and non-
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nucleoside inhibitors of the HCV RNA-dependent RNA polymerase, NS5A 
inhibitors, and cyclophilin inhibitors. IFN-sparing regimens, with or without RBV, 
are also currently being tested (101) 
1.11.3 Liver Transplantation and Recurrence 
HCV-related end-stage liver diseases, such as cirrhosis and HCC, are the 
most common indication for liver transplantation in western countries (332). 
However, universal reinfection of liver allografts with HCV (143) is a major 
problem (35, 143). Thus, de novo liver injury can be demonstrated by histology 
as early as 9 days post-transplant, but most typically develop after 3 months with 
heterogeneous clinical presentation, severity and outcome (140). This injury 
might be attributed to the host-mediated immune response that is enhanced by 
the increased viral load. In addition, donor age is an independent factor that 
determines the outcome of liver transplantation where older age of the donor is 
associated with greater disease severity and faster disease progression as well 
as poorer graft and patient survival (36, 411 , 351). Other factors that modulate 
the outcome of liver transplantation include differences in the virus virulence, 
genetic differences between recipients and the type and amount of 
immunosupression or alcohol consumption following liver transplantation (35. 
351). In fact. persistence of HCV in immune cells may act as an extrahepatic 
reservoir that is believed to be implicated in the reinfection of allografts and the 
degree of liver damage (8. 433), as well as the recurrence of CHC after liver 
transplantation . 
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CHAPTER TWO: 
PURPOSE OF THE STUDY AND GENERAL APPROACH 
Molecular and clinical evidence accumulated in the last decade indicates 
that HCV is not only hepatotropic but also Iymphotropic virus . Several well 
designed and executed studies convincingly documented that HCV can infect 
different cell subsets of the host's immune system, including T lymphocytes. In 
th is regard , both T cells in HCV-infected patients with CHC and asymptomatic 
persistent infection, as well as cultured primary T cells from healthy donors 
infected ex vivo were found to support active replication of biolog ically competent 
HCV. Further, the current understand ing of the nature of the HCV ability to infect 
human hepatocytes and the mechanism of virus entry has been almost entirely 
based on the results from studies investigating interactions between a highly 
unique HCV JFH-1 strain, related replicon -based viruses or HCV pseduoparticles 
and a specific clone of human hepatoma Huh7 cells displaying an immuodeficient 
phenotype. These studies generated a plethora of notable data. however they 
failled , so far, to identify molecule/s determining HCV hepatocyte-specific tropism 
or to confirm that the receptors uncovered by using the JFH-1-Huh7 cell model in 
fact contribute to infection of normal human hepatocytes by naturally occurring 
HCV in vivo. On the other hand, molecules determining susceptibi lity of T 
lymphocytes to infection with wild-type HCV have not yet been investigated and, 
therefore, remain unknown. In this context, the objectives of our studies were 
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1. To establish a reproducible culture system capable of supporting HCV 
replication by applying readily available human T cell lines and wild -type, 
naturally occurring HCV_ Susceptibility of T cell lines to HCV infection and their 
ability to support HCV replication will be determined by molecular and 
immunological approaches, including identification of HCV expression , virus 
genome replicative intermediates and de novo synthesized of viral proteins. For 
comparison, equivalent studies will be carried out in primary T lymphocytes 
isolated from healthy donors exposed ex vivo to the same test HCV inocula 
2. To address the issue of why only some, but not other, human T cell 
lines can support HCV replication, the cell lines examined in this study will be 
evaluated for expression of CD3, C04, COB and CDS to confirm thei r T cell 
phenotype and they will be assessed for transcriptional activity of the genes 
encoding factors known to determine cell susceptibility or its lack to HCV infection 
or viral infections in general, such as tetraspanin C081 , IFN-o. IFN-V and the 
interferon regulatory factors 3 and 7. Moreover, a role of C081 in determining 
receptiveness to HCV infection will be examined in T cell lines found to be 
susceptible to HCV in the course of this study 
3_ Following our finding made in the course of the preparation of this 
thesis dissertation that only T cell lines expressing CDS appear to be prone to 
infection with naturally occurring. wild -type HCV, the aim will be to investigate a 
role of this molecule in mediating susceptibility of T cell lines and primary T 
lymphocytes to HCV invasion. Among others , the study will include examination 
of the relation between the level of CDS display on T cells and their receptiveness 
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to HCV, the effect of CD5 upregulation on the susceptibility to HCV of the cells 
which display CD5 protein only after activation, and the effects of blocking of CD5 
receptors with CD5-specific mAb and by knocking down CD5 expression in HCV-
susceptible T cells using sequence-specific shRNA. To further confirm CD5 role 
in HCV infection, CD5-negative HEK-293 fibroblasts will be transfected with 
human CD5 cDNA and examined for evidence of HCV replication after exposure 
to naturally occurring HCV. In a supplementary study, expression of CD5 mRNA 
and protein will be examined in PHH and hepatoma-derived Huh7. Huh7.5 and 
HepG2 cells to recognize whether this molecule may also contribute to HCV 
towards hepatocytes. 
4. To assess whether or not CD5 is functioning on T lymphocytes as a 
HCV receptor in conjunction with other HCV candidate receptors identified using 
the JFH-1-Huh7.5 cell system. For this purpose, T cell lines found to be 
susceptible or not to infection with wild-type HCV, total human PBMC and 
primary human T lymphocytes will be analyzed for expression of SR-B1 , CLDN -
1. CLDN-4, CLDN -6 , and OCLN and the identified levels of both mRNA and 
protein expression will be compared to those in Huh7.5, HepG2 and control HEK-
293 cells. Following our finding that OCLN, in addition to CD5 and CD81 , may 
contribute to T cell receptiveness to HCV, infection experiments with T cell lines 
with knocked down expression of OCLN will be carried out. In a parallel study , 
the level of expression of HCV candidate receptors , such as CD5, CD81, OCLN 
and SR-B1, will be examined before and after exposure to HCV. The purpose of 
this study will be to assess whether exposure to HCV downregulates expression 
55 
of the molecu les mentioned above, which may provide indirect evidence for their 
involvement in HCV entry to T cells 
5. To investigate whether the HCV JFHh clone, that is a derivative of 
JFH-1 clone and carries adaplive mutations, and shows approximately 1000-fold 
greater infectivity towards Huh7.5 cells Ihan the classical HCV JFH-1 strain can 
replicate in T cell lines found to be prone to wild-type HCV. This may eventually 
establish more simplified in vitro system of HCV propagation in T lymphocytes 
In parallel , the susceptibility of hepatoma Huh7.5 cells to infection with plasma-
derived wild-type HCV will be assessed. 
The establishment of reproducible in vitro infection system utilizing readily 
available T cell lines and molecularly unmodified, naturally occurring HCV of 
different genotypes will be of significant importance not only in regard to the 
identification of factors determining host's susceptibility to HCV infection, 
particularly those mediating HCV Iymphotropism, but also for evaluation of the 
effectiveness of the current and future antiviral agents against HCV propagating 
at this extrahaptocellular compartment. The system can be also applied in 
studies determining functional consequences of HCV replication in T cells and for 
recognizing molecular mechanisms underlying HCV-induced T cell functional 
hindrances. 
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CHAPTER THREE: 
HEPATITIS C VIRUS INFECTION OF HUMAN T LYMPHOCYTES IS 
MEDIATED BY CDS 
This study has been published in Journal of Virology 2012; 86(7):3723-35 
3.1 Introduction 
HCV is one of the main causes of chronic liver disease. Although infection 
of hepatocytes is mostly responsible for manifestations of hepatitis C, the virus 
also invades the immune system by as yet an unidentified mechanism. Using 
human T cell lines and primary T lymphocytes as targets and patient-derived 
HCV, we aimed to identify how HCV gains entry to these cells. HCV replicat ion 
was determined by detection of replicative (negative) HCV RNA strand and viral 
proteins, while specific antibody. knocking down gene expression and making 
otherwise resistant cells prone to HCV were employed to identify a receptor 
molecule determining permissiveness to HCV infection. The results revealed that 
only primary T cells and T cell lines which express CD5 protein are prone to 
HCV. This implied that T cell susceptibility to HCV requires CD5, a Iymphocyte-
specific glycoprotein belonging to the scavenger receptor cysteine-rich family, 
despite that the cells express CD81, the postulated customary HCV co-receptor. 
Blocking of T cell CD5 with antibody or silencing with specific shRNA decreased, 
while increasing CD5 expression by mitogen stimulation augmented susceptibil ity 
to HCV. Moreover, transfection of naturally CD5 -nonreactive HEK-293 fibroblasts 
with CD5 facilitated infection of these otherwise HCV-resistant cells. In contrast to 
T cells, hepatocytes do not express CD5 The data revealed that CD5 is a 
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molecule essential for HCV entry to human T lymphocytes. This finding provides 
a direct insight into the mechanism of HCV Iymphotropism and defines a target 
for potential interventions against HCV propagating at this extrahepatic 
compartment 
HCV infects over 170 mil1ion people global1y and causes chronic hepatitis in 
up to 80% of patients - a condition that can progress to cirrhosis . liver cancer and 
is the leading reason for liver transplantation . Although HCV is conventional1y 
known to infect hepatocytes. a significant body of molecular and clinical evidence 
indicates that HCV also invades and replicates in ceUs of the immune system (42. 
86.94, 151, 304. 436). These cel1s may in turn serve as a reservoir in wh ich 
biologically competent virus persists 
HCV ability to infect human cel1s is currently interpreted in the context of 
the interactions identified between HCV JFH-l strain or HCVpp and human 
hepatocarcinoma cel1 lines Based on these data, tetraspan in C081 (28), 
glycosaminoglycans (1 47). SR-Bl (28. 191). the tight junction protein ClON-1 
(102) and OClN (32, 232, 323) have been proposed to being involved in HCV 
entry to human hepatocytes. On the other hand. factors determining HCV 
Iymphotropism remain entirely unknown. Analysis of HCV compartmentalization 
in infected patients demonstrated virus replication in both T and B lymphocyte 
subsets (93, 214, 296. 312, 314) The susceptibility of normal human T 
lymphocytes in vitro to infection with patient-derived HCV and their abi lity to 
support the entire cycle of HCV replication have been shown (242. 243). HCV 
propensity to infect the immune system is consistent with a significantly greater 
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prevalence of Iymphoproliferative disorders, such as non-Hodgkin's lymphoma 
and mixed cryoglobulinemia, and perhaps mucosa~associated lymphoid tissue 
lymphoma in patients infected with HCV (69, 118,151,436). It also is possible 
that HCV residing in immune cells , as in other persistent viral infections (72, 161 , 
272, 301), is an important contributor to long~term virus persistence and that the 
infected immune cells are reservoirs from which infection can spread, for 
example, in patients grafted with new livers due to HCV~related end-stage 
disease or in recipients of seemingly HCV-negative donor organs (260, 266, 
394). 
3.2 Materials and Methods 
3.2.1. Cells 
PBMC were isolated from two healthy donors who have no history and 
molecular evidence of HCV exposure, as confirmed by HCV RNA analysis of 
sera by RT-PCR/NAH assay with sensitivity <10 virus genome equivalents (vge) 
per ml and the absence of anti-HCV antibody by enzyme immunoassay (Abbott 
Molecular, Mississauga, Ontario , Canada) (242, 315) . Primary T lymphocytes 
were affinity purified from monocyte-depleted PBMC by negative selection using 
MACS magnetic microbeads (Miltenyi Biotec, Auburn , CAl , as reported (243, 
319). T cells were 97-98% pure by flow cytometry. In some experiments, PBMC 
and primary T cells were stimulated with 5 !-Ig/ml phytohemagglutinin (PHA; 
Sigma-Aldrich, Oakville, Ontario , Canada) for 72 h in the presence of 20 IU/ml 
human recombinant interleukin-2 (rI L-2; Roche Molecular Diagnostics, 
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Pleasanton, CAl, as reported (242, 315). Molt4 (CRL-1582) and Jurkat (TI8-152) 
cells were acquired from the American Type Culture Collection (ATCC, 
Manassas, VA). PM1 cells were supplied by the National Institutes of Health 
AIDS Research and Reference Reagent Program (Rockville, MD) and CCRF-
CEM cells (CEM, ACC-240) by the Deutsche Sammlung von Mikroorganismen 
und Zellkulturen GmbH (Braunschweig, Germany). Molt4, Jurkat and CEM cell 
lines were originally derived from patients with acute T lymphoblastic leukemia 
(125), while PM1 from a patient with acute cutaneous T cell lymphoma (241). The 
cells were cultured at 1 x 105 cells/well in 5 ml of culture medium containing RPMI 
1640 supplemented with 10% heat-inactivated fetal calf serum (FCS) , 2 mM 
glutamine and 0.1 mM nonessential amino acids, all from Invitrogen Life 
Technologies (Burlington, Ontario, Canada). In some experiments, the cells were 
stimulated for 72 h with phorbol myristate acetate (PMA; Sigma-Aldrich) at 50 
ng/ml in the presence of 500 ng/ml ionomycin (Sigma-Aldrich) . In preliminary 
experiments , this treatment was found to be non cytopathic and augmenting 
efficiently CD5 expression on the T cell lines investigated (see Table 3.1) . Cells 
not exposed to PMAlionomycin , but cultured under the same conditions, served 
as controls 
Human hepatoma Huh? cells , naive or carrying HCV AB12-A2 replicon, 
were kindly provided by Drs. Joyce Wilson and Christopher Richardson formerly 
from the Ontario Cancer Institute (Toronto, Ontario, Canada), while Huh? 5 cells 
infected with HCV JFH-AM2, a recombinant strain of HCV JFH-1 carrying a 
synonymous mutation at nucleotide 1681 of E2 and one nonsynonymous 
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Table 3.1. CDS and CD81 protein expression following T cells stimu lation 
CD5 CD81 
Cell Type Untreated Treated b Untreated Treated b 
% Positivity (MFI) a 
Molt4 99.8 (84) 100 (104) 998 (106) 96A (54) 
Jurkat 97 (77) 100 (103) 988(171) 663 (38) 
PMl 10 (18.8) 53.6 (30.1) 954 (107) 800 (57) 
CEM 6.3 (6.4) 20.6 (14.5) 977 (166) 557(79) 
PBMC 68 (45) 86 (70) 989 (260) NT ' 
Primary T cells 86 (56) 97(75) 998 (213) NT 
a MFI, mean fluorescence intensity. 
b T cell lines were treated with PMA (50 ng/ml) and ionomycin (500 ngfml) for 72 
h. whereas monocyte-depleted PBMC and T cells affinity-purified from those 
PBMC were cu ltured in the presence of PHA (5 IJg/ml) and IL-2 (20 IUfml) for 72 
hr. Percent of CD5 or CD81 positive cells was determined in untreated and 
treated cells by flow cytometry using respective specific antibodies and 
appropriate isotype antibody as controls. MFI values were read from flow 
cytometry plots 
C NT, not tested 
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mutation in each of E2, p7, NS2 and NS5A sequences, were provided by Dr 
Rodney Russell from Memorial University (St. John's, Newfoundland, Canada) 
(352). These cells served as positive HCV detection controls in selected 
experiments. Human hepatoma HepG2 (H6-8065) and HEK-293 (CRL-1573) 
cell lines were supplied by ATCC. The hepatoma cell lines were maintained in 
Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 
10% FCS. PHH isolated by microperfusion of a healthy portion of the liver of a 
58-year old male donor were supplied by Dominion Pharmakine (Derio-Bizkaia , 
Spain) 
3.2.2. HCV Inocula 
Plasma from 5 patients (3 males and 2 females; aged between 44 and 54 
years) with progressing CHC, carrying HeV genotype 1a or lb at levels 1.1 x 105 
- 4.3 X 107 vge/ml. served as HeV infectious inocula (Table 3.2). PBMC of these 
individuals contained HeV at 2 x 103 to 2.8 X 105 vgeflJg total RNA (Table 3.2). In 
some experiments, HeV JFH-l strain derived from hepatoma Huh7 cells was 
used as inocula (403) . 
3.2.3. HCV Infection Assay 
Cultured T cell lines, either intact or stimulated with PMAJionomycin for 72 
hat 1 x 105 cellsfwell, PHA-stimulated monocyte-depleted PBMC and primary T 
lymphocytes at 1 x 106 cellslwell were supplemented with 5 ml of culture medium 
in 6-well plates and exposed for 24 h to HeV-positive plasma at -1 x 105 HCV 
vge or to an equivalent volume of normal human plasma as a control or, in some 
experiments, to -1 x 104 vge of JFH-l virus. Then, the cells were extensively 
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Table 3.2. Virological characterist ics of patients with chronic hepatitis C whose 
plasma served as HCV inocula ~ 
Case HCV Plasma PBMC Age (yrs)1 HCV RNA HCV RNA load 
Sex (M/F) genotype load (vge/ml) b (vge/~g tota l RNA) b 
47/F 1a 1.1 x 105 1.8 X 104 
52/M 1a 8.6 x 105 2 X 103 
51 IM-a c 1a 2.9 x 107 2.8 X 104 
51/M-b c 1a 7.3 x 105 NA ' 
44/M 1a 5 x 106 1.6 X 103 
54/F 1b B.3 x 104 1.1 X 105 
.. M, male; F , female; vge, virus genome equivalents; n.a., not available 
b HCV RNA positive strand measured by real-time RT -PCR using RNA 
extracted from 250 ~I of plasma or 1 ~g of total RNA from PBMC 
C Samples a and b collected one year apart 
d NA , not available. 
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washed, suspended in fresh culture medium and cu ltu red for 4-5 days post-
infection (d .p.i.). In the case of PBMC and primary T cells exposed to HCV, 
culture medium was alternatively supplemented wi th PHA (5 IJg/ml; Sigma-
Aldrich) or PHA and r1L-2 (20 IU/ml ; Roche) and cells maintained in culture for 14 
days, as reported in our previous studies (242, 243) 
3.2.4. Inhibition of HCV Infection in T cells by Treatment with Telaprevir 
TLPV or VX-950 , a HCV-specific protease inhibitor was purchased from 
Vertex Pharmaceutica ls (Cambridge, MA) and used to treat Molt4 T cells infected 
wi th wild-type HCV (227) . In preliminary experiments , na"lve Molt4 cells were 
exposed to increasing concentrations of TLPV ra nging from 0.8 to 80 IJM in the 
presence of 0.5% DMSO for 7 days to determine cell nontoxic concentrations 
Cell number and viabil ity were determined by Irypan blue exclusion using 
Countess Cell cou nter (Invitrogen) . TLPV concentrations equal to and below 4 
IJM were fou nd to be nontoxic. Accordingly, 2 x 105 Molt4 cells were incubated in 
duplicate with plasma-derived HCV in the presence or absence of 1 IJM and 4 IJM 
of TLPV in 0.5% DMSO. Then, cells were harvested after 7 d.p.i . for evaluation 
of HCV RNA positive and negative strand expression . Molt4 cells exposed to 
HCV and incubated in RPMI medium supplemented with 0.5% o MSO in the 
absence of TLPV were used as infection control. 
3.2.5. Inhibition of HCV Infectivity with Anti-CDS and Anti-CDB1 Antibody 
In order to ascertain the role of COS and C081 in HCV entry to T cells, 
Molt4 at 1 x 105 cells/reaction were incubated for 30 min at 4°C and then for 30 
min at 37°C with either anti-COS mAb (clone C05-507; Invitrogen) , anti-C081 
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mAb (clone JS-81: BO Biosciences Pharminogen, Mississauga, Canada) or 
appropriate isotype antibody control at 2.5 1-19 in 50 1-11 of cul ture medium. The 
treated cells were transferred to a 6-well plate, supplemented with 5 ml culture 
medium, and inocu lated with a patient's plasma containing approximately 1 x 105 
HCV genome copies or, in some experiments, with -1 x 104 vge JFH-1 . After 24 
h, cells were extensively washed, supplemented with fresh culture medium, and 
after 4 to 5-day culture , harvested for analysis 
3.2.6. Sifencing of CDS by RNA Interlerence 
Lentiviral transduction particles encoding 5 different human CDS shRNA 
(clones TRCN0000057653 to TRCN0000057657; designated as M-3 to M-7) with 
a titre between 1.5 x 107 and 2.2 x 107 infectious virus together with a non-target 
control transduction particles (#SHCOO1V) were prepared by Sigma-Aldrich. The 
particles were used to transduce 1 x 103 Molt4 cells in 100 1-11 RPMI 1640 medium 
at 1, 3 and 5 mu ltiplicity of infection in 96-well plates in the presence 01 2 5 ).Ig/ml 
polybrene (Sigma-Aldrich) . Cells were incubated for 24 h at 37°C and then 
allowed to revive in fresh medium for 24 h. Successfully transduced cel ls were 
selected in the presence of 1.7 I-Ig/ml pu romycin (Sigma-Aldrich) for 7 days. The 
level of CD5 knockout was determined by flow cytometry with anti-CD5 mAb 
Clones M-S and M-6 showed the greatest inhibition of CD5 protein expression 
(see Figure 3.9) and were used as targets in HCV infection experiments fol lowing 
the procedure described above. 
3.2.7. Cloning of CDS and Transfection of HEK-293 CelJs 
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Complete CD5 cDNA sequence was amplified using total RNA from 
normal human PBMC and primers 5'-GCAGATCTATGCCCATGGGGTCTCTGC-
3' (sense) and 5'-GCGAATTCTIAGGAGGAGCGATGCAGAACC-3' (antisense) 
containing 8gnl and EcoR1 restriction sites (underlined) , respectively, at 95°C for 
30 sec (denaturation), 59°C for 30 sec (annealing) , and 72°C for 90 sec 
(extension) for 40 cycles. The 1444-base pair amplicon was cloned using PCRII 
TOPO TA system (Invi trogen) and the fragment excised was sequenced in both 
directions. The resulting sequence was identical to that of human COS deposited 
in GenBank under accession number NM-14207. To create a transcription 
vector, the COS DNA was excised from the TOPO TA by digestion with EcoRI 
and 8gnl restriction enzymes and ligated into the pIRES2-EGFP vector encoding 
the GFP (BD Biosciences, Clontech, Mountain View, CAl. DH5a E coli cells 
were transformed with the pIRES2-EGFPCD5 construct, cul tured and enriched in 
LB kanamycin agar and then in broth. Plasmid DNA was purified using Qiaquik 
kit (Invitrogen). HEK-293 cells , which natu rally do not express COS and are not 
susceptible to HCV, were grown to 70% confluence in a 6-well plate and 
transfected with 4 1)9 of pIRES2-EGFPCDS vector or with empty vector in the 
presence of 10 1)1 Lipofectamine in 250 1)1 Opti-Mem medium (both Invitrogen) 
After 24 h, cells were supplemented with fresh medium and left to revive for 6 h 
Transcription efficiency was evaluated by GFP positivity via fluorescent 
microscopy. CD5 gene expression was ascertained in transfected 293 cells by 
RT-quantitative-PCR, while CD5 protein by flow cytometry and confocal 
microscopy analyses For HCV infection, the cells were exposed to plasma 
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containing -1 x 106 HCV genome copies or to -1 x 104 vge JFH-1. Inocula were 
removed after 48 h, cells extensively washed, supplemented with fresh medium, 
and cultured for 4 to 8 d.p_i. prior to analysis 
3. 2.8. RNA Ex traction and cDNA Synthesis 
Total RNA was extracted from 5 x 106 to 1 X 107 cells or 300 1-11 cell culture 
supernatant with Trizol or Trizol lS . respectively (Invitrogen) . Mock extractions 
were performed in parallel as contamination controls (315). RNA predestined for 
quantification of cellular gene expression was treated with DNAse and 
transcribed to cDNA with Maloney murine leukemia virus reverse transcriptase 
(Invitrogen) as reported (319, 315) 
3. 2.9. Detec tion of HCV Genome by RT-PCRlNucfeic Acid Hybridization 
HCV genome was detected by PCR using complementary DNA derived 
from 1 or 2 I-Ig of total RNA and primers aga inst HCV 5'UTR and virus E2 region 
as described previously (315) . PCR cycling parameters were as deta iled before 
(315). Contamination controls routinely typically included a water sample instead 
of test cDNA. a mock extraction, and cDNA derived from PBMC of a healthy 
donor or from Mol14 or Jurkat cells exposed to normal human plasma (NHP; 
mock infection) . As positive controls . cDNA from PBMC of patients with CHC 
providing for this study WHV inocula and the cloned HCV UTR-E2 (rHCV UTR-
E2) fragment were used (315) _ The specificity of the signal detection and validity 
of controls were always confirmed by amplicon hybridization with 32P_labeled 
recombinant HCV UTR-E2 (rHCV UTR-E2) (315). The sensitivity of this assay 
was generally <10 vge/ml «2 IU/ml) or <2.5 vge/l-lg of lotal RNA In addition, 
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when feasible, HCV genome was also evaluated by a rea l-time PCR using 
UghtCycier 480 (Roche Diagnostics, Mannheim, Germany) under previously 
established conditions (3 15) 
3.2.10. Detection of HCV Replication by Tth-Based RT-PCRlNAH Assay 
HCV RNA negative (replicative) strand was determined by a strand-
specific RT-PCR/NAH assay using rTh DNA polymerase (315). This enzyme 
catalyzes the polymerization of nucieotides into DNA using an RNA template in 
the 5'-->3" direction in the presence of manganese and the polymerizat ion of 
nucieotides into duplex DNA in the 5'---;3' direction in the presence of 
magnesium. Details of this assay were described previously (3 15) 
Contamination controls were the same as those described above for the slandard 
HCV genome detection assay PCR cycling parameters were as reported 
previously (315) . Suffice to mention here that specificity of this assay comes 
from the RT step in which a sing le HCV genome-specific sense primer (denoted 
as UTR1 in reference 315) was used to prime the synthesis of HCV cDNA from 
the viral RNA template. Subsequently, the first -round (direct) PCR was in itiated 
by the addition of the HCV-specific antisense primer (denoted as RTU1 in 
reference 315). In this negative strand detection assay, len-fold serial di lutions of 
HCV synthetic RNA (sRNA) negative strand were used as semi -quantitative 
standards , while those of HCV sRNA positive strand as the specificity control. 
As in the case of the standard HCV genome detection assay outlined above, the 
specificity of PCR signals and validity of controls were confirmed by nucleic acid 
hybridization using the 32P_labeled rHCV UTR-E2 fragment (315). In Hlis end, 
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this assay detects - 100 vge per reaction of the correct (negative) strand , while 
nonspecifically identifying .::.106 vge per reaction of the pos itive strand (Figure 3.1) 
(315, 316) . Given that total RNA templates used for this assay were usually 
between 2 to 4 IJg, the overa ll sensitivity of this negative strand detection assay 
was about 25-50 vge/lJg of total RNA (315) 
3.2.11 . RT-PCR Quantification of Cellular Gene Transcription 
The level of expression of CDS and CD81 in naIve and PMA/ionomycin- or 
PHA-stimulated T cell lines, PBMC and primary T cells, human hepatoma cell 
lines and isolated PHH were quantified by real-time RT-PCR As well, 
expression of cytokines potentially influencing the susceptibi lity of T cells 10 HCV 
infection , such as IFN-a, IFN-y , as we ll as IFN regulatory factor 3 (IRF-3) and 
IRF7 were identified by real-time RT-PCR. Beta-actin (f.l.-actin) and hypoxanthine 
phosphoribosyltransferase (HPRT) were measured as loading and expression 
controls. Primer sequences are shown in Table 33. All amplifications were 
carried out using cDNA derived from 50 ng of DNAse-treated RNA in a 
lightCycier 480 (Roche Diagnostics) for 40 cycles under the fo llowing conditions' 
denaturation at 95°C for 30 sec, annealing for 30 sec at 59°C for CDS, at 58°C for 
IFN-a, IFN-y, IRF3, and IRF7, at 57 °C for f.l.-actin , at 56 °C for CD81 and al55 °c 
for HPRT, and extension at 72°C for 20 sec. 
3. 2.12. Flow Cytometry 
To determine or confirm phenotypic characteristics of the T cel l lines used 
as HCV targets , the cells were stained with alexafluor488 -conjugated anti-CD3 
mAb (BD Pharminogen), phycoerythrin (PE)-conjugated anti-CD4 mAb 
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Table 3.3. Primer sequences used for real-time RT -PCR analysis 
Gene FOlWard primer Reverse primer 
CDS 5'-TCAAGCGTCAAAAGTCTGCC-3' 5'-AGCCACACTGGAGGTIGTIG-3' 
CDS1 5'-ACAAGGACCAGATCGCCAAG-3' 5'-AGTCAAGCGTCTCGTGGAAG-3' 
IFN-o 5'-CAGCCTGAGTAACAGGAGGA-3' 5'-GCAGATGAGTCCTTIGTGGT -3' 
IFN-y 5'-TCAGCTCTGGATCGTTTTGG-3' 5'-TGTITIAGCTGCTGGGGACA-3' 
IRF3 5'-T ACGTGAGGCATGTGCTGA-3' 5'-AGTGGGTGGCTGTTGGAAA T -3' 
IRF7 5'- GCCCTIGCCTCCCCTGTIAT-3' 5'-CCACTGCAGCCCCTCATAG-3' 
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Figure 3.1. Verification of the specificity and the sensitivity of HCV RNA 
negative (replicative) strand detection by the strand -specific RT-PCRINAH. 
(A) Ten-fold serial dilutions of synthetic HCV RNA negative strand or (8) 
synlhetic HCV RNA positive strand were amplified using HCV-specific antisense 
primer, rTth DNA polymerase and conditions described in Materials and Methods 
Contamination controls included water added instead of synthetic RNA and 
amplified by direct (OW) and nested (NW) reactions and mock (M) treated as test 
RNA. Specificity of RT-PCR products was further verified by NAH uSing 32p _ 
tabelled rHCV 5'-UTR-E2 fragment as a probe. Positive signals showed the 
expected 244-bp 5'-UTR sequence-specific fragments . As shown. the assay 
detects 100 copies of the correct (negative) strand, while nonspecifically 
identifying :::.106 copies of the positive strand 
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(Chemicon International . Temecula, CAl and PE-conjugated anti-CD8 mAb 
(Chemicon). Detection of CD5 was done with allophycocyanin (APC)-conJugated 
anti-CD5 mAb (Invitrogen), while that of CD81 with fluorescein isothiocyanate 
(FITC)-Iabeled CD81 mAb (Invitrogen). Briefly, approximately 1 x 106 cells per 
reaction were washed twice with phosphate-buffered saline and exposed to mAb 
or isotype antibody control on ice for 45 min. Cells were washed and then 
examined with a FACSCalibur cytometer (Becton Dickinson Biosciences, 
Mountain View, CAl. The results from 104 gated cells were analyzed with 
CeliQuest Pro software (Becton Dickinson Biosciences) 
3.2.13. Confocal Microscopy 
To detect HCV NS5A and core proteins as well as C05 protein, cells were 
fixed with 2% paraformaldehyde and permeabilized with 0.25% saponin. Double 
staining with rat anti-tubulin (Chemicon) and with either mouse anti-HCV NS5A 
mAb (Chemicon) or appropriate isotype antibody control (Bo Biosciences) was 
done as previously reported (314). For staining of HCV core protein, cells were 
exposed to anti-HCV core mAb (Dainippon Sumitomo Pharma . Osaka. Japan) for 
20 min on ice, washed and then incubated with aJexaFluor488-labeled anti-
mouse IgG mAb (Molecular Probes. Eugene, OR) for 20 min at ambient 
temperature. After washing . the cells were treated with 4' .6-diamidino-2-
phenylindole (DAPI; 0.1 j.Jg/ml) (Vector Laboratories, Inc .. Ontario, Canada) and 
examined. Huh7 cells na'lve or carrying HCV AB12 -A2 replicon and HuH7 5 cells 
infected with JFH-AM2 were used as controls. For double stain ing with anti-CDS 
and anti-NS5a, cells were first exposed to anti-NS5a mAb overnight at 4 °C. 
73 
washed and then exposed to Cy2-labeled donkey anti-mouse antibody (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PAl on ice for 60 min. 
Subsequently, the cells were treated with APC-conjugated anti-CDS mAb 
(Invitrogen) for 30 min on ice, washed and counterstained with DAPI Slides 
were examined under an Olympus BX50WI microscope with a FlouView FV300 
confocal system (Olympus America Inc., Melville, NY). Approximately 1000 cells 
per preparation were examined, positive cells were counted , and the percentage 
of the positive cells versus the total cell number calculated 
3.2.14. Western Blotting 
To further ascertain that productive HCV infection was established in T 
celts, the presence of virus E2 protein was examined by immunoblolting in Molt4 
cells infected with plasma-derived HCV. Thus , the infected cells collected at 5 
d.p.i. were dissolved in ice-cold RIPA buffer (1 % NP-40, 0.5% DOC . 0.1% 50S, 
150 mmol/l NaCI in 50 mmol/l Tris, pH 8.0 (Sigma-Aldrich) and proteins 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) at 20 I-Ig protein/lane. After blotting onto a nitrocellulose membrane by 
wet transfer using the Bio-Rad SO cell system (B io-Rad Laboratories, 
Mississauga, Ontario, Canada) (243, 274), the blots were exposed to 5% 
skimmed milk in Tris-buffered saline (pH 7.4) for 1 hour at room temperature and 
then overnight at 4°C to anti-E2 mouse mAb diluted 1 :500 (provided by Dr Arvind 
Patel. University of Glasgow, Glasgow, United Kingdom) Reactions were 
developed with horseradish peroxidase-conjugated goat anti-mouse IgG F(ab'h 
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antibodies (Jackson ImmunoResearch) and signals visualized using an ECl 
detection kit (Sigma-Aldrich) 
3.2.15. Statistical Analyses. 
Data were analyzed using Prism 4 software (GraphPad Software. Inc., 
San Diego, CAl . Statistical significance was determ ined by two-tailed Mann-
Wh itney or unpaired Student's-t test and P values less than 0.05 were con sidered 
sign ificant 
3.3 Results And Discussion 
To identify factors facilitating T cell susceptibility to infection wi th wild -type 
HCV, we explored a previously established T lymphocyte-based HCV infection 
system in which plasma from patients with CHC serves as infectious inocula 
(242. 243) . In search of the most suitable and readily accessible human T cell 
targets , other than mitogen-induced primary T lymphocytes (242, 243) , the 
susceptibility of Molt4, Jurkat, CEM and PM1 human lymphoblastic T cell lines to 
infection with genotype 1 HCV was investigated. This initial study showed, as 
previously reported (243, 373), that Molt4 and Jurkat cells as well as human 
primary T lymphocytes are susceptible to HCV and can support HCV replication. 
as identified by detection of virus RNA negative (replicative) strand (Table 3.4 
and Figure 3.2) . Susceptibi lity of Molt4 and Jurkat ce lls to HCV infeclion was 
also confirmed by cytoplasmic detection of HCV NS5a and core proteins (Figure 
3.3) 
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Table 3.4. HCV infection of human T cell lines, PBMC and primary T lymphocytes with wild-type virus carried in 
plasma of CHC patients 
T cell lines Primary HCV PBMC 
inoculum: HCV Molt4 Jurkat PM1 CEM T celis 
Patient genotype HCV RNA positive strand I HCV RNA negative strand 3 
47/F 1. 104/102 103/50 NO' NO NT' NT 
52/M 1. 104/102 104/102 NT NT NT NT 
51/M-a 1. 1x103/5x102 NT NO NT NT NT 
51/M-b 1. 1.3x103/5x102 5.4x10'/5x102 34/ND NO 6.7x103/5x102 5.6x103/ 5x102 
44/M 1. 1.5x107/103 2x10s/103 25/ND NO 1x105/103 1x1Os/103 
54/F 1b 1.3x103/102 NT NT NT 5.5x104/10 3 1x104/10 3 
a HCV RNA-positive strand was determined by real-time RT-PCR or nested RT-PCR/NAH, whereas HCV RNA-negative 
strand by the strand-specific RT-PCR/NAH , as described in Mate rials and Methods. HCV load was expressed in vge/lJg 
total RNA. 
b NO, not detected: either both HCV RNA positive and negative strands or virus RNA negative strand only. 
C NT, not tested 
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Figure 3.2. Infection of T cell lines with HGV. (A) Molt4, Jurkat, PM1 and 
GEM T cells were exposed to HGV 441M. HeV RNA positive and replicative 
strands were detected by RT-PCRlNAH assays as described in Materials and 
Methods. Synthetic HCV RNA positive strand (sHCV RNA pos) at 105 
copieslreaction and rHCV UTR-E2 fragment were used as positive and specificity 
controls for the HCV RNA positive strand detection. Synthetic HCV RNA positive 
(pos) and negative (neg) strands at 105 copieslreaction confirmed the assay 
specificity for detection of the virus RNA negative strand. Water amplified in 
direct (OW) and nested (NW) reactions and a mock extract ion served as 
contamination controls. The positive signals showed the expected 244-bp 
oligonucleotide fragments 
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Figure 3.3. Evidence of infection of Molt4 and Jurkat T cell lines w ith wild -
type HeV. (A) Detection of HCV NS5A in infected Molt4 by confocal microscopy. 
Cells nuclei were counterstained with OAPl to identify nuclei and examined under 
transmitted light (Tl ; central panel) to visualize the cytoplasm. Im<Jges captured 
at X60 . (8) Identification of HeV E2 protein in Molt4 cells infected with wild-type 
HCV by Western blotting using anti-E2 mAb. Huh? cells carrying rl lCV AB12-
A2Fl replicon were used as a positive control , while naIve Huh? cd:; <Jnd Molt4 
cells exposed to normal human plasma (NHP) served as ncgClt lvc controls 
Detection of ~-act in protein served as a loading control. (C) Detcc ~ion of HeV 
NS5A and core protein in Jurkat cells infected with patient-derived I :CV inocula 
Un infected cells were used as controls. Nuclei were counterslaincJ with DAPI 
Images captu red at X60 
The percentages of NS5a-positive Molt4 cells enumerated under a confocal 
microscope ranged between 2 and 5% and the higher number of positivity cells 
correlated with the greater copy number of intracellular HCV RNA (see Table 
3.4). In agreement with these findings was the identification of virus E2 protein in 
HCV-infected Mort4 T cells by Western blotting at the level which was evidenlly, 
but not surprisingly, lower than that displayed by Huh7 cells carrying HCV A812-
A2FL replicon (Figure 3.38). Furthermore, treatment of Molt4 cells with 1 ~M or 4 
~M TLPV inhibited replication of HCV, as was evidenced by the absence of 
detectable HCV RNA replicative strand in these cells (Figure 3.4). However, in 
one of two repeats treated with 1 ~M of TLPV, HCV RNA positive strand was 
detected, suggesting not complete inhibition of virus propagation at this lower 
drug concentration in this particular culture. On the other hand, Molt4 cells 
exposed to HCV in the absence of TLPV readily demonstrated replication of the 
virus (Figure 3.4) . In contrast to Molt4 and Jurkat cells, PM1 cells were 
infrequently reactive for HCV RNA positive strand and did not display detectable 
levels of NS5a or core protein, while CEM cells were consistently negative 
following exposure to virus (Figure 3.2 and Table 3.4). To identify reasons 
behind the discrepant susceptibility to HCV infection between the T cell lines. we 
re-evaluated their phenotypic characteristics and assessed expression of CD81 
as well as that of selected innate immunity response genes which are known to 
limit viral infection 
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Figure 3.4. Inhibition of HCV infection in Molt4 T cells treated w ith th e HCV-
specific protease inhibitor TLPV. Moll4 cells infected with wild-type HCV were 
treated with 1 ~M or 4 ~M of TLPV or left untreated (UT) for 7 days post infect ion. 
HCV RNA positive strand was detected by RT -PCR with 5'-UTR-spccific primers 
and amplicon specificity verified by NAH. Virus negative (repl icative) strand was 
identified by the strand-specific RT-PCR/NAH assay in which synthetic HCV RNA 
positive (pas) and negative (neg) strands at 102 and 105 copics!r[;action were 
used as specificity controls. As positive controls , total RNA fro:; ] Molt4 cells 
infected with HCV but not treated with TLPV were used Other contro ls were as 
described in the legend to Fig . 1 
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In addition, we determined expression of CD5 which we had hypothesized 
to be involved in HCV entry based upon its essentially lymphocyte-restricted 
expression and, as is SR-B1, inclusion in the scavenger receptor cysteine-rich 
family (28, 361). 
The flow cytometry data confirmed that Molt4 and Jurkat T cell lines were 
uniformly CD3 positive , essentially CD8 negative and variably CD4 reactive 
(Table 3.5). Interestingly, CD81 was displayed on comparable cell numbers 
(mean 98.2%, SEM 0.5) and with similar mean fluorescence intensity (MFI 106-
171 ), as it was on fresh normal human PBMC and primary T cells (mean 99.1%. 
SEM 0.5; MFI 213-260) Inversely, CD5 was displayed by a significantly 
(P<0.0001) greater number of Mo!t4 (mean 98%, SEM 0.6; MFI 84), Jurkat (mean 
92%, SEM 2.7 ; MFI 77) and primary T cells (mean 80%, SEM 4.9; MFI 61) than 
on PM1 (mean 5.8%, SEM 1.6; MFI 34) or CEM cells (mean 5.6%, SEM 1.6; MFI 
32) . The expression of CD81 and CD5 proteins corresponded well to the 
transcriptional levels of the respective genes. Indeed, CD81 mRNA level was not 
significantly different in all T cell lines, while CD5 transcription was significantly 
(P<0.0001) greater in HCV-permissive Molt4, Jurkat, PBMC and primary T cells 
than in HCV-resistant PM1 and CEM cells (Figure 3.5). Therefore, the results 
suggested that T cell receptiveness to HCV infection requires CD5 and is unlikely 
mediated by CD81 alone. Furthermore, expression profiles of IFN-a, IFN-y, IRF-
3 and IRF-7 transcription revealed no apparent correlation with T cell 
susceptibility to infection with wild-type HCV (Figure 3.5) 
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Table 3.5. Surface markers expressed on T cell lines 
Cell line CD3 %" CD4% CD8% CD81 % CD5% 
Jurkat 99.8 0.28 99.5 97.12 
Molt4 95 55 05 99.4 96.5 
PM1 10 88 0.75 82.8 10 
CEM 18 90 1.5 92.1 
• percentage of positive cells by flow cytomelry analysis. 
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Figure 3.5. Expression of CD81 , CD5, IFN-a, IFN·V, IRF·3 and IRF·7 genes 
quantified in T cell lines, PBMC and primary T cells by r(!al ·time RT·PCR 
using an equivalent of 50 ng total RNA per reaction. Expression levels were 
normalized against that of B-actin. Data bars show mean v~lues .± SO of 
normalized copies of gene of interest 
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Since our previous studies consistently demonstrated that ex vivo mitogen 
stimulation of normal human T lymphocytes predisposes them to HCV infection 
(242, 243) and, with some exceptions, augments HCV replication in PBMC from 
HCV-infected individuals (314, 315), we tested whether stimulation of PM1 or 
CEM cells may make them prone to HCV. In this regard , treatment with PHA or 
PMA had been shown to upregulate CDS on T lymphocytes (237). Hence , we 
exposed T cell lines to nontoxic concentrations of PMA (50 ng/m l) \·,ilh ionomycin 
(500 ng/ml), while normal human PBMC and purified primary T cells were treated 
with PHA prior to infection, as reported (243) . As expected, Ihe CDS surface 
display was increased on all T cell lines examined (Table 3.1) I·!owever. while 
PM1 became prone to HCV infection, CEM remained virus resis :~Jljt (Figure 3.6). 
This permissiveness appeared proportional to the cell positivity for CDS. In fact, 
while 10% (MFI 18.8) of naive PM1 were CDS positive , 53 .6% (MFI 30. 1) of them 
became CDS reactive after stimulation. Treatment of CEM ~l u ..:mented CDS 
positivity from 6.3% (MFI 6.4) to 20.6% (MFI 14.5) , but this ~l ;)peared to be 
insufficient to facilitate HCV infection. Following the same trc:J tment , CDS 
expression on Moll4 and Jurkat cells was increased (Table 3 1), and the cell 
receptiveness to HCV infection augmented, albeit unremark:l!.Jty (data not 
shown). Notably, stimulation of the T cell lines downregulated eX;.H ession of cell 
surface CD81 (Table 3.1), making the postulated CDS contribution 10 HCV T cell 
entry even more compelling. 
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Figure 3.6. Upregulation of CDS on non permiss ive PM1 ce lls confers their 
susceptibility to HCV infection. (A) HGV-resistant PM1 and GEM cells were 
treated with PMAlionomycin for 72 h and examined for CDS protein expression 
by flow cytometry. Stimulation significantly augmented CDS positivity of PM1 but 
not GEM cells. The percentage of positive cells after stimulation is indicated in 
the upper right corner of each plot. (8) Untreated (UT) and treated/stimulated (T) 
PM1 and GEM cells were exposed to HCV SlIM-b for 24 h. extensively washed, 
supplemented with fresh medium, and after S-day culture harvested for analysis. 
HGV RNA expression was detected in stimu lated PM1 but not in stimu lated CEM 
cells, while untreated cells were HCV nonreactive, ind icating that an increase in 
CDS expression on PM1 cells coincided with acquisition of their permissiveness 
to HCV infection. The results from two independent infection experiments are 
illustrated. (C) r..-actin expression in PM1 and GEM cells shown in (8) 
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In the context of the above findings and since no relevant information was 
available , we tested whether human hepatocytes are endowed in CDS Flow 
cytometry revealed that hepatoma Huh7, Huh7.S and HepG2 cells 
essentially CDS nonreactive, while they, with the exception of HepG2, were 
strongly CD81 positive (Figure 3.7). Quantification of CDS mRNA by real-time 
RT-PCR revealed trace CDS mRNA levels in the hepatoma cells and PHH, and 
comparably high CD81 mRNA levels (data not shown) 
Taken together, it would be highly unlikely that COS can contribute to HCV 
infection of hepatocytes. To ascertain the role of COS in HCV entry to T cells , 
Molt4 cells and freshly purified human T lymphocytes were preincubated with 
anti-CDS mAb and then exposed to HCV Under the same conditions, 
interference of anti-CD81 mAb with HCV infectivity was examined. Blocking of 
either CDS or CD81 abolished or significantly decreased susceptibility of Molt4 
and primary T cells to HCV infection (Figure 3.8). Incubation with appropriate 
isotype controls (Figure 3.8) or unrelated mAb to CD6 (data not shown) was 
without effect. 
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Figure 3.7. CD81 and CDS protein expression by human hepatoma-derived 
cell lines and naive HEK-293 cells . The proteins' display was determined by 
flow cytometry with anti-CoB1 and anti-CDS antibodies as well as appropriate 
isotype controls. The percentage of positive cells is indicated in the upper right 
corner of each plot. 
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Figure 3.8 . Inhibition of HCV infection of T cells with anti-CDS and anti-
CD81 antibody. (A) Molt4 cells (Experiments 1-3) or fresh primary T cells 
(experiment 4) were exposed to HCV 44/M (Experiments 1 and 4), HCV 51/M-b 
(Experiment 2) and HCV 51 IM-a (Experiment 3) in the presence of anti-CD5, anti-
CD81 or relevant isotype antibody control. Infection outcome was evaluated by 
RT-PCR/NAH. (8) Plot presentation of the data on inhibition of HCV RNA 
expression determined by RT-PCR/NAH assay in cells challenged with HCV 
which were obtained for all experiments performed including those shown in (A). 
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Overall, the data from 7 separate experiments with anti -C~S mAb and 4 
with anti-COB1 mAb using three different HCV inocula gave a mean inhibition of 
67.2% (SEM 11 .6) and 49.1% (SEM 2S.6), respectively, in HCV RNA expression 
in Molt4 target cells (Figure 3.88). 
Furthermore, silencing of CDS expression with lentiviruses encoding CDS-
specific shRNAs significantly (P<O.OS) inhibited HCV RNA expression which was 
accompanied by the loss of virus RNA replicative strand in MoIt4 cells relative to 
those transduced with control shRNA or untreated cells (Figure 3.9A and 8) 
This finding was supported by the significantly lower level (P<O.OS) of HCV RNA 
released by CDS-silenced cells compared 10 those produced by untransduced 
Molt4 or by Molt4 transduced with scrambled shRNA (Figure 3.90) . It should be 
noted that selection of the cells in the presence of puromycin led to a partial 
decrease in their susceptibility to HCV infection as evidenced by the lower levels 
of HCV RNA in cells transduced with scrambled shRNA relative to those of 
untransduced cells (Figure 3.9E) . The level of CD81 expression was not affected 
in these experiments (Figure 3.9C) . The involvement of CDS in the HCV entry 
was finalIy examined by transfection of CDS-negative, CD81-positive human 
embryonic kidney 293 fibroblasts with comp lete human CDS cONA and then 
exposing transfected cells to HCV. Up to 8S% of HEK-293 celIs became CDS 
reactive (designated as 293-COS), while those transfected with the empty vector 
(293-EV cells) remained negative (Figure 3.10 A) . At 4 days post virus exposure, 
293-COS cells, but not 293-EV cells , expressed virus pos itive and negative RNA 
strands (Figure 3.10 8) and displayed NSSa protein (Figure 3.10 C) 
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Figure 3.9. Inhibition of CD5 expression in Molt4 cells makes them res istant 
to HCV infection. (A) Clones M-S and M-6 of lentiviral particles encoding COS-
shRNA were most effective in knocking down COS protein as revealed by flow 
cytometry with anti-CDS antibody. (8) Inhibition of transcription of CDS but nol (C) 
C081 with M-S and M-6 clones as quantified by real-lime RT-PCR. (D) Molt4 
transduced with clone M-S or M-6, scrambled shRNA or native cells were 
challenged with HCV 44/M and after 7 -day culture HCV released to culture 
supernatant was quantified by real-time RT-PCR. (E) Replicating virus was 
identified by detection of HCV RNA negative strand. Specificity and 
contamination controls were the same as described in the legend to Fig . 3. 1. B-
actin expression was used as a loading control , and recombinant human actin 
(rActin) as a positive control. 
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The association between cell positivity with CDS and cytoplasmic 
expression of NSSa protein was clearly apparent This demonstrated that the 
presence of CDS facilitated infection of these otherwise CDS-negative and HCV-
nonpermissive cells, albeit at a relatively low level (~ 1% of NSSA-positive cells) 
It is of note that our attempts to infect T cell lines, primary T cells and 
PBMC or 293-CDS cells with laboratory HCV JFH-1 strain were not successful. 
This may suggest that the ability to infect T lymphocytes is a characteristic of 
native, patient-derived HCV and, as we have found , does not depend on HCV 
genotype (G_ Skardasi and T.I. Michalak, unpublished data) (242) . 
This study is the first to identify a molecule essential for the cell -specific 
HCV entry to human lymphocytes. In addition to primary T lymphocytes, only T 
cell lines displaying moderate to high levels of CDS protein were found 
susceptible to HCV infection despite of comparable expression levels of CDB1 , 
the accepted customary HCV co-receptor Since anti-CDS and anti-CD81 mAb 
inhibited infection of permissive T cells, this may argue that both of these 
molecules are required for HCV entry to T cells. Notably, the ability of anti-CDB1 
to inhibit infection of human T cells with wild -type HCV was previously 
documented (242, 243)_ Considering the restricted expression of CDS, which in 
adults is essentially limited to T cells and a minor subset of B cells , it is likely that 
while CD81 may contribute to a broad recognition of cells by HCV, CDS facilitates 
HCV tropism specifically towards lymphocytes. On this note, while we clearly 
documented in this study the involvement of CDS in T cell susceptibility to HCV 
infection, it remains to be established whether this protein may also playa role in 
100 
HCV entry to B cells. Since the factors mediating HCV entry to hepatoma Huh? 
cells reported thus far are not unique to hepatocytes, CD5 is the first molecule 
identified that governs cell permissiveness to HCV in a cell-type specific manner. 
Our findings provide not only a direct insight into the nature of HCV 
Iymphotropism, but also open new options for the development of antiviral 
approaches targeting HCV that propagates in the lymphatic system. Although 
this is not yet fully appreciated site of extrahepatic HCV occurrence, it may in fact 
constitute under certain clinical conditions the largest reservoir of a potentially 
pathogenic virus 
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Figure 3.10. HEK-293 cells transfected with CDS become susceptible to 
HCV. (A) HCV-resistant, CDS-negative 293 cells were transfected with plasmid 
encoding human CDS. (8) 293 cells transfected with COS (293-CoS) or empty 
vector (293-EV) were exposed to HCV S1fM-b inoculum and examined for HCV 
RNA positive and negative strands by RT-PCR/NAH as described in Materials 
and Methods. Specificity and contamination controls were outlined in the legend 
to Fig . 1. B-actin expression was used as a loading control. (C) 293-EV, 
uninfected 293-COS and 293-COS challenged with HCV 44/M or S1/M-b inoculum 
were stained with anti-COS and anti-NSSa antibody, and examined by confocal 
microscopy. Nuclei were counterstained with oAPI. Images captured al X60 
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CHAPTER FOUR: 
DIFFERENTIAL EXPRESSION OF HEPATITIS C VIRUS 
CANDIDATE RECEPTORS IN HUMAN T LYMPHOCYTES PRONE 
OR RESISTANT TO WILD-TYPE VIRUS AND HEPATOMA CELLS 
SUSCEPTIBLE TO INFECTION WITH HCV JFH-1 CLONE. 
4.1. Introduction 
Hev is a hepatolropic virus that also propagates in the human immune 
system. Recently, a lymphocyte-specific CDS glycoprotein has been identified as 
an essential factor for infection of normal human T lymphocytes with wild-type 
HeV. However, several other molecules have been proposed as receptors 
mediating HeV tropism towards human hepalocyles based on the studies 
applying laboratory adapted HeV strains or pseudoparticles and hepatoma cell 
lines . To assess whether these candidate receptors may playa role in infection 
of T lymphocytes, we characterized expression of SR-81, CLON-1 , 4 and 6 and 
OCLN. as well as CDS and CD81, in HeV-prone and resistant T cell lines and 
primary T lymphocytes in comparison to Huh7.5 and HepG2 hepatoma cells and, 
when feasible, PHH. The results showed that, although SR-B1 was transcribed 
in all cell types examined, only HCV-resistant PM1 and CEM T cells and 
hepatoma cell lines displayed SR-81 protein. CLDN-1 protein was detected 
exclusively in HCV-resistant PM1 cells, while CLDN-4 and CLDN-6 were found at 
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exclusively in HCV-resistant PM1 cells, while CLDN-4 and CLDN-6 were found at 
comparably high levels in all cells tested, except HepG2 cells, Interestingly, 
OCLN was displayed by HCV-susceptible MoJt4 and Jurkat T cell lines, but not by 
PBMC and occasionally only at low levels by primary T celis, Finally . CDS was 
presented by HCV-susceptible Molt4 and Jurkat T cell lines, primary T cells and 
PBMC but not by HCV-resistant T cell lines and hepatoma cells , while CD81 was 
expressed at comparable levels in all cells, except HepG2. Since involvement of 
CDS and CD81 was previously documented, a role of OCLN in infection of T 
lymphocytes by wild-type HCV was the focus of the subsequent investigation. In 
this regard, knocking down OCLN with specific shRNA in HCV-prone Jurkat T 
cells inhibited HCV infection, while de novo infection with HCV downregulated 
OCLN and CD81, upregulated CDS, but did not modify SR-B1 expression. It was 
also uncovered that suppression of OCLN in T cells inhibited the display of HCV 
envelope protein without modifying virus genome transcription The data 
suggested that while OCLN may playa role in infection of virus-susceptible T cell 
lines, its contribution to infection of normal human primary T cells is less likely, 
pointing to a difference in factors determining permissiveness of cultured tumor-
derived and primary cells to HCV. Overall, while no association between 
expression of SR-B1 or CLDN-1 and T cell susceptibility to HCV infection was 
found, CDS was confirmed to be essential for HCV Iymphotropism with CD81 
contributing as a potential coreceptor. Our study narrowed the range of cellular 
factors utilized by wild-type HCV infecting human T lymphocytes amongst those 
previously identified as receptors using HCV preparations and Huh7,S cells. 
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Their identification may affect future development of preventive and therapeutic 
strategies against HCV. 
HCV is a positive single stranded RNA virus that chronically infects more 
than 170 million people. This infection represents a major health problem 
worldwide despite significant advancements in blood -screening techniques 
Currently, there are no vaccines preventing HCV infection, however the new 
therapies show a significantly improved anti-viral potency and augmented rates of 
virus elimination as determined by measurements of plasma HCV RNA by the 
currently available clinical laboratory assays (57 , 227, 262). The efforts to 
establish a robust HCV culture system have succeeded in recent years by 
transfecting human hepatoma Huh7 cells with a full -length HCV derived from a 
Japanese patient with fulminant hepatitis C (JFH-1), which resulted in secretion 
of in vitro infectious HCV particles (HCVcc) (231 , 403, 430) . This infection model 
and other HCV surrogate systems, such as HCVpp (28, 346) , were utilized to 
identify receptors mediating HCV infection of Huh7 cells and related cell lines. As 
a result, tetraspanin C081 (322), glycosaminoglycans (147), SR-B1 (28 , 363), 
and the TJ proteins CLDN-1 (102) and OCLN (32, 323) have been proposed as 
factors determining HCV tropism to human hepatocytes. However, it remains 
uncertain to what degree these models reflect natural infection of hepatocytes 
with wild-type virus . An attempt to infect PHH with HCV JFH-1 clone using 
micropatterened co-cultures resulted in detection of virus trace signals that 
sustained for several weeks as revealed by highly sensitive reporter systems; 
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however neither HCV RNA positive and negative strands nor viral proteins were 
detected (324). 
Accumulated experimental and clinical evidence indicate that HCV infects 
not only hepatocytes but also cells in extrahepatic compartments, particularly 
those of the immune system, as well as astrocytes and glial cells (127, 412). In 
regard to infection of circulating lymphoid cells, studies on HCV 
compartmentalization in patients with either symptomatic chronic or clinically 
silent infection documented HCV replication in both T and B lymphocyte subsets 
and in monocytes (93, 314). The susceptibility of human primary T lymphocytes 
ex vitro and particular T cell lines to infection with patient-derived HCV and their 
ability to support the entire cycle of HCV replication in culture have also been 
demonstrated (242, 243, 360, 373). The propensity of HCV to infect the host's 
immune system is consistent with a significanlly greater prevalence of 
Iymphoproliferative disorders, such as mixed cryoglobulinemia and non-
Hodgkin's lymphoma, in patients infected with HCV (42 . 69, 149, 192,347). In 
contrast to the several cellular molecules proposed to be mediators of HCV 
tropism towards hepatocytes. factors determining HCV Iymphotropism are just 
being recognized . In our recent study. a lymphocyte-specific glycoprotein CDS, 
belonging to the scavenger receptor cysteine-rich family. has been found to be 
essential for infection of human T lymphocytes with wild-type HCV (360). A 
contribution of CD8l to infection of T cells has also been demonstrated (242, 
243, 360). In the current study, the expression of SR-Bl , CLDN-l , CLDN-4, 
CLDN-6 and OCLN, as well as CDS and CD81, in HCV-prone and HCV-resistant 
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human T cell lines and in human primary T lymphocytes was investigated to 
assess their potential contribution to HGV infection of lymphocytes and to 
compare their expression with that in hepatoma JFH-1 -prone Huh7.5 and JFH-1-
resistant HepG2 cell lines. Based on the results from this comparative analysis, 
we subsequently examined involvement of OGLN in HCV Iymphotropism 
4.2. Materials and Methods 
4.2.1. Cell lines, primary celJs and culture conditions. 
Molt4 (CRL-1582) and Jurkat (TIB-152) T cell lines were provided by the 
ATGG (Manassas, VA). PM1 cells were acquired from the National Institutes of 
Health AIDS Research and Reference Program (Rockville, MOl and CCRF-CEM 
cells (GEM, ACC-240) from the Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (Braunschweig, Germany). Molt4, Jurkat and GEM cell lines 
were originally derived from patients with acute T lymphoblastic leukemia (125), 
while PM1 from a patient with acute cutaneous T cell lymphoma (241 ). The cells 
were cultured at 1 x 105 cells/well in 5 ml of medium containing RPMI 1640 
supplemented with 10% heat-inactivated FCS, 2 mM glutamine and 0.1 mM 
nonessential amino acids (Invitrogen). In some experiments, the cells were 
stimulated for 72 h with PMA (Sigma-Aldrich) at 50 ng/ml in the presence of 500 
ng/ml ionomycin (Sigma-Aldrich) , as reported (360) 
PBMC were isolated from two healthy donors by gradient centrifugation in 
Ficoll-HyPaque (Pharmacia Biotech, Quebec, Canada) (315) . Primary T 
lymphocytes were affinity-purified from monocyte-depleted PBMC by negative 
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selection using MACS magnetic microbeads (Miltenyi Biotec). as reported (319, 
360). CD4+ and CD8+ T cell subsets were isolated from PBMC by affinity 
chromatography using AutoMacs Pro-Separator system (Mi ltenyi Biotec) 
following the manufacture's instruction. T cells and their subsets were 97-98% 
pure by flow cytometry analysis. For some experiments, PBMC and affinity-
purified primary T cells were stimulated for 72 h with 5 1J9/ml PHA (Sigma-Aldrich) 
in the presence of 20 IU/ml human r1L-2 (Roche Molecular Diagnostics). as 
described (243. 315) . 
HCV replicon AB12-A2FL Huh7 cell line, containing full-length HCV 
genotype 1 b was provided by Drs Christopher Richardson and Joyce Wilson 
formerly from Ontario Cancer Institute, University of Toronto, Canada. The 
human hepatoma Huh7.5 cells were provided by Dr. Rodney Russell from 
Memorial University of Newfoundland, SI. John's. NL Canada. Human hepatoma 
HepG2 (HB-B065) and HEK-293 (CRL-1573) cell lines were supplied by ATCC. 
The cells were maintained in DMEM supplemented with 10% FCS. PHH isolated 
by micro perfusion of a healthy portion of the liver of a 58-year old male donor 
were purchased from Dominion Pharmakine (Derio-Bizkaia. Spain) (163). 
4.2.2. HCV Infection. 
Cultured T cell lines, either intact or stimulated with PMAlionomycin for 72 
h at 1 x 105 cells/well , supplemented with 2 ml of culture medium in 6-wetl plates 
were exposed for 24 h to -1 X 105 vge of HCV genotype 1 a-positive plasma poor 
prepared from patients with progressing CHC who were antiviral treatment naive 
Infectivity of the pool was established in preliminary experiments using Molt4 and 
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Jurkat T cell lines and PHA-stimulated primary T lymphocytes, as previously 
reported (243, 360) . Cells exposed under identical conditions to an equivalent 
volume of NHP served as negative controls. After exposure to HCV or NHP, the 
cells were extensively washed , suspended in fresh culture medium and cultured 
for 4-7 d.p.i ., as reported in detail previously (360). 
4.2.3. Silencing of OCLN by RNA Interference. 
Lentiviral transduction particles encoding different human OCLN-specific 
shRNA (clones: TRCN0000158463, TRCN0000158804. TRCN0000159413. 
TRCN0000159613 and TRCN0000159771 ; designated as C-1 to C-5) with a titer 
between 2.9 x 107 and 3.9 x 107 infectious virus and 4.6 x 107 non-target control 
transduction particles (#SHC001V; designated as irr) were prepared by Sigma-
Aldrich . 1 x 103 Jurkat cells in 1001-11 RPMI 1640 medium was transduced at 4 
multiplicity of infection (Mal) in 96-well plates in the presence of 2.5 I-Ig/ml 
polybrene (Sigma-Aldrich). Cells were spun down at 4 °c for 10 min at 2.000 
rpm. incubated at 37°C for 24 h, and allowed to revive in fresh medium for 
another 24 h. Transduced Jurkat cells were selected in the presence of 2 IJg/ml 
puromycin (Sigma-Aldrich) for 7 days. The level of OCLN expression was 
determined by real-time RT-PCR and Westem blotting (see below). Only C-1 , C-
2 and C-3 were used in subsequent experiments , since C-4 and C-5 were found 
to be toxic to Jurkat cells. Subsequently. Jurkat cells transduced with C-1. C-2 or 
C-3 or with the control scrambled shRNA (i.e., irr), and the nontransduced cells 
were used as targets in HCV infection following the procedure described above 
4.2.4. RNA and Transcription to cDNA. 
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Total RNA was extracted using Trizol (Invitrogen) RNA used for 
quantification of cellu lar genes was treated with DNAse, as reported (316) . cDNA 
was transcribed with Moloney murine leukemia virus RT (Invitrogen), as 
previously described (315, 360, 319) 
4.2.5. HCV Detection. 
HCV RNA positive and negative (replicative) strands were detected using 
cDNA derived from 1 or 2 ~g and 2 or 3 ~g, respectively, of total RNA and the 
strand-specific amplification conditions reported in detail previously (315, 360) 
The specificity of the signal detection and validity of controls were normally 
confirmed by NAH with 32P_labeled rHCV UTR-E2 as a probe (315). The 
sensitivity of RT-PCR/NAH assay for HCV RNA-positive strand identification was 
<10 vge/ml «2 IU/ml) or <5 vge/~g of total RNA. while that for HCV RNA-
negative strand was 25-50 vge/lJg of total RNA (315, 360) . 
4.2.6. Cloning of SR-B1 and tight junction gene sequences. 
To facilitate quantification of the levels of expression of SR-B1 and TJ 
genes in the cells examined, cDNA transcribed from human PBMC or liver was 
amplified by PCR with primers shown in Table 4.1. Amplified fragments were 
cloned into the dual promoter vector PCRII using the TOPO TA cloning system 
(Invitrogen) and then excised and sequenced in both directions to confirm the 
gene specificity. The cloned fragments were used as quantitative standards to 
establish the sensitivity of real-time RT-PCR assays and to determine the copy 
numbers of the amplified gene sequences. Human CD5 and CD81 gene 
fragments were previously generated (360) . 
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Table 4.1. Primer sequences used for real-time RT -peR analysis 
Gene Forward primer Reverse primer 
CDS S'-TCAAGCGTCAAAAGTCTGCC-3' S'-AGCCACACTGGAGGTTGTTG-3' 
COBl S'-ACAAGGACCAGATCGCCAAG-3' S'-AGTCAAGCGTCTCGTGGAAG-3' 
OCLN 5'-TGCATGTTCGACCAA TGC-3' S'-AAGCCACTTCCTCCATAAGG-3' 
SR-81 5'-TCGCAGGCA TTGGACAAACT -3' S'-CTCCTTATCCTTTGAGCCCTTTT-3' 
ClON-1 S-TACTCCTATGCCGGCGACA-3' S'-GACATCCACAGCCCCTCGT-3' 
CLDN-4 S'-CATCGGCAGCAACATTGTCA-3' S'·GCACCTT ACACGT AGTTGCT -3' 
CLON-6 S'-AGAAGGATTCCAAGGCCCG-3' S'-GATGTTGAGTAGCGGGCCAT-3' 
Actin S'-CATCCTCACCCTGAAGTACC-3' S'-CATACTCCTGCTTGCTGATCC-3' 
HPRT S'-TGACACTGGCAAAACAATGCA-3' S'-GGTCCTTTTCACCAGCAAGCT-3' 
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4.2.7. Real-Time RT-PCR. 
The expression of SR-B1 , CLON-1, CLON-4, CLON-6, OCLN, C081 and 
C05 was quantified by real-time RT-PCR during 40 cycles using the UghtCycier 
480 (Roche Molecular Diagnostics) Reactions were perfonned in 10 IJL 
volumes , each containing 2 IJL cDNA derived from 50 ng DNAse-treated RNA 
using primer pairs shown in Table 4.1 _ Annealing temperature of 56°C were used 
for amplification of OCLN, CD81 , [3-actin and HPRT, while 60 °C annealing 
temperature for SR-B1, CLoN-1, -4 and -6 and C05. Expression of genes of 
interest was evaluated in at least 4 separate experiments. [3-actin and HPRT 
were used as loading controls. The sensitivity of the real-time RT-PCR assays 
was determined using serial. 10-fold dilutions of the cloned fragments of the 
genes of interest and was found to be between 10 to 102 copies/reaction. In 
regard to HCV RNA positive strand quantification, the copy numbers were 
enumerated by real-time RT-PCR using 10-fold serial dilution of rHCV UTR-E2, 
as described previously (314) 
4.2.8, Western Blotting. 
Cells were treated with ice-cold RIPA buffer (1 % NP-40, 0.5% DOC, 0.1% 
50S, 150 mmollL NaCI in 50 mmollL Tris , pH B.O; Sigma-Aldrich) and cellular 
debris removed by centrifugation. Proteins were separated by 50S-PAGE at 20 
\-Ig proteinllane or as indicated and then blotted onto a nitrocellulose membrane 
(Amersham Biosciences) by wet transfer using the Bio-Rad SO cell system (Bio-
Rad) (274). The blots were incubated with 5% skimmed milk in Tris-buffered 
saline, pH 7.4 , for 1 h at room temperature and exposed overnight at 4°C to 
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working dilutions of appropriate antibodies diluted in the same blocking buffer 
Mouse mAb to SR-B 1 (clone 2S/CLA-1) and OClN (clone 19) were purchased 
from B.D. Biosciences, rabbit antibodies to ClDN-1 and ClDN-2 were from 
Invitrogen, wh ile rabbit antibodies to ClDN-6 (ab7S0SS) and CDS (abS2964) 
were acquired from Abcam Inc. (Cambridge, MA). In some instances, the 
presence of HCV envelope protein in infected lymphocytes and control AB12-
A2Fl Huh7 cells was detected with anti-E2 mouse mAb provided by Dr. Arvind 
Patel , University of Glasgow, Glasgow, United Kingdom), as reported (360) . 
Detection of l3-actin with specific rabbit mAb (Sigma-Aldrich) served as protein 
loading control. Reactions were developed with horseradish peroxidase-
conjugated goat anti-rabbit or goat anti-mouse IgG F{ab'h antibodies (Jackson 
ImmunoResearch) and visualized using an ECl detection kit (Sigma-Aldrich). 
Protein signals were quantified by densitometry using the computer-assisted 
image processing app lication ImageJ from the National Institute of Health (1S0) . 
For comparative eva luations, the density of the protein signals detected in 
Huh7.S cells we re taken as 100%, except for COS protein for which the signa l 
detected in affinity-purified primary T cells was used as 100% (see Figure 4.5) . 
4.2.9. Statistical Analyses. 
Results were analyzed by a one way ana lysis of variance or unpaired 
Student t test with Welch's correction using GraphPad Prism software (Graph Pad 
Software Inc.). Differences between experimental cond itions were considered to 
be sign ificant when two-sided P values were below or equa l to 0.05. 
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4.3. Results 
4.3.1. Moft4 and Jurkat T Cells and Primary T Lymphocytes Demons trate 
Comparable Susceptibility to Infection with Wild-Type HCV. 
Primary human T cells, PBMC from which the T cells were derived, and T 
cell lines, including HCV-prone Moll4 and Jurkat cells and HCV~resistant PM1 
and CEM cells (360) , were exposed to patient-derived HGV and subsequently 
examined for expression of HGV RNA, as described in Materials and Methods 
As the results showed (Figure 4.1) , Moll4 and Jurkat T cells displayed HCV RNA 
positive strand at levels comparable to those in primary T lymphocytes and 
PBMG (P=0 .6) , while GEM cells where entirely nonreactive and PM1 cells only 
occasionally demonstrated a low level, i.e. , in one of 3 experiments (Figure 4. 1A) 
These results were compatible to those previously reported , including the 
observation that PM1 cells have potential to become prone to HCV infection 
when activated (360). 
Similarly as HCV RNA positive strand, the negative strand was detected at 
similar levels in Molt4 and Jurkat T cells and in primary T cells and PBMC after 
exposure to the same HCV inocula, as illustrated for one of the inoculum in 
Figure 4.1B. In contrast, PM1 and CEM cells, which have been found in the 
previous study to be resistant to HCV infection (360) , were HCV RNA replicative 
strand nonreactive following exposure to the same infectious virus . 
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Figure 4.1. Identification of HCV in T cell lines and primary T lymphocytes 
investigated. Molt4, Jurkat, PM1 and CEM T cell lines, affinity-purified primary T 
cells and PBMC were exposed to plasma-derived, wild-type HCV and 
subsequently evaluated for the expression of HCV RNA positive strand by real-
time RT-PCR and HCV RNA negative strand by RT-PCR/NAH _ T cell lines were 
analyzed after 7 d.p.i. Primary human T cells and PBMC isolated from healthy 
donors were exposed to the same virus as T cell lines and analyzed for HCV 
after 14 d_p_i., as described in Materials and Methods. (A) Quantification of HCV 
RNA positive strand. Data represent means from 3 separate experiments and 
are presented as percentage of the expression found in primary T cells that was 
taken as 100%_ (B) Representative example of the detection of HCV RNA 
negative strand by RT -PCR/NAH in the cells from one of 3 experiments shown in 
A Synthetic HCV RNA positive (pos) and negative (neg) strands at 105 
copies/reaction confirmed the assay specificity for detection of the virus RNA 
replicative (negative) strand. Water amplified in direct (OW) and nested (NW) 
reactions and a mock extraction served as contamination controls The positive 
signals showed the expected 244-bp oligonucleotide frag ments 
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4.3.2. Uniformly High Expression of CDS1 and Aberrant Transcription of 
SR·B1 Characterize T Cells Either Prone or Resistant to HCV Infection. 
Comparative analysis revealed that CD81 was ubiquitously expressed at 
similarly high levels in primary T cells. their CD4+ and CD8+ subsets and in all T 
cell lines investigated. independent of whether they were or were not susceptible 
to HCV infection. as well as in Huh7.5. PHH, and control HEK·293 cells (Figure 
4.2A) . The exception was HepG2 cells. Thus. C081 mRNA levels typically 
ranged between 106 and 107 copies per I-Ig of total RNA, but HepG2 cells 
transcribed the gene at about 1 03·fold lower levels (Figure 4.2A) 
Both HCV·susceptible and resistant T cell lines expressed SR· B1 at 
Significantly higher (P=0.007) levels than primary T cells . purified CD4+ or CD8+ 
T lymphocyte subsets or total PBMC. In general . primary T cells , their subsets 
and PBMC transcribed SR·B1 at the mean level of 3.9 x 103 .!. SEM 628 
copies/l-lg RNA, which was 2 to 3-fold lower (P=0.007) than that detected in the T 
cell lines (Figure 4.2B) . Moreover, HCV-resistant PM1 and CEM cells transcribed 
significantly more (P=0.001) SR-B1 compared to virus-prone Moll4 and Jurkat T 
cells. In regard to Huh7.5 and HepG2 hepatoma cells, no significant difference in 
SR-B1 expression was found (Figure 4.2B). Further. PHH expressed about 10-
fold less SR-B1 mRNA than Huh7.5 cells (P=0.001) (Figure 4.3B) . There also 
was sign ificantly lower transcription of SR-B1 in HCV-prone Moll4 and Jurkat 
cells (P=0.0001) and in primary T cells , their subsets and PBMC (P=0 .0001) than 
in Huh7.5 cells. 
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Figure 4.2. Quantification of CD81 and SR-B1 transcription in T cell lines, 
primary T cells, their CD4+ and CD8+ subsets, total PBMC, hepatoma-
derived cell lines, and human primary hepatocytes. (Al Expression levels of 
CD81. (8) Expression levels of SR-81 . An equivalent of 50 n9 DNAse-treated 
RNA was used as template for real-time RT-PCR quantifications. The results 
represent means ± SEM from 4 or more independent experiments and are 
presented as copies/tJ9 total RNA. For other details see Materials and Methods. 
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It is of note that the expression levels of house-keeping (l,-actin and HPRT 
genes were closely comparable in all cell types tested, with one minor exception 
Thus, the (l,-actin mRNA levels ranged between 107 to 108 copies/lJg total RNA 
with no statistically significant variations except PHH, in which approximately 10-
fold lower transcription level was detected (data not shown). For HPRT, highly 
comparable mRNA levels were detected in all cells examined, including PHH 
4.3.3. Expression of CLDN-1, -4 and ·6 Does Not Coincide with T Cell 
Susceptibility to HCV Infection. 
CLDN-1 mRNA level was found to be high in Huh7.5 cells (3 x 105 .!. SEM 
2x104 copies/lJg total RNA) , while HepG2 and PHH showed 10 to 100-fold lower 
copy numbers (P=0.002 and P=0.003. respectively) (Figure 4.3A) . In contrast, 
HCV-susceptible Molt4 and Jurkat T cells essentially did not express CLDN-1 , 
while PM 1, but not CEM, transcribed CLDN-1 at the level greater than 104 
copies/lJg RNA. Primary T cells, their CD4+ and CD8+ subtypes and PBMC 
demonstrated CLDN-1 mRNA levels between 1 x 102 and 1.5 x 102 copies/lJg 
RNA, which were significantly lower (P=0.0001) than that detected in Huh7,5 
cells (Figure 4.3A) 
The level of CLDN-4 expression was closely comparable in both HCV-
prone and HCV-resistant T cell lines, as well as in primary T cells or P8MC, and 
the differences in their transcription levels were not greater than 10-fold (Figure 
4.38). CD4+ and CD8+ T cell subtypes transcribed approximately 10-fold more 
CLDN-4 than the total primary T cells and these levels were comparable to that 
found in Huh7,5 celis. 
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Figure 4.3. Quantification of ClON-1 , ClON-4 and ClDN-6 expression in T 
cell lines and primary T lymphocytes, their subsets , P8MC, hepatoma cells 
and primary hepatocytes. (Al Expression levels of ClON-1; (8) Expression 
levels of ClON-4. and (C) Expression levels of ClON-6. The results are 
presented as mean copies1~g total RNA from at least 4 independent experiments 
123 
HepG2 transcribed CLDN-4 most efficiently and at levels which were significantly 
higher (P=0 .0001) than those detected in other cell types tested (Figure 4.38) . 
PHH showed CLDN-4 mRNA at the level comparable (P=0.7) to that identified in 
primary T cells and HCV-susceptible Molt4 and Jurkat T cells , which were 
approximately 100-fold lower than the level found in HepG2 cells (P=0.0001) 
In regard to CLDN-6, no significant difference (P=0 .14) was found in this 
gene expression between HCV-prone and resistant T cell lines and Huh7.S cells, 
while primary T cells , P8MC and PHH tended to transcribe approximately 10-fold 
lower levels than Huh7.S cells (P=0.01) (Figure 4.3C) . As in the case of ClDN-4, 
HepG2 cells expressed the highest levels of CLDN-6 among the cells tested 
(P=O.0001) 
4.3.4. High Expression of CD5 in Primary and Cultured T Cells and OCLN in 
T Cell Lines Coincides with Susceptibility to HCV Infection. 
In rega rd to CDS, which transcription is lymphocyte restricted and the 
presence of CDS protein has been identified to be essential for infection of T cells 
with HCV (360), it was confirmed that the gene expression was significantly 
greater (P=0.0001) in HCV-prone primary T lymphocytes, their C04+ and C0 8+ 
subsets , PBMC and in Molt4 and Jurkat T cell lines, as well as in HEK-293 cells 
transfected with human CDS serving as a control , than in virus-resistant PM 1 and 
CEM T cells (Figure 4.4A) . Furthermore, PHH and HepG2 cells did not 
transcribe this gene, while hepatoma Huh7.S cells displayed COS mRNA at the 
mean level of 9.6 x 103 .:t SEM 1.6 x 103 copies/lJg RNA (Figure 4.4A) . 
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Figure 4.4. Quantification of OCLN and CDS transcription in T lymphocyte 
lines and other cell types investigated in this study. (Al OCLN expression 
levels . (8) Expression levels of CD5. The results represent mean copieS/1J9 total 
RNA from at least 4 independent experiments. 
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OCLN mRNA was expressed at high levels (10 5_106 copies/l-lg RNA) in 
Huh7.5, HepG2, PHH and HEK-293 cells, while it was transcribed at 
approximately 10-fold lower (P=0.007) levels in HCV-susceptible Molt4 and 
Jurkat cells (Figure 4.4B). However, HCV-resistant PM1 and CEM cells, as well 
as PBMC and CD4+ and CD8+ T cell subsets transcribed OClN at 101-103-fold 
lower (P=0.0001) levels than the susceptible T cell lines (Figure 4.4B) . The total 
primary T cells demonstrated approximately 10-fold greater expression than their 
subsets or tota l PBMC and the reason behind that is not yet clear 
4.3.5. Display of CD5 and OCLN Proteins is Most Closely Associated with T 
Cells Susceptibility to HCV Infection. 
T cell lines, primary T cells, total PBMC, as well as Huh7.5 and HepG2 
cells were examined for the display of the HCV candidate receptor proteins by 
probing with appropriate antibodies. In regard to SR-B1 , this protein was 
displayed in HCV-resistant CEM (-6S% of the signal detected in Huh7.S cells) 
and PM1 (-40%), and at evidenlly lower levels in HCV-prone Molt4 (11%) and 
Jurkat (20%) T cells (Figure 4.SA). In contrast, HepG2 displayed approximately 
30% more of SR-B1 protein and control HEK-293 cells transfected with human 
CDS about twice less than Huh7.S cells . These results overall well corresponded 
to SR-B1 mRNA levels detected in the same celilypes (Figure 4.2B) . However, 
primary T cells , their CD4+ and CD8+ subsets and total PBMC were found to be 
SR-B1 protein ne9ative (Figure 4.SA and B) . This indicated that the SR-B1 
mRNA detected in these cells by real-time RT-PCR, ranging between 103 and 104 
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copies/l-lg RNA (Figure 4.28) , were not translated to the protein amounts 
detectable by Western blotting (Figure 4.5) 
In regard to the tight junction proteins, CLDN-1 protein was detected only 
in HCV-resistant PM1 T cells (-30% of the signal exhibited by Huh7.5 cells) and 
in HepG2 hepatoma cells (-1700;", of the signa l identified in Huh7.5 hepatoma 
cells), and at a lower level (-25"'/",) by control HEK-293 cells transfected with CDS 
(F igure 4.5A and 8) . Notably, primary T cells , their CD4+ and CD8+ subsets and 
total P8MC, as well as HCV-prone Molt4 and Jurkat cells were entirely CLDN-1 
protein nonreactive (Figure 4.5A and 8). This was consistent with ClDN-1 
mRNA data which showed the levels below 103 copies/lJg RNA in primary T cells 
and undetectable levels in HCV-prone Mo!t4 and Jurkat T cells (Figure 4.3A) . 
On the other hand , CLDN-4 a:1d CLDN-6 proteins were detected in all cell types 
at the levels which were essentially similar to that detected in Huh7.5 cells 
(Figure 4.5A) Again, CLDN-4 and CLDN-6 mRNA levels overall well-
corresponded to the protein signals identified in individual cell types (Figure 4.3A 
and 8). 
In regard to OClN protein, HCV-susceptible Molt4 and Jurkat cells 
displayed approximately 90% and 21 0% of the protein signal detected in Huh7.5 
cells , respectively (Figure 4.SA) . However, primary T lymphocytes presented the 
protein at about 10-fold lower level than Huh7.5 cells, while PBMC were 
nonreactive. Furthermore, PM1 and CEM T cells exhibited trace levels of OClN 
comparing to Huh7.5, i.e ., approximately 5% of the signal detected in Huh7.5 
cells (F igure 4.5A) . 
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Figure 4.5. Differential display of HCV candidate receptor proteins in HCV· 
prone and resistant T cell lines, primary T cells and their subsets, PBMC 
and hepatoma cell lines. Proteins were separated at 25 J-lglwell by 5DS-PAGE 
and after blotting probed with appropriate antibodies. l3- actin served as a loading 
control. (A) Identification of SR-B1 . CLDN-1. CLDN-4. CLDN-6. OCLN. CD5 and 
actin in T cell lines. primary T cells. PBMC. Huh7.5. HepG2 and in control HEK-
293 cells transfected with human CD5. The level of a given protein in a particular 
cell type is presented as a relative percentage of this protein signal detected in 
Huh7.5 thai was taken as 100%. except CD5 protein for which display in primary 
T cells was taken as 100%. (8) Detection of SR-81. CD5. CLDN-1 and actin in 
CD4+ and CD8+ subsets of primary T cell and in T cell lines investigated. The 
level of each protein in a particular ceillype was measured at least twice and was 
presented as a relative percentage of the protein density signal detected in PM1 
cells that was taken as 100%. 
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HepG2 and control CDS-transfecled HEK-293 demonstrated the protein at levels 
more than 4-fold and ?-fold greater than Huh7.S cells, respectively (Figure 4.SA). 
The density of OCLN protein signals appeared to well coincide with the gene 
expression levels detected in the same cells (Figure 4.4A) 
CDS protein was indentified in HCV-susceptible Molt4 and Jurkat T cell 
lines, primary total T cells and PBMC (Figure 4.SA) and in T cell subsets (data 
not shown) and at trace levels in PM1 but not in CEM cell lines. Huh7.S and 
HepG2 cells were CDS protein nonreactive, while control CDS-transfected HEK-
293 cells showed the protein signal at a level comparable to that detected in 
primary T cells and T cell lines prone to HCV (Figure 4.SA). In general , there 
was a good agreement between CDS protein display and the CDS gene 
transcriptional activity identified in the cells investigated. 
4.3.6. HCV Infection Downregulates CD81 and OCLN but Augments CDS 
Expression in Virus-Prone T Cell Line. 
Jurkat and Molt4 T cells exposed to wild-type HCV or NHP were cultured 
for S days and examined for expression of CDB1 . SR-81 , OCLN and CDS by the 
appropriate real-time RT-PCR assays. The result showed a significant decrease 
in the level of transcription of CDBl (P=O.OO1) and OCLN (P=O.OOOB) in HCV-
infected cells comparing to those uninfected, as was shown for Jurkat cells 
(Figure 4.6) . In contrast, CDS mRNA levels were significantly (P=O.Ol) 
augmented in infected cells , while that of SR-B1 remained unchanged after 
infection (P=O.54) (Figure 4.6) . 
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Figure 4.6. Transcription of, OCLN, CD81, CD5 and SR-B1 in Jurkat cells 
infected with wild-type HCV. Jurkat T cells infected with plasma-derived HCV 
or exposed to the equivalent amount of normal human plasma (NHP) were 
cultured for 5 days and then evaluated for the expression of (Al COB1 . (8) OCLN. 
(C) COS and (D) SR-81 by appropriate real-time RT-PCR assays. The results 
are presented as ratios of mean copy numbers/)Jg total RNA from 4 independent 
experiments of a given gene to actin 
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This differential effect of HCV infection on the expression of CD81 , OClN 
and CDS, but not SR-B1 gene, provided supporting evidence that the respective 
proteins might be engaged in the infection process induced by HCV in T cells. 
4.3.7. Knockdown of OCLN Inhibits HCV Replication in HCV-Prone T Cell 
Line. 
Since the data on the gene and the protein expression implied that OClN 
may contribute to the susceptibility of Molt4 and Jurkat T cells to HCV infection, 
although rather unlikely to the receptiveness of primary T lymphocytes to this 
virus, the effect of the suppression of OClN transcription on the infectivity of 
Jurkat cells with wild-type HCV was investigated. In this regard. Jurkat cells were 
transduced with OClN-shRNA C-1 , C-2 or C-3 or with the control irrelevant 
shRNA, and then exposed to HCV. The results showed that the level of OClN 
expression was Significantly (P=O.0001) down regulated in OClN-shRNA-
transduced cells compared to control cells treated with irrelevant shRNA (Figure 
4.7A). It also is of note that mRNA levels of CD81 (Figure 4.78), SR-81 (Figure 
4.7C) and CDS (Figure 4.70) were not affected by treatment with either OClN-
shRNA or irrelevant shRNA. Further, the display of OClN protein was inhibited 
by -50% after transduction with OClN-shRNA comparing to the control cells 
(Figure 4.7E). Most interestingly, although the knocking down of the OClN 
expression had no effect on the level of HCV RNA positive and negative 
(repl icative) strands detected after exposure to virus, comparing to the control 
cells transduced with irrelevant shRNA (Figure 4.7F and G, respectively) , the 
display of HCV E2 protein was totally inhibited in celis treated with OClN-shRNA 
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but not in those with irrelevant shRNA (Figure 4.7H). This suggested that in fact 
downregulation of OCLN severely affected HCV replication , most likely on the 
posltranscriptionallevel. 
4.4. Discussion 
Despite that HCV is a hepatotropic virus and infection of hepatocytes is 
chiefly responsible for manifestations of hepatitis C, sUbstantial experimental and 
clinical evidence indicate that HCV replication can also be supported by cells of 
the immune system, including T lymphocytes. The HCV RNA negative strand, 
representing virus genome replicative intermediate, viral proteins and virus 
sequences distinct from those occurring in the liver have been identified in total 
PBMC, T and B lymphocytes, CD4+ and C08+ T cell subsets, and in monocytes 
from patients with CHC (93, 203, 216, 299, 314, 339, 413) and from individuals 
with clinically apparent sustained virological response to FNa or IFNa-RBV 
therapy for CHC (312, 314-316, 319, 339). HCV infection resulting in production 
of infectious virus has also been documented in de novo infected mitogen-
stimulated normal human T lymphocytes (242, 243, 437) , cultured B cells (23, 
287) and monocytes (93, 214) . A recent study from this laboratory has shown 
that naturally occurring HCV utilizes C05, a lymphocyte unique glycoprotein, to 
infect T cells (360) . This protein is not displayed by PHH or hepatoma-derived 
cell lines, indicating that HCV uses a distinct molecular strategy to enter into 
hepatocytes and lymphocytes 
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Figure 4.7. Effect ofOCLN knockout on infection of Jurkat T cells with wild· 
type HCV. Jurkat cells transduced with either OCLN-specific shRNA or control 
irrelevant (irr) shRNA were infected with wild -type virus as described in Material 
and Methods. The levels of transcription of (A) OCLN, (8) CD81, (C) SR-81 and 
(D) CDS were evaluated at 7 d.p.i. using appropriate real-time RT-PCR assays. 
The data are presented as mean copy numbers/~g total RNA from 2 independent 
experiments. (E) Western blot identification of OCLN protein in Jurkat cells 
transduced with either irr-shRNA or OCLN shRNA. I>--actin served as a loading 
control. The level of OCLN protein in the cells transduced with OClN shRNA is 
presented as a relative percentage of the OClN protein signal detected in control 
that was taken as 100%. (F) Quantification of HCV RNA positive strand in Jurkat 
cells transduced with either control irr-shRNA or three separate clones of OClN 
shRNA and subsequently infected with wild-type HCV. The data represent the 
mean copy (vge) numbers ± SEM from 2 independent experiments. (G) Detection 
of HCV RNA negative (repl icative) strand in Jurkat cells transduced with either irr-
shRNA or three different clones (C1 -C3) of OClN shRNA and infected with HCV, 
as indicated in (F). Intact Jurkat cells not transduded or infected with HCV were 
used as a negative control. OW, NWand mock as described in the legend to Fig 
4.1. (H) HCV E2 protein detection in Jurkat cells transduced with irr -shRNA or 
with three OClN shRNA clones (C1 -C3) and then infected with HCV by Western 
blotting. Huh7 replicon expressing and na"lve Huh7 cells served as HCV E2 
positive and negative controls, respectively. ~-actin served as a loading control 
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Subsequently, this may contribute to different kinetics of virus replication 
and persistence in these two very distinct cell types . As in other chronic viral 
infections (72 , 302) , HCV-infected T cells constitute a reservoir in which virus can 
persist independently from its progeny multiplying in hepatocytes. In this regard , 
distinct HCV variants have been identified in the different compartments of virus 
occurrence, i.e ., liver and circulating Iymphomononuclear cells (93, 94 , 296, 296, 
299, 312), and HCV has been detected in PBMC but not in the livers of 
individuals with persistent low-level (occult) infection (299, 312, 312, 339) . It has 
also been suggested that HCV variants inhabiting lymphatic cells can reinfect 
newly transplanted livers (82 , 216, 340) . Furthermore. HCV immune evasion and 
drug resistance may result, at least in part, from the virus ' ability to persistently 
replicate in the lymphoid cell compartment , as in the case of hepatitis B virus 
infection in patients on suppressive antiviral therapy (73) 
The host's factors facilitating HCV infection of human cells were mainly 
recognized using HCV JFH-1 clone or HCVpp and human hepatoma cell lines 
The JFH-1-Huh7.5 model provides a robust system for HCV replication. In this 
system. JFH-1 HCVcc infect hepatoma Huh7.5 cells which are characterized by a 
deficient innate immune response due to the lack of RIG-I expression, perturbed 
signalling and endocytic pathways, and dysfunctional mitochondria (51, 52 , 83, 
188, 205, 207) . On the other hand, the genetic variance between JFH-1 or 
related HCV clones and the wild-type HCV may additionally affect the nature and 
the strength of interactions with molecules mediating HCV cell attachment and 
entry, increasing the uncertainty to what degree the initial stages of infection of 
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primary hepatocytes with wild-type virus are mirrored in the JFH-1 -Huh7.5 
system (403). In this regard, JFH-1 produced in Huh7.5 cells have failed to infect 
human PBMC or primary T cells in culture (255), which are prone to wild-type 
HCV in both in vivo and in vitro conditions (243,314). Also, JFH-1 HCVcc were 
not able to efficiently infect chimpanzees (193) or polarized PHH in MPCCs 
despite that these cells display all proposed HCV receptors (324) 
Previously, we have found that some T cell lines, such as CEM and 
unstimulated PM1, are resistant to infection with wild-type HCV, in contrast to 
Molt4 and Jurkat cells which can support propagation of wild-type virus (360). In 
the current study, we have also established that Molt4 and Jurkat cells are 
susceptible to infection and maintain HCV replication at approximately the same 
levels as primary T lymphocytes after exposure to the same HCV inocula. In 
order to identify cellular factors , other than CD5 and CD81 (360), which 
determine T cell susceptibility to HCV, we analyzed expression of the proposed 
HCV candidate receptors in HCV-prone and resistant T cells , and compared 
them to JFH-1-susceptible Huh7.5 and JFH-1-resistant HepG2 hepatoma cells. 
This comparative analysis revealed that some of the postulated HCV receptors 
are not involved in determining HCV Iymphotropism, while others, such OCLN. 
may contribute to infectivity of T cell lines but seemingly unlikely primary T cells . 
Considering distribution of the ind ividual HCV receptors proposed in the 
cells tested, the expression of tetraspanin CD81, which is known to require other 
cellular factors to mediate HCV binding and entry into hepatocytes (77), was 
detected at comparable levels in all lymphocytic and non-lymphocytic cells 
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examined, except HepG2 (see Fig. 2A). Although CD81 was found to contribute 
to infection of T cells , based on the fact that antibodies against CD81 inhibited 
infection with wild-type virus of both primary T cells and Molt4 and Jurkat cells 
(243, 360) , CD81 is not the limiting factor of the infection since HCV-resistant 
PM1 and CEM cells express CD81 at similar levels as those prone to this virus 
Another HCV candidate receptor is SR-81 . expressed at high levels in 
liver tissue and is considered an important HCV entry factor. Studies using 
soluble HCV E2 protein and HepG2 cells lacking CD81 but expressing SR-B1 
showed infection of these cells. This interaction was found to be highly selective 
since neither mouse SR-BI nor the closely related human scavenger receptor 
CD36 was able to bind E2 (363) . However, although antibodies to SR-B1 
markedly inhibited the binding of E2 or HCV-like particles to primary tupaia 
hepatocytes, they were not able to block infection with wild-type , plasma-derived 
HCV (24), implying an important limitation of the surrogate soluble E2 or HCV-like 
particles when applied for recognition of the actual wild-type virus-host cell 
interactions. Considering lymphocytes, a significantly (P=O .007) lower expression 
of SR-B1 was detected in T cell lines, primary T cells and PBMC, which was 
comparable to thaI identified in Huh7.5, HepG2 and PHH. Moreover, HCV-
resistant PM1 and CEM cells transcribed significantly (P=O .001) more SR-B1 
than HCV-susceptible Molt4 and Jurkat T cells. Also, despite being susceptible 
to HCV, primary T cells, their subsets and P8MC did not display SR-81 protein . 
This conclusively excluded the contribution of this protein to HCV Iymphotropism. 
This finding appears to be consistent with that reported by others where soluble 
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truncated HCV E2 protein and PBMC, B cells, monocytes and dendritic cells as 
targets were used (420) . Taken together, the data from this and previous studies 
imply thai while CD81 is involved, likely as a co-receptor, SR-B1 is not required 
for recognition of T lymphocytes by HCV 
Although a pivotal contribution of CDS to HCV T cell tropism has been 
previously delineated (360), we re-analyzed expression of CDS in the context of 
other HCV candidate receptors in the current study. In general, the data obtained 
remained in agreement with those previously reported (360) and showed CDS 
gene transcription at significantly (P=0.0001) greater levels in HCV-susceptible 
versus resistant T cells. This difference coincided with the detection of COS 
protein in HCV-susceptible but not in HCV-resistant T cells, providing direct 
evidence for the association between T cell CDS-positivity and their susceptibitity 
to infection. This was verified in our previous study by inhibition of HCV infection 
with C~S-specific antibody and shRNA, and by making CDS-deficient HEK-293 
fibroblast permissive to wild-type HCV infection after their transfection with 
human COS cDNA (360). In contrast to T cells, Huh7.S and HepG2 cells did not 
display CDS protein , as previously reported (360). 
Recent studies have demonstrated the role for T J proteins in the 
susceptibility of Huh7.S cells to infection with JFH-1 clone (170, 232) . However, 
the expression of these proteins in lymphoid cells and their potential role in 
detennining permissiveness of these cells to HCV remained unknown. We 
compared the levels of CLDN-1, CLoN-4, CLON-6 and OCLN mRNAs and 
proteins in the cells examined. CLON-1, a protein previously reported to be an 
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HCV entry factor mediating infection of hepatic cells, as determined by examining 
HCVpp and HCVcc preparations and Huh7.S cells (102), was expressed only by 
hepatoma cells and PM1 T cells, which are resistant to HCV infection unless 
activated (360) . Thus , the results clearly showed that ClDN-1 is not involved in 
determining susceptibility of primary T lymphocyte to HCV. Further, ClDN-4 and 
ClDN-6 mRNA and proteins were identified at comparable levels in both HCV-
susceptible and resistant cells, making their potential contribution to HCV 
infectivity towards T lymphocytes highly unlikely. In this regard , others have also 
shown that human PBMC transcribe ClDN-6 but not ClDN-1 (429), which is 
consistent with our findings. The study mentioned also reported that human 
hepatoma cell line Bet7402 was recognized by HCVpp, although the celis did not 
express ClDN1 (429) . This indicates that ClDN-1 is dispensable not only for 
infection of lymphocytes but also for infection of non-lymphoid cells. 
OClN, which is another member of the T J protein family. was shown to 
mediate infection of Huh7.S celis by HCVcc and to be likely involved at the late 
stage of HCV entry (323) . Although expressed at significantly higher levels in 
hepatic cells, OClN was both transcribed and translated in HCV-prone Molt4 and 
Jurkat T cells at much greater levels than in HCV-resistant PM1 and CEM cells 
and, importantly, primary T cells and PBMC. To confirm potential relevance of 
OClN to T cell susceptibility to HCV infection, the effect of OClN-knockout on 
the level of HCV replication in Jurkat T cells was investigated. While both HCV 
RNA positive and negative strands were detected at comparable levels in the 
cells transduced with OClN-shRNA or irrelevant-shRNA, virus E2 protein was 
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detected only in the control cells treated with irr-shRNA. This observation 
appears to be consistent with the prellious report which showed no effect of 
OCLN silencing on the HCV RNA lellel in Huh? cells carrying genomic or 
subgenomic HCV replicons (32) . The reason why HCV E2 protein was absent in 
the cells with silenced OCLN is not clear. It might be due to the interaction 
between E2 glycoprotein and OCLN and to the possibility that OClN facilitates 
translocation of the lIiral protein to the appropriate intracellular compartment 
and/or prellents its premature release from the infected cell. In this regard, HCV 
E2 and OCLN halle been found to partially co-localize in hepatocyte endoplasmic 
reticulum and cO-immunoprecipitate (31). Ollerall , the data obtained imply that 
OCLN can posttranscriptionally affect the HCV E2 protein display without 
influencing the lIirus genome transcription in infected T cells 
In agreement with the prellious observations, where down regulation of 
OClN and CloN-1 was identified in Huh? cells after infection with HCVcc (232), 
the lellel of OClN and C081 expression significantly decreased in Jurkat T cells 
infected with wild-type HCV. Meanwhile, the transcription of COS became 
augmented and that of SR-S1 unchanged. These findings can be interpreted as 
an indication that HCV downregulates OCLN and C081 molecules to prellent 
superinfection, as it has been postulated before (232), prolliding also ellidence for 
the importance of these proteins in the HCV infection process in lymphocytes 
On the other hand , upregulation of COS expression may protect cells from 
apoptosis and allow for more prolonged and robust HCV replication in the cells 
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infected (81 , 134, 398, 439). Certainly, further investigations are necessary to 
assess validity of these hypotheses 
The data obtained in this study contribute to our understanding of the 
nature of HCV Iymphotropism, which remains a vaguely recognized property of 
naturally propagating virus . Overall , they imply that the virus utilizes a distinct set 
of cellular factors to gain entry into lymphocytes in comparison to that expected to 
mediate HCV tropism towards human hepatocytes Among the molecules 
analyzed, on ly expression of CD5 is uniquely restricted to lymphocytes, implying 
a central role of this glycoprotein in HCV Iymphotropism. No association between 
expression of SR-B1 or CLDN-1 and the susceptibility of T cells to HCV infection 
was found , while contribution of CD81 as a potential co-receptor was confirmed. 
The role of OCLN as an HCV entry factor to T cells remains ambiguous since this 
protein is essentially absent or displayed at trace quantities in primary T cells but 
is robustly presented by T cell lines known to be susceptible to HCV. 
Considering a surprisingly large number of cellular receptors implicated in HCV 
entry to hepatocytes, it cannot be excluded that other, not yet identified 
molecules are involved in the HCV tropism towards both T cells and other cell 
subsets in the human lymphatic system. 
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CHAPTER FIVE: 
WILD-TYPE HEPATITIS C VIRUS AND HCV JFH-1 CLONES 
CONTRASTINGL Y DIFFER IN THEIR ABILITY TO INFECT HUMAN 
LYMPHOCYTES AND HEPATOMA CELLS. 
5.1. Introduction: 
Hepatitis C virus (HCV) is a hepatolropic virus that also infects cells of the 
immune system. HCV clones cultivated in human hepatoma Huh-7.S cells have 
significantly advanced our understanding of HCV replication and candidate 
hepatocyte receptors. However, naturally occurring wild-type HCV. in contrast to 
the HCV JFH-1 clone, is unable to infect Huh-7.S cells, while it can replicate in 
human primary T cells and selected T cell lines as recently documented (360) . 
To better understand this incongruity, we examined the susceptibility of primary T 
cells, PBMC and T cell lines to infection with wild-type HCV, the classical HCV 
JFH-1 and a cell culture-adapted JFH 1T known to be highly infectious to Huh-7.S 
cells. We also tested whether Huh-7.S cells are prone to virus readily infecting T 
lymphocytes. The results revealed that while primary T cells and Molt4 and 
Jurkat T cell lines were susceptible to wild-type HCV, they were resistant to 
infection with either JFH1 T or JFH-1 . However, JFH1T clone interacted more 
firmly , although non-productively, with the cells than JFH-1 . Further, Huh-7 .S 
cells robustly supported replication of JFHh but not wild-type virus despite using 
highly sensitive detection assays. In conclusion, JFH-1 and JFHh clones were 
unable to establish productive infection in human primary T cells, PBMC and T 
cell lines known to be prone to wild-type virus, while Huh-7.S cells were totally 
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totally resistant to infection with patient-derived HCV. The data showed that the 
ability to infect lymphocytes is a distinctive characteristic of native virus but not 
laboratory adapted HCV clones 
HCV is a hepatotropic virus that also infects cells of the immune system. 
Studies applying HCV clones cultivated in human hepatoma Huh7.5 cells have 
sign ificantly advanced our understanding of the HCV replication strategy and 
candidate receptors potentially mediating infection of human hepatocytes. 
However, naturally occurring wild-type HCV, in contrast to JFH-1 clone , is unable 
to infect Huh7.5 cells, while it can enter and rep licate in human primary T cells, 
PBMC, and selected human T cell lines. In order to better recognize this 
incongruity, we examined the susceptibility of affinity-purified primary T cells, total 
PBMC and T cell lines to infection with wild-type HCV, the classical HCV JFH-1 
strain and its triple mutant JFH1 T known to be highly infectious to Huh7.5 cells. 
We also tested whether Huh7.5 cells are prone to patient-derived virus readily 
infecting T cells when measured by highly sensitive HCV detection assays. The 
resu lts revealed that while primary T cells and Molt4 and Jurkat T cell lines were 
susceptible to wild-type virus , as previously reported , they were resistant to 
infection with either JFH1 T or JFH-1. Nonetheless, JFHh clone more firmly, 
although non-productively, interacted with the lymphoid cells than JFH-1, as 
quantification of the cell-associated HCV RNA positive strand revealed . On the 
other hand , Huh7.5 cells robustly supported propagation of JFHh but not at all 
wild-type virus desp ite employing highly sensitive detection assays In 
conclusion, JFH-1 and JFHh clones were unab le to establish productive 
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infection in human primary T cells, PBMC and T cell lines known to be prone to 
wild-type virus, while Huh7.5 cells were totally resistant to infection with patient-
derived HCV. The data showed that the ability to infect lymphocytes is a 
distinctive characteristic of native virus but not laboratory adapted HCV clones 
HCV is a small enveloped RNA virus belonging to the Flaviviridae fam ily 
that affects as a symptomatic chronic infection over 170 million people worldwide 
(2) . This form of infection frequently progresses to cirrhosis and hepatocellular 
carcinoma (396) 
In addition to this clinically apparent chronic infection, HCV can persist as 
a si lent, essentially asymptomatic infection in the liver and the immune system 
which is usually detectable by thorough testing for HCV genome expression 
using nucleic acid amplification assays of enhanced sensitivity (64, 312-315, 
339)1 . Overall , the evidence accumulated in the last decade indicates that HCV 
not only infects hepatocytes but also enters and replicates in immune cells , 
including T lymphocytes (42 , 86, 94. 151,222, 304). 
Since the discovery of HCV (67), there have been significant efforts to 
estab lish a robust in vitro cell culture system and a small animal model 
supporting the entire replication cycle of native, naturally occurring virus (269, 
403). With the isolation and cloning of an HCV strain from a Japanese patient 
with fulminant hepatitis (JFH-1) (403) this goal was partially achieved and a clone 
propagating to very high levels in human hepatoma Huh7.5 cell line and 
producing viral particles infectious to these cells has been established. This 
robust system and its subsequent modifications provided an important tool for 
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molecular studies of the HCV life cycle and preclinical testing of novel antiviral 
strategies. However, the degree to which this system mimics the actual events 
occurring during in vivo infection of human hepatocytes with wild-type HCV 
remains unsettled. In this regard . Kato et al. (2001) demonstrated a significant 
genetic distance between JFH-1 and the wild-type HCV derived from patients 
with CHC (194) . The phylogenetic analysis showed that although JFH-1 clone 
clusters with genotype 2a viruses from patients with CHC, there are numerous 
nucleotide deviations from the wild-type virus sequences which are most 
prominent in the 5·-UTR and in the core, NS3 and NS5A genomic regions with a 
mean genetic distance of 0.1136 ~ 0.0073 (194) . These differences, in addition 
to the unique immune-deficient milieu existing within Huh7.5 cells and 
abnormalities in their signalling and endocytic pathways and function of 
mitochondria, may account for the clone's ability to replicate in Huh7 (51 , 83, 188, 
205,207). Although JFH-1 clone is high ly infectious to Huh7.5 cells, it displays a 
very low replication capacity and liver pathogen ic potency with short course of 
infection in experimentally infected chimpanzees, which represent the closest 
immunopathogenic model of human HCV infection and hepatitis C (193, 231) 
Further, it has been shown that administration of plasma-derived HCV to 
chimpanzees induces infection of PBMC (371 , 372) , whereas a similar situation 
has not yet been reported for JFH-1 . Considering findings in HCV-infected 
patients, HCV genome, its negative (replicative) strand, unique variants distinct 
from these occurring in the liver or plasma, and intracellularly expressed viral 
proteins have been identified in different subsets of circulating immune cells (127, 
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222, 314). The ability of patient-derived HCV to infect in vitro PBMC, T and B 
lymphocytes, and monocytesl macrophages has also been shown by several 
groups (42 , 86, 94, 151,222, 304) . In contrast, JFH-1 was found to be non-
infectious to human lymphoid cells (255, 292) . 
In the current study, we utilized an adapted JFH-1 virus, designated as 
JFHh clone, which has been found to be highly infectious to Huh7.5 cells with 
100~1000-fold greater production of viral particles than the classical JFH-1 strain 
(187, 352). We aimed to identify if such highly infectious, readily available virus 
can infect human primary T cells andfor T cell lines previously identified to be 
prone to infection with wild-type HCV (242, 243, 360) and, if so. whether the 
clone can be utilized in studies on HCV Iymphotropism. For comparison , the 
same target cells exposed to the classical JFH-1 clone or patient-derived HCV 
were analyzed. Further, to conclusively determine whether hepatoma Huh7.5 
cells are truly resistant to infection with wild-type HCV, we investigated the cells 
exposed to infectious HCV derived from patients with progressing CHC for the 
expression of HCV genome and evidence of virus replication using highly 
sensitive HCV RNA detection assays. 
5.2. Material and Methods 
5.2.1. Cel/lines, Primary Cells and Culture Conditions. 
Molt4 (CRl -1582) and Jurkat (T I B~ 152) T cell lines were provided by the ATCC 
(Manassas). These cells were found to be susceptible to wild~type, patient~ 
derived HCV and be able to support its replication , as documented in our 
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previous studies (360). PM1 cells were acquired from the National Institutes of 
Health AIDS Research and Reference Program {Rockville, MO} and CCRF-CEM 
cells (CEM, ACC-240) from the Deutsche Sammlung von Mikroorganismen und 
Zellkultu ren GmbH (Braunschweig). These two T cell lines were not permissive 
to infection with naturally occurring HCV; however PM1 cells could be infected 
with wild-type HCV after simulation with PMA and inomycin, as previously 
reported {360} . The cells were cu ltured at 1 x 105 cells/well in 5 ml of medium 
containing RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM 
glutamine and 0.1 mM nonessential amino acids (Invitrogen). Total PBMC were 
isolated from healthy donors by gradient centrifugation in Ficoll -HyPaque 
(Pharmacia) , as described elsewhere (315) . Primary T lymphocytes were affinity-
purified from monocyte-depleted PBMC of a healthy human donor by negative 
selection using MACS magnetic microbeads (Mi ltenyi Biotec) , as reported (319, 
360). T cells were 98% pure by flow cytometry evaluations. PBMC and affinily-
purified primary T cells were stimulated with 5 ~g/ml PHA (Sigma-Aldrich) for 24 h 
before exposure to virus (243) . The human hepatoma-derived Huh7.5 cells were 
propagated in OMEM (Invitrogen) supplemented with 10% FCS and 1% penicillin-
streptomycin 
5.2.2. HCV JFH·1 and JFH1r Infectious Strains, 
The classical HCV JFH-1 stra in and its derivative JFH1 T, provided by Or 
Rodney Russell , Memorial University, St. John 's, Nl , Canada, were used for a 
comparative infection study of T cells and Hu7.5 cells. The JFH1 T strain carries a 
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synonymous point mutation in each of E2 , p7, NS2 and NS5A coding sequences 
and has demonstrated 100 to 1000-fold greater ability to infect Huh7.5 cells than 
the classical JFH-1 virus (352). 
JFH-1 or its triple mutant JFH1 r was propagated in Huh7.5 cells following 
the protocol reported elsewhere (187, 352) . Briefly, cells were transfected with 
RNA transcribed from linearized DNA plasmids using lipofectamine transfection 
reagent (Invitrogen) . Then , the cells were washed and cultured in DMEM for 72 
h. The resulting culture supernatants were assayed for the virus infectious titre 
by limiting dilutions in a plaque formation assay and titres were expressed as the 
number of focus-forming units (FFU) per ml of culture supernatant as reported 
(187. 352). In addition, JFH-1 and JFHh genome copy numbers were quantified 
by real-time RT-PCR as described below and reported in detail before 
5.2.3. Wild-type, Patient-Derived HCV 
Plasma from 2 male patients age 44 and 52 years with progressing 
antiviraltherapy-na'lve CHC carrying HCV genotype 1a at levels 5 x 10· and 7 x 
105 vge/ml , respectively, served as HCV infectious inocula. PBMC of these 
individuals contained HCV RNA positive strand at 1.6 x 102 and 2 x 103 vge/j.Jg 
total RNA and were HCV RNA replicative strand reactive. In preliminary 
experiments, the inocula demonstrated comparable infectivity towards HCV-na"lve 
Moll4 and Jurkat cell lines as well as total PBMC and primary T cells 
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5.2.4. Infection Assays with Wild-Type HCVand JFH Strains. 
T cell lines, primary T cells and PBMC were cultured in 6-well plates 
supplemented with 2 ml of culture medium. For primary T cells and PBMC, the 
cells were pretreated with PHA 5 J,Jg/ml for 24 h before exposure to inocula. Then, 
cells were exposed to -1 x 105 vge of wild-type, patient-derived HCV or 1 x 105 
vge of JFH-1 or the triple JFH1 T mutant In addition, cells treated under identical 
conditions and exposed to an equivalent volume of NHP served as negative 
controls. After exposure to either HCV viruses or NHP, the cells were extensively 
washed and cultured for 7-10 d.p.i. in the presence of either PHA alone or PHA 
and human recombinant interleukin-2 (ll-2; 20 IU/ml; Roche Molecular 
Diagnostics) , as reported (243) . For T cell lines, the cells were extensively 
washed after exposure to inoculum, supplemented with fresh medium and 
cultured for 4-7 d.p.i., as reported in detail previously (360) . 
For infection of Huh-7.5 cells, the cells were seeded at 5 x105 cellslwell in 
S-well chamber slides and after 24 -h incubation exposed to identical virus copy 
numbers (104 vge/ml) of HCVcc-containing filtered culture supernatant or wild-
type HCV. Cells incubated with NHP or culture supernatant from noninfected 
Huh7.5 cells were used as controls. After 4-h exposure, the inocula were 
removed , and cells were washed and cultured for 3 days. 
5.2.5. RNA Extraction and cDNA Transcription. 
Total RNA was extracted from 1 x 106 10 1 x 107 cells using Trizol or from 
250 J,JI patient plasma or 300 J,JI cell culture supernatant with Trizol S reagent 
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(both Invitrogen). Mock extractions were performed in parallel as contamination 
controls (315). cDNA was transcribed with Moloney murine leukemia virus RT 
(Invitrogen) , as previously described (315, 360, 319) . 
5.2.6. Detection of HCV by RT-PCRlNAH Assays. 
HCV RNA positive and negative (replicative) strands were detected using 
cDNA derived from 2 IJg and 4 IJg of total RNA. respectively, and the strand-
specific amplification conditions were reported in detail previously (315. 360) 
The specificity of the signal detection and validity of controls were routinely 
confirmed by NAH with 32P_labeled rHCV UTR-E2 as a probe (315). The 
sensitivity of RT-PCR/NAH assay for HCV RNA-positive strand identification was 
<10 vge/ml «2 IU/ml) or <5 vge/lJg of total RNA. while that for HCV RNA-
negative strand was 25-50 vge/lJg of total RNA, as reported (315, 360). The 
relative density of the RT -PCR/NAH signals was quantified by densitometry 
computer-assisted analysis using ImageJ software from the National Institutes of 
Health (Washington, DC) and presented in relative density units 
5.2.7. Quantification of HCV by Real-Time RT-PCR. 
Enumeration of HCV RNA copy numbers was done by real-time RT-PCR 
during 45 cycles using the lightCycier 480 (Roche Diagnostics) and conditions 
as previously reported (360). Briefly. reactions were performed in 10 IJL volumes, 
each containing 2 IJl cDNA derived from 50 ng of total RNA using primers 
described before (315. 360) Ten-fold serial dilutions of rHCV UTR-E2 were used 
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as standards to determine the HCV genome copy numbers The sensitivity of the 
assay was between 10 and 102 vge/reaction 
5.2.8. Detection of HCV Proteins by Confocal Microscopy. 
Huh7.5 cells exposed to wild-type HCV or infected with JFH1T as a 
positive control were grown on chamber slides and then fixed in cold acetone for 
2 min, washed with phosphate-buffered saline. pH 7.4 (PBS). and incubated with 
anti-HCV core mouse mAb (B2; Anogen-YES Biotech Laboratories. Ontario. 
Canada) at 1:1000 for 20 min at ambient temperature. Subsequently, cells were 
washed with PBS and incubated with Alexa Fluor 488 conjugated anti-mouse 
antibody for 20 min. 
Finally. cells were washed again and mounted using Vectashield hard set 
mounting medium with DAPI (Vector Laboratories). To detect HCV NS5A protein 
in Molt4 and Jurkat cells infected with wHCV. cells were fixed with 2% 
paraformaldehyde and permeabilized with 0.25% saponin . Staining with mouse 
anti-HCV NS5A mAb (Chemicon) or appropriate isotype antibody control (BD 
Pharminogen) was done as previously reported (360). Cells were examined 
under a confocal microscopy and images recorded at x10 and/or x40 
magnifications 
5.2.9. STA TIS TICAL ANAL YSES. 
Results were analyzed by a one way ana lysis of variance or unpaired 
Student t test with Welch's correction using GraphPad Prism software (GraphPad 
154 
Software, Inc.). Differences between experimental conditions were considered to 
be significant when two-sided P values were below or equal to 0.05. 
5.3. Results 
5.3.1. Susceptibility of Primary T Lymphocytes to Infection with JFH-1 and 
JFH1r. 
Primary human T cells from healthy donors were exposed to either 
classical JFH-l strain or the triple mutant JFHh and after 7 or 10-day culture 
evaluated for the expression of HCV RNA. As shown in Figure S.lA, the HCV 
RNA positive strand was detected in T cells exposed to JFHl r virus but not to 
JFH-1 virus. In agreement with this obselVation, HCV RNA was also detected in 
the supernatant of T cells exposed to JFHh but not in the supernatant from the 
cells incubated with JFH-l (Figure S.lA). Comparable results were obtained 
from two experiments in which T cells obtained from a healthy donor were tested 
(Figure S.lA). To assess whether the detection of HCV RNA positive strand in 
the cells exposed to JFHh reflected active virus replication or virus potentially 
adhered to the cells, the expression of HeV RNA negative (replicative) strand 
was evaluated. The results showed that the detection of the HCV RNA positive 
strand did not coincide with the presence of the virus replicative intermediate in 
primary T cells exposed to JFHh (Figure 5.18) 
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Figure 5.1. Determination of the presence of HCV genome positive and 
negative (replicative) strands in human primary T cells exposed to HCV 
JFH·1 or JFHh. Primary T cells affinity purified from a healthy donor were 
exposed to the same copy numbers of JFH-1 or JFHh clones in two parallel 
experiments (Exp 1 and Exp 2), as described in Materials and Methods. (A) 
Identification of HCV RNA positive strand. Synthetic HCV RNA positive strand 
(sHCV RNA) at 105 copies/reaction was used as positive and specificity control. 
(B) Testing for HCV RNA negative strand. Synthetic HCV RNA positive (pos) 
and negative (neg) strands at 105 copiesJreaction confirmed the assay specificity 
for detection of the virus RNA negative strand. Water amplified in direct (OW) 
and nested (NW) reactions and a mock extraction served as contamination 
controls . The positive signals showed the expected 244-bp 5'-UTR sequence-
specific fragments 
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Therefore , the data demonstrated that neither JFH-1 nor JFHh was able 
to establish replication in primary T lymphocytes, although JFH1 T tended to 
adhere more fi rmly than JFH-1 to these cells. 
5.3.2. Infectivity of Wild-Type HCV Versus JFH1 T Towards T cell Lines and 
Huh7.5 Cells 
Mo1t4, Jurkat, PM1 and GEM T cells, as well as Huh7.5 cells, were 
exposed to the same copy numbers of patient-derived (wild-type) HCV or JFHh 
virus. After culture the cells were evaluated for expression of HCV by real-time 
RT-PCR. As shown for wild-type virus in Figure S.2A, HCV RNA positive strand 
was detected in Molt4 and Jurkat T cell lines but not in PM1 or CEM cells, while 
Huh7.S cells showed trace signals not exceeding 10 vge/lJg total RNA. On the 
other hand, T cell lines exposed to JFH1 T showed variable but overall very low 
levels of the HCV RNA positive strand ranging between 10 and 103 vge/lJg tota l 
RNA, while Huh7.S cells , as expected, displayed very high levels exceeding 107 
vge/lJg total RNA (Figure S.2A) . Further. Molt4 and Jurkat T cells after exposure 
to wild-type virus showed 10J_ 105_fold greater levels (P=0.001) of HCV RNA 
positive strand expression comparing to those exposed to the same copy 
numbers of JFH1 1 (Figure S.2A and B) . In order to determine which cells were in 
fact infected, the expression of HCV RNA negative strand was examined. In 
agreement with the previous findings (360), only Molt4 and Jurkat T cells lines 
exposed to patient-derived HCV expressed HCV genome replicative intermediate 
(Figure S.2C) In contrast, PMl and CEM T cells exposed to wild-type virus, as 
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well as all cell types exposed to JFH1 r virus, except Huh7.5 cells (Figure 5.2C) , 
were HCV RNA negative strand nonreactive . Thus, these results confirmed that, 
on one hand, wild-type HCV recognizes and infects cultured T cells which have 
been previously identified to be susceptible to this type of virus (360) but it does 
not infect Huh7.5 cells and, on the other hand, they showed that JFHH clone, 
similarly as JFH-1 , does not infect wild-type virus-susceptible T cell lines 
However, in contrast to JFH-1 , JFHh, showed a greater ability to interact with the 
celis , likely with their plasma membranes, as the results on HCV RNA positive 
strand detection indicated (Figure 5.1A) 
5.3.3. Wild-Type HCV but not JFH1 r Virus Infects Circulating Lymphoid 
Cells 
To further test whether human PBMC are susceptible to laboratory 
adapted JFH1r, PHA-stimulated PBMC obtained from a healthy donor were 
exposed to 1 x 105 vge of JFHh or to naturally circulating HCV from 3 different 
patients with progressing CHC. After culture, as described in Materia ls and 
Methods, cells were evaluated for the expression of HCV RNA positive and 
negative strands. The results showed that ci rcu lating lymphoid cells exposed to 
patient-derived HCV became HCV RNA both positive and negative strand 
reactive, while those exposed to JFH1 r displayed weak positive strand signa ls 
and were negative strand nonreactive (Figure 5.3). The data demonstrated that 
PBMC were prone to infection with wild-type virus , which is consistent with the 
previous reports (243, 360), but not to infection with JFHh 
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Figure 5.2. Infectivity of wild-type HCV and JFH1 T clone toward s different 
human T cell lines and Huh7.5 cells. Molt4 and Jurkat T cell lines susceptible 
to wild-type HCV (wHCV), PM1 and CEM T cells resistant to infection with that 
virus, and hepatoma Huh7.5 cells were exposed to comparable numbers of 
wHCV or JFH1 T, as oullined as in Materia ls and Methods. (A) Quantification of 
HCV RNA positive strand by real-time RT-PCR. (8) Molt4 and Jurkat cells 
exposed to wHCV or JFHh were evaluated for the presence of HCV RNA 
positive strand by RT -PCR/NAH. The relative density of the RT -PCR/NAH 
signals was quantified by densitometry as described by Materials and Methods 
The data represent mean .:!: SO from 4 experiments. (C) Identification of HCV 
RNA negative strand in T cell lines and Huh7.5 cells exposed to wHCV or JFHh 
clone . Specificity and contamination controls for Band C were as those 
described in the legend to Figure 5.1. (0) Identification of HCV NS5a protein in 
Molt4 and Jurkat cells exposed to JFHh clone (HCVcc) or wild-type HCV 
(wHCV) by confocal microscopy. Green fluorescence represents HCV NS5a 
protein in HCV-infected cells. The cells were counterstained with OAPI to identify 
nuclei and examined under transmitted light (TLl to visualize the cytoplasm The 
images were captured al X6D magnification. 
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Figure 5.3. Wild-type HeV but not JFHh virus infects human 
Iymphomononuclear cells. PHA-stimulated PBMC isolated from a healthy 
donor were exposed to 1 x 105 copies of JFHh virus or wHCV from 3 different 
patients with progressing untreated CHC. (A) Identification of HCV RNA positive 
strand. (B) Detection of HCV RNA negative (replicative) strand. Specificity and 
contamination controls were as those described in the legend to Figure 5.1. 
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5.3.4. Huh7.5 Cells are not Susceptible to Infection with Wild-Type HCV 
Finally, to further our understanding of the differences in infectivity 
between wild-type HCV and the JFH1r virus, Huh7_5 cells were exposed in 
parallel to _104 vge/m l of either JFH1T or wild-type virus. Following 3-d.p.i. 
culture, the cells were examined for the expression of HCV core protein. The 
data showed that while Huh7_5 cells robustly supported replication of JFH1r 
virus, they were not susceptible to infection with the wild-type HCV, as illustrated 
in Figure 5.4. 
5.4. Discussion 
Although HCV is a highly hepatotropic virus , the data accumulated in recent 
years have convincingly documented that the virus also invades and replicates in 
cells of the immune system lymphocytes (42 , 86, 94, 151, 222,304) . The lack of 
small animal models and a robust lissue culture system capable of supporting 
infection with wild-type HCV hindered the studies on the virus-host cell 
interactions naturally occurring in vivo, particularly those mediating the initia l 
host's cell target recognition and associations with functionally important 
intracellular factors or pathways operating within naturally infected cells. Since 
hepatoma Huh7 cells significantly differ from normal human hepatocytes due to 
their deficient innate immune response, perturbed physiological functions and 
functionally altered mitochondria (51. 83, 188, 205, 207) and since the JFH-1 and 
related clones are highly adapted to propagate in these cells and they are 
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Figure 5.4. Huh7.5 cells are susceptible to infection with JFH1 T but not to 
wild-type HCV. Equal numbers of Huh7.5 cells were exposed to comparable 
copy numbers of either JFHh virus or wHCV. Cells exposed to NHP or DMEM 
served as negative controls. Green fluorescence represents HCV core protein in 
HCV-infected celis. Nuclei were counterstained with DAP!. The images were 
captured at X40 magnification 
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molecularly distinct from wild-type virus, the virus-cell interactions observed in 
this system should be interpreted with caution. 
The finding that molecularly intact, wild-type HCV can productively infect 
normal human primary T cells (242, 243) (Skardasi, G. and Michalak, T.I. - in 
preparation) provides the means to investigate naturally occurring events, 
although in the context of lymphoid cells only, and to assess, for example, the 
effectiveness and the mode of action of agents interfering with replication of fully 
infectious and pathogenic HCV. The application of the HCV-T cell in vitro 
infection model already led to the finding that unique HCV variants emerge during 
replication in primary T cells (243) , that the lymphocyte-specific CD5 molecule is 
essential for HCV infection of T lymphocytes (360), and that a number of 
molecules proposed to mediate HCV tropism towards hepatocytes unlikely playa 
role in infection of primary lymphocytes indicating that the virus may utilize 
different receptors to enter its natural cell targets (Sarhan et al. - submitted). 
However, in an attempt to simplify investigations on HCV Iymphotropism, a 
search for a readily available and well characterized virus was undertaken. Cell 
culture-derived JFH 1T clone showing greatly enhanced infectivity and robust 
replication in Huh7.5 cells, compared to the classical JFH-1 virus (187, 352), 
appeared to be the best candidate. Therefore, in the current work, we wanted to 
delineate, via comparative analysis of the infectivity towards different T 
lymphocyte targets , whether JFH1 T virus would be a suitable analogue of wHCV 
in studies on HCV Iymphotropism 
168 
Analysis of the HCV RNA positive strand revealed a strong signal in 
primary T cells exposed to JFH1 T and non in the cells exposed to JFH-1, 
suggesting that JFH1 T clone tended to bind to the T cells more tightly than JFH-1 
despite routinely performed extensive washing of the cells after inoculation with 
virus (see Figure 5.1). However, examination for HCV RNA negative (replicative) 
stand revealed the lack of detectable signal , indicating that JFH1 T did not 
replicate in primary T celis or that its replication progressed at a very low level not 
identifiable by otherwise highly sensitive RT-PCR/NAH assay (sensitivity -100 
copies/reaction) . Detection of HCV RNA positive strand in culture supernatants 
of T cells exposed to JFHh could be interpreted in support of this possibility 
JFHh clone also interacted to a variab le degree with all other types of T cells 
examined, including T cell lines either susceptible or not to infection with wHCV, 
as the analysis of HCV RNA positive strand showed (see Figure 5.2A, Band 
5.3A) . However, HCV RNA rep licative strand was not detected in any of the cells 
except Huh7.5 cells, as expected (see Figure 5.2C). In future, it would be 
interesting to explore whether this non-productive interaction between JFH1T and 
T cells reflects naturally occurring wHCV-cell binding or is a phenomenon unique 
to this clone since JFH-1 virus did not display such binding reactivity 
In contrast to cells exposed to JFH1 T virus, PBMC as well as Molt4 and 
Jurkat T cell lines exposed to wHCV demonstrated readily detectable HCV RNA 
replicative strand (see Figure 5.2C and 5.38), while PM1 and CEM cells, known 
to be resistant to infection with wHCV (360) (Sarhan et al. - submitted), were 
negative strand nonreactive (see Figure 5.2C). Taken together, a clear picture 
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emerged indicating that while molecularly intact, patient-derived wHCV was 
infectious and capable of replication in primary lymphoid cells and T cell lines 
previously identified to be prone to this type of virus (242, 243, 360) (Sarhan et al. 
- submitted) , the highly infectious to Huh7.5 cells JFH1 T clone was unable to 
establish repl ication in either primary lymphocytes or wHCV-prone T cell lines 
Similarly , it has been shown that JFH-1 HCVcc does not infect B or T 
lymphocytes, monocytes, macrophages, or dendritic cells from healthy donors 
(255). Also, T cells and PBMC were not recognized by HCV pseudoparticles, 
however they were found to enter hepatoma Huh7 and HepG2 cells transfected 
with CD81 , and to human primary hepatocytes (77) 
On the other hand, Huh7.5 cells were highly susceptible to infection with 
JFHh clone, as documented before (187, 352), while being entirely resistant to 
infection with wHey despite the fact that highly sensitive assays for detection of 
HCV RNA positive and negative strands were used throughout the study. This 
was consistent with the results on HCV core protein staining in Huh7.5 cells 
exposed to JFHh or wHCV. Thus, cells exposed to JFH1 T but not those 
incubated with wHCV were reactive for this protein . 
The results from this study document a contrasting difference between 
wild-type, patient-derived HCV and JFH1 T or JFH-1 clones in infectivity of human 
primary and cultured lymphocytes, and they showed that the mutations 
introduced to JFHh greatly enhancing its infectivity of Huh7.5 cells were without 
effect on infection of lymphocytes. This divergence could be attributed, as 
already mentioned, to the significant genetic differences between the naturally 
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occurring HCV and the cloned and cell culture-adapted JFH viruses. However, at 
this stage, it cannot be completely excluded that the plasma-derived HCV may 
contain a minor subpopulation of Iymphotropic variants or carry host factors 
predisposing virus to attach. enter and/or preferentially replicate in lymphoid cells . 
which are absent in the preparations of the cell culture-derived JFH-related 
viruses . In conclusion. our study clearly shows that primary lymphocytes and 
selected T cell lines can support replication of wild-type HCV but not the 
otherwise highly infectious and replication efficient JFH-1-related strain. Since 
JFH-1-derived viruses are unlikely suitable for investigations on HCV 
Iymphotropism. there is a need for generation of HCV clones displaying 
properties more closely resembling those of the wild-type virus which can be 
applied for the type of investigations mentioned. Nonetheless, this and our 
previous studies (19. 20, 33) (Sarhan et al. - submitted) showed that. although 
using wild-type virus for in vitro experimentations is highly challenging, it is also 
fully feasible and can generate valuable data which cannot be obtained 
otherwise 
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CHAPTER SIX: GENERAL DISCUSSION 
Human hepatocytes are considered the primary and the main site of HeV 
replication. However, as summarized before (Section 1.7), there is also 
substantial molecular and clinical evidence implying that HeV invades and 
propagates in extrahepatic sites , including cells of the immune system (243 , 273, 
319, 360). Cellular factors and molecules that mediate the susceptibility of T 
cells to HeV infection were not investigated to any significant degree until the 
studies presented in this thesis . HeV candidate receptors potentially mediating 
virus tropism toward hepatocytes, such as COB1, SR-B1 and the TJ proteins 
ClDN-1 and OCLN, have been identified as being involved in HeV infection of 
human hepatoma Huh7 cells , mainly by using nonpathogenic HCV 
pseudoparticles and other HCV surrogate models . However, overexpression of 
these molecules does not allow many HCV resistant cells to become HCV 
susceptible, suggesting that other factors necessary for HCV cell entry and 
infection of are yet to be identified 
The main purpose of our studies was to identify a mechanism by which 
wild-type , patient-derived HCV recognizes and enters human primary T 
lymphocytes, which are one of the sites of HCV replication in the host's immune 
system_ In this regard , the susceptibility of freshly isolated human T cells and 
different human T cell lines to infection with wild-type HCV was examined to 
uncover the nature of cellular factors mediating the T cell permissiveness to HCV 
and to identify which of the HCV hepatocyte candidate receptors may contribute 
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to infection of human primary T cells, their CD4+ and CD8+ subsets , total PBMC 
and T cell lines, which were found to be prone to HCV infection in the course of 
my study, in comparison to hepatoma-derived Huh7.S and in HepG2 cell lines, 
PHH and control HEK-293 cells. Furthermore, we compared the infectivity of 
naturally occurring, plasma-derived HeV and Huh7.S cells highly infectious HCV 
JFH-1 clone to human T lymphocytes and Huh7.5 cells. 
For this purpose, we established an in vitro T cell culture system using 
readily available T cell lines which have been isolated from patients with acute 
lymphoblastic leukemia or acute T cell lymphoma and employed a HeV-primary 
T lymphocyte infection system previously developed in this laboratory (243, 319) 
De novo infection with HCV was identified by detection of HCV RNA positive and 
negative (replicative) strands and expression of virus NSSA, E2 or core proteins. 
Specificity of HCV binding to cellular molecules of interest was confirmed by 
blocking experiments with specific antibodies or shRNAs and, in some 
investigations, by transfection of the naturally HCV resistant cells with cDNA 
encoding a molecule identified as HCV T cell receptor. 
The advantages of our T cell cultu re system rely on the fact that we used 
easy to handle target human cells and molecularly intact wild-type HCV virus as 
inocula. Moreover, the cells can be exposed to and support infection of naturally 
occurring HeV of different genotypes. In contrast, this is not feasible in the 
current JFH-1-Huh7.S culture model in which a clone , adapted in culture HCV 
genotype 2b displaying multiple mutations when compared to wild-type virus , is 
used. On the other hand, hepatoma-derived Huh? cells, as indicated before 
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(Sections 1.10.2.3) , were shown to have a perturbed intracellular innate immune 
response, dysfunctional mitochondria and aberrant signalling and endocytosis 
pathway (51, 52 , 83, 188, 207,83). Although the JFH-1-Huh7.5 culture system 
supports robust HCV production that allow the study on JFH-1 entry and its 
interactions with host factors at different stages of virus life cycle , the genetic 
distance between JFH-1 (and related clones) and the wild-type HCV (403) and 
distinctive characteristics of Huh7 cells likely affects , although to an unknown 
degree, the properties of the interactions observed. Among others , JFH-1 
produced in Huh7.5 cells failed to infect human PBMC (255) , which were found to 
be susceptible to wild-type virus both in vivo and in vitro (Section 1.7.2). This 
finding is not surprising , as JFH-1 HCVcc also failed to efficienlly infect polarized 
PHH and chimpanzees (324) . 
Our HCV-T cell culture model is certainly less robust than the JFH-1-Huh7 
system and requires highly sensitive methods to detect and quantify replicating 
virus and virions released by infected cells . However, the highly sensitive and 
well controlled assays available in our laboratory allow the identification of 
specific HCV RNA positive strand at levels below 5 vge/lJg of total RNA and virus 
RNA negative strand at 25-50 vge/lJg of total RNA (360). For comparison , the 
infection of PHH with wild-type HCV in vitro has been shown to have a very low 
efficiency which further declined after 8 days with no evidence of the production 
of virions (131 , 280, 281) . Furthermore, less than 15% of the sera from CHC 
patients were found to be infectious to PHH in other studies (131). Therefore, it 
is more appropriate to compare our wild-type HCV-T cell culture system with the 
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PHH cultures exposed to patient derived virus but not to the artificial JFH-1 
system. In this case , the HCV-T cell culture system appears to be more efficient, 
reproducible , and convenient. 
Moreover, it has been proposed that infection of immune cells with HCV 
contributes to HCV persistence by acting as a reservoir of the pathogenic virus 
and by likely altering the ability of the infected immune cells to mount a n effective 
anti-viral response . Persistence of HCV in this compartment is also implicated in 
the pathogenesis of extrahepatic disorders and can be responsible for reinfection 
of the grafts after liver transplantation (290, 328, 366, 434) . The persistence of 
HCV in immune cells may also contribute to virologic relapse after successful 
antiviral treatment (312, 315) and influence the response to IFN-a treatment 
(154). For these reasons, as well as to advance our understanding of the 
principal biological properties of HCV, it was important to uncover cellular 
molecules that mediate the permissiveness of immune celis, specifically T 
lymphocytes, to HCV infection. We examined the receptiveness of four human T 
cell lines (Molt4 , Jurkat, PM1 and CEM) to infection with wild-type HCV. The 
differential analysis of their susceptibilily to HCV led to the discovery that 
lymphocyte unique CDS molecule, belonging to the scavenger receptor cysteine-
rich domain superfamily (342) , is essential for recognition of T lymphocytes by 
this virus. This finding not only defines the molecule involved in determination of 
HCV lymphotropism but also a new target for potential interventions against HCV 
propagating althis extrahepatic compartment 
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Subsequently, to fu rther characterize the differences between HCV-
susceptible and nonsusceptible T cells , we assessed the cells for the expression 
of receptors such as CD3, C04, COB and COB1 in addition to the pan-T marker 
C05. All cells were CD3 positive , COB1 positive, COB negative with variable 
expression of C04. Interestingly, only T cells susceptible to HCV expressed C05 
molecules. The level of infection of these susceptible cells with HCV was 
inhibited by C05-specific antibodies and shRNAs and was comparable to that of 
COB1 blocking. We also found that the differential susceptibility of the examined 
T celilines was not correlated to the transcription levels of IFN-a and IFN-V, IRF3 
and IRF7 molecules. On the other hand, upregulation of C05 in PM1 celis 
confered susceptibility to HCV infection. Moreover, the naturally resistant HEK-
293 cells become susceptible to HCV infection, although at low levels , when 
transfected with a plasmid containing CD5. The results revealed that only primary 
T cells and T cell lines which express C05 protein are prone to HCV. Th is implied 
that T cell susceptibility to HCV requires C05, a lymphocyte-specific glycoprotein 
that belongs to the scavenger receptor cysteine-rich domain superfamily (342) 
Considering the restricted expression of C05 in T celis, it is likely that CD5 
specifically faci litates HCV Iymphotropism. This finding defines a new target for 
potential interventions against HCV propagation at this extrahepatic 
compartment 
HCV cell entry to hepatocytes appears to be a multi-step process that 
involves a number of different host cell factors. Following in itial engagement with 
GAGs and the lOl receptor, HCV entry proceeds via interactions with the C081, 
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SR-BI , and the tight-junction proteins CLDN1 and OCLN (103) . These receptors 
have been previously shown to be necessary for HCV infection of hepatoma 
Huh7 cells, but whether or not they are necessary for infection of human T 
lymphocytes by wild-type virus was not investigated. To assess the role of HCV 
hepatocyte candidate receptors in infection of T cells, we examined primary T 
cells , CD4+ and CD8+ T lymphocyte subsets , total PBMC and T cell lines for the 
level of expression of these postulated receptors in comparison to hepatoma-
derived cells , PHH and HEK-293 cells. The level of mRNA transcription and 
protein expression were identified using quantitative real-time RT-PCR and 
Western blotting, respectively. Our findings showed that CD81 is unlikely the 
limiting factor for HCV infection of T cells since both nonsusceptible (PM1 and 
CEM) and susceptible (Mo1t4 and Jurkat) T cell lines, as well as primary T cells, 
expressed similar levels of CD81. Further, we found that SR-B1, a molecule 
highly expressed in liver tissue and which is considered to be an important HCV 
hepatocyte entry factor (28, 65) seems not to playa role in T cell susceptibility to 
HCV infection. Thus, primary T cells , CD4+ and CD8+ T cell subsets and PBMC, 
despite being susceptible to wild-type HCV (203, 314) , were found to express 
significantly lower levels of SR-B1 mRNA comparing to Huh7.5 and HepG2 cells 
and no SR-B1 protein . Our results in regard to SR-B1 expression in lymphoid 
cells appears to be compatible with other studies (255, 420) 
The resistance of PM1 T cells to HCV infection despite the expression of 
CLDN-1 and the susceptibility of Molt4 and Jurkat T cells to HCV which are 
CLDN-1 negative, indicates that CLDN-1 is also likely irrelevant to 
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permissiveness of normal human T cells as well as Molt4 and Jurkat T cell lines 
to infection with naturally occurring HCV. Our findings were consistent with what 
has been shown before that CLDN-1 and SR-BI were not detectable in 
lymphocytes (255, 429) and that CLDN-1 could be absent in cells which are 
HCV-susceptible, such as the human hepatocellular carcinoma cell line 8el7402 
(429) . In regard to CLON-4 and CLON-6, no correlation between the level of 
expression and susceptibility of T cells to HCV infection was identified 
OCLN expression was significantly higher in hepatoma cells and PHH, and 
in HCV-susceptible lymphoid cells Molt4 and Jurkat T cell lines than in primary T 
cells, PBMC and HCV-resistant PM1 and CEM T cells. In fact. we were not able 
to detect OCLN protein in PBMC, however traces were identified in primary T 
cells. It has been reported that OCLN is not expressed by peripheral lymphoid 
cells, but it has been shown to be expressed in activated T cells under certain 
conditions (13). In regard to the role of OCLN in HCV infection of T cells, we 
found that OCLN-knockdown did not interfere with virus attachment and 
replication but it interfered with HCV E2 protein expression. This may suggest 
that OCLN may act at later, intarcellular stages in HCV infection of T cells 
Further, the downregulation of OCLN after infection of Jurkat T cells with HCV 
again implied its role in the infection process 
Taken together, our data showed that the lack of association between T 
cell expression of SR-B1 or CLDNs and the susceptibility to HCV infection, while 
CDS and CD81 were identified to be essential to HCV Iymphotropism. In 
addition , OCLN appears to be likely involved in infection of the susceptible T cell 
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lines but its precise role is not clear. A study by Marukian et at. (2008) reported 
that JFH-1 HCVcc does not infect PBMC and that SR-B1 and ClDN-1-
transfected B cells did not become infectable with HCVpp. The authors 
suggested that OClN could be the missing receptor for infection of lymphoid 
cells . However, they also showed that lymphocytes do not support replication of 
transfected HCV RNA, implying that multiple blocks in HCV infection of 
lymphocytes may exist, at last when a laboratory virus is used for this type of 
experimentation. The study by Marukian et at. (2008) was built on the use of 
modified JFH-1 and HCVpp, the authors did not test the effect of OClN or other 
T J proteins on the infection of PBMC or T cells with wild-type HCV 
The recent identification of the T J proteins as candidate hepatocyte 
receptors for HCV was considered to be an important step in the development of 
a small animal model for HCV infection. However, investigators were unable to 
induce replication of HCV in mouse cells, suggesting that other host-specific 
factors than CD81 and OClN might be required to support of the complete life 
cycle of HCV in mice. 
In the third project completed in the course of my thesis work , we wanted 
to delineate via comparative analysis of HCV cell susceptibility, whether JFHh 
virus, known to be highly infectious to Huh7.5 cells , would be a suitable 
alternative to wHCV in studies of HCV Iymphotropism In this regard , the 
infectivity of HCV JFH-1 and its culture adapted clone JFH1 T (352) towards T 
cells were tested in comparison to the plasma-derived wild-type HCV. In parallel, 
the susceptibility of hepatoma Huh7.5 cells to infection with wild-type HCV was 
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assessed. We found that primary T cells, PBMC and T cell lines known to be 
prone to plasma-derived HCV (360), were not susceptible to either JFH-1 or 
JFHh clones . On the other hand, Huh7.5 cells were only susceptible to the JFH-
1 clones but not to patient-derived HCV which was infectious to T cells. The 
preferential replication of plasma-derived HCV but not JFH clones in lymphoid 
cells document a contrasting difference between the wild-type, patient-derived 
HCV and JFHh or JFH-1 clones, and show that the mutations introduced to 
JFHh greatly enhanced the clone infectivity towards Huh7.5 cells but not to 
lymphocytes. This divergence could be attributed, as already mentioned, to the 
significant genetic differences between the naturally occurring HCV and the 
cloned and cell culture-adapted JFH viruses Thus , our study clearly showed that 
human primary lymphocytes and selected, readily available T cell lines can 
support replication of wild-type HCV but not the otherwise highly infectious and 
replication efficient JFH-1-related strain. Since JFH-1-derived clones are unlikely 
suitable for investigations of HCV Iymphotropism, there is a need for generation 
of HCV clones with properties more closely resembling those of the wild-type 
virus that can be utilized in the study of HCV Iymphotropism. Nonetheless, we 
demonstrated that although using wild-type, patient-derived virus for in vitro 
experimentations is highly challenging it is also fully feasible and can generate 
valuable data which cannot be obtained otherwise. 
Overall, our studies applied a physiologically relevant infection system 
reflecting natural behaviour of wild-HCV and its interactions with human cells. 
Applying this system, we discovered that CD5, a lymphocyte-specific glycoprotein 
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belonging to the scavenger receptor cysteine-rich family, is an essential factor for 
infection of T cells by molecularly unmodified, wild-type virus. In consequence, 
we showed that HCV utilizes different cellular molecules to infect different cell 
types naturally prone to infection with this virus. We also narrowed the range of 
cellular molecules utilized by a pathogenic HCV in infection of T lymphocytes 
among those previously proposed based on studies applying laboratory adapted 
HCV strains or HCVpp and Huh7.5 cells. Further, we demonstrated that the 
current JFH-1 -based infectious HCV clones are not su itable for studies on HCV 
Iymphotropism. While identification of CD5 and other cellular factors mediating 
susceptibility of human T cells may affect development of future preventive and 
therapeutic strategies against HCV, further studies are required to delineate 
nature of receptors determining permissiveness of other types of immune cells to 
infection with pathogenic HCV 
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CHAPTER SEVEN: CONCLUSIONS AND FUTURE 
DIRECTIONS 
7.1. Conclusions 
The findings presented in this dissertation can be summarized and 
concluded as follows 
1. We have established reproducible in vitro HeV infection system using 
readily available human Mol14 and Jurkat T cell lines and wild-type HeV derived 
from patients actually infected with HeV as inocula. Using T cell lines as 
infection targets , we had overcome a drawback of our previous HCV-T cell 
infection model in which freshly isolated human PBMC were used as a source of 
HeV target T cells. The current system is as efficient as the previous one, 
considering the rate of HeV replication , but certainly is more straightforward and 
less work demanding. Although our HCV-T cell infection system is significantly 
less robust than the culture adapted JFH-1 strains propagating in hepatoma 
Huh7.5 cells, it offers important advantages for investigations of interactions 
between naturally occurring virus and host cells, and as a tool to further study 
cellular and viral factors promoting HCV Iymphotropism and affecting HCV 
repl ication in immune cells , which cannot be investigated otherwise. 
2. Differential analysis of HCV infection in permissive and resistant T cell 
lines and in primary T lymphocytes led us to discover that CD5 is a T cell-specific 
molecule that is important for HCV infection of human lymphocytes. We also 
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found that COal contributes to HCV infection, but it is not the limiting factor for 
HCV infection of resistant T cell lines 
3. Analysis of the expression of the proposed HCV hepatocyte candidate 
receptors previously identified using JFH-l and related clones or HCVpp and 
Huh7.5 cells revealed that, in addition to C05 and COal , OCl N is involved in 
HCV infection of permissive human T cells lines, but rather unlikely in infection of 
primary T lymphocytes. We also uncovered that SR-Bl and tight junction protein 
ClON-l do not playa role in HCV Iymphotropism. 
4. Comparing HCV cell tropism of the wild-type, patient-derived HCV and 
the JFH clones towards lymphoid cells and hepatoma-derived cells, we 
demonstrated that JFH-l or the adapted JFH1T strain , which is known to be 
highly infectious to Huh7.5 cells, can efficienlly infect Huh7 cells but not human 
primary T lymphocytes or T cell lines known to be susceptible to wild -type HCV. 
In contrast, wild-type HCV derived from infected patients was only infectious to 
the lymphoid cells but not to Huh7.5 cells . 
7.2. Future Directions 
1. Further efforts should be made to improve the efficiency of the HCV-T 
lymphocyte infection system. Serial passage of virus in T lymphocytes and 
subculture of HCV-infected T cells may produce virions that may more efficiently 
infect virus-naive T cells and allow for more robust HCV propagation in these 
cells . It is not excluded that HCV variants preferentially infecting and replicating 
in T cell cultures could be created Their sequence analysis and examinations of 
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biophysical properties may potentially explain the difference between 
hepatotropic and Iymphotropic HCV strains 
2. The exact molecular mechanism of CDS interaction with HCV virions is 
yet unknown. Therefore, creating CDS clones with site mutations may help 
identify certain CDS regions that interact with the virus. Also, transfection of 
these mutated or truncated clones of CDS into T cells with knockout CDS may 
enhance our knowledge about its function during the HCV attachment and 
potentially in the subsequent stages of the virus intracellular life cycle. On the 
other hand, although HCV E2 protein most likely mediates binding to CDS, it 
would be to appropriate to formally document this expectation. 
3. The mechanism of HCV infection of other immune cells expressing 
CDS, such as a minor subpopulation of B cells , or not expressing CDS, such as 
monocytes, macrophages and the majority of mature circulating B cells, should 
be investigated to explain in full the nature of HCV Iymphotropism. 
4. It has been postulated that the occurrence of Iymphoproli ferative 
disorders in HCV-infected patients, such as B cell non-Hodgkin's lymphoma and 
mixed cryoglobulinemia, could be related to the expansion of CDS-positive B 
cells . The mechanism of this expansion is unknown and examination of this 
issue would be a clinically important area of further investigations. In addition, 
recognition of the possible differential susceptibility of CDS-positive and CDS-
negative B cells to HCV infection may advance our understanding of the 
contribution of CDS to HCV Iymphotropism 
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5. Whether or not soluble CDS can be used as a component of anti-HCV 
therapy to limit virus spread and to prevent the establ ishment of HCV reservoir in 
the lymphatic system will requ ire separate studies 
In the studies presented in this dissertation, we uncovered important, 
previously unknown aspects of HCV biology that improved our understanding of 
the nature of HCV Iymphotropism. These findings may shape the future 
strategies of anti-HCV treatment and the ways how the progression of HCV 
infection and its therapy are monitored. We believe that HCV residing in immune 
celis may contribute to the failure of antiviral treatment and infection relapse. We 
also think that future therapies should consider combating HCV in this 
extrahepatic reservoir. 
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